date generated: 2023-08-30
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
x | |
---|---|
0610005C13Rik | 1.7086294 |
0610009B22Rik | -2.3583781 |
0610009E02Rik | -0.4921631 |
0610009L18Rik | -1.5061599 |
0610010K14Rik | -0.7608005 |
0610012G03Rik | -0.6314820 |
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 1604 |
num_genes_in_profile | 17472 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8440 |
num_profile_genes_not_in_sets | 9032 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used:
GMT file of genesets: mouse_msigdb_reactome_2022-02-16.gmtGene sets metrics | |
---|---|
num_genesets | 1604 |
num_genesets_excluded | 425 |
num_genesets_included | 1179 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
ERYTHROCYTES TAKE UP CARBON DIOXIDE AND RELEASE OXYGEN | 10 | 1.41e-04 | -0.695 | 1.54e-03 |
ADENYLATE CYCLASE ACTIVATING PATHWAY | 10 | 1.95e-04 | 0.680 | 2.03e-03 |
REGULATION OF RUNX1 EXPRESSION AND ACTIVITY | 17 | 6.32e-05 | 0.560 | 8.09e-04 |
ENDOSOMAL VACUOLAR PATHWAY | 10 | 3.88e-03 | -0.527 | 2.56e-02 |
TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR | 11 | 2.83e-03 | -0.520 | 1.97e-02 |
INTERACTION BETWEEN L1 AND ANKYRINS | 27 | 4.35e-06 | 0.511 | 8.55e-05 |
RETINOID CYCLE DISEASE EVENTS | 10 | 7.39e-03 | -0.489 | 4.22e-02 |
SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYMES | 29 | 6.40e-06 | -0.484 | 1.13e-04 |
LGI ADAM INTERACTIONS | 14 | 2.77e-03 | 0.462 | 1.95e-02 |
YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION | 11 | 9.97e-03 | 0.449 | 5.37e-02 |
CLASS I PEROXISOMAL MEMBRANE PROTEIN IMPORT | 20 | 5.16e-04 | -0.448 | 4.82e-03 |
P75NTR REGULATES AXONOGENESIS | 10 | 1.52e-02 | -0.443 | 7.35e-02 |
THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION | 15 | 3.18e-03 | -0.440 | 2.14e-02 |
PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING | 11 | 1.16e-02 | 0.440 | 6.05e-02 |
DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TYPE | 20 | 1.13e-03 | 0.421 | 9.22e-03 |
CD28 DEPENDENT VAV1 PATHWAY | 11 | 1.75e-02 | -0.414 | 8.17e-02 |
RORA ACTIVATES GENE EXPRESSION | 18 | 2.58e-03 | 0.410 | 1.86e-02 |
MITOCHONDRIAL TRANSLATION | 93 | 1.33e-11 | -0.406 | 2.61e-09 |
RECEPTOR MEDIATED MITOPHAGY | 11 | 2.00e-02 | -0.405 | 8.88e-02 |
CRISTAE FORMATION | 31 | 1.04e-04 | -0.403 | 1.23e-03 |
BRANCHED CHAIN AMINO ACID CATABOLISM | 21 | 1.53e-03 | -0.399 | 1.20e-02 |
PENTOSE PHOSPHATE PATHWAY | 13 | 1.30e-02 | -0.398 | 6.52e-02 |
METABOLISM OF POLYAMINES | 58 | 1.59e-07 | -0.398 | 6.05e-06 |
COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDING | 26 | 4.46e-04 | -0.398 | 4.28e-03 |
NEGATIVE REGULATION OF NOTCH4 SIGNALING | 54 | 4.32e-07 | -0.398 | 1.34e-05 |
FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC | 19 | 2.78e-03 | -0.396 | 1.95e-02 |
ASSEMBLY OF THE PRE REPLICATIVE COMPLEX | 65 | 3.29e-08 | -0.396 | 1.69e-06 |
SIGNALING BY LEPTIN | 10 | 3.01e-02 | 0.396 | 1.18e-01 |
TIGHT JUNCTION INTERACTIONS | 17 | 4.74e-03 | -0.396 | 3.04e-02 |
UNWINDING OF DNA | 12 | 1.86e-02 | -0.392 | 8.47e-02 |
CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES | 47 | 3.49e-06 | -0.391 | 7.49e-05 |
RESPIRATORY ELECTRON TRANSPORT | 102 | 1.02e-11 | -0.390 | 2.41e-09 |
SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1 | 13 | 1.49e-02 | -0.390 | 7.25e-02 |
PHOSPHORYLATION OF THE APC C | 18 | 4.69e-03 | -0.385 | 3.03e-02 |
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12 | 20 | 2.90e-03 | -0.385 | 2.01e-02 |
SYNAPTIC ADHESION LIKE MOLECULES | 21 | 2.31e-03 | 0.384 | 1.70e-02 |
GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATION | 31 | 2.37e-04 | -0.381 | 2.45e-03 |
SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE | 87 | 7.74e-10 | -0.381 | 5.71e-08 |
METHYLATION | 11 | 2.99e-02 | -0.378 | 1.17e-01 |
ADENYLATE CYCLASE INHIBITORY PATHWAY | 13 | 1.83e-02 | 0.378 | 8.47e-02 |
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS | 26 | 9.17e-04 | 0.376 | 7.66e-03 |
ORC1 REMOVAL FROM CHROMATIN | 68 | 8.69e-08 | -0.375 | 3.63e-06 |
PCNA DEPENDENT LONG PATCH BASE EXCISION REPAIR | 20 | 3.73e-03 | -0.375 | 2.47e-02 |
SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN | 12 | 2.50e-02 | -0.374 | 1.04e-01 |
SCF SKP2 MEDIATED DEGRADATION OF P27 P21 | 59 | 7.83e-07 | -0.372 | 2.20e-05 |
PROTEIN UBIQUITINATION | 70 | 7.66e-08 | -0.372 | 3.34e-06 |
PROCESSING AND ACTIVATION OF SUMO | 10 | 4.22e-02 | -0.371 | 1.47e-01 |
FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | 18 | 6.98e-03 | -0.367 | 4.03e-02 |
COMPLEX I BIOGENESIS | 56 | 2.06e-06 | -0.367 | 4.67e-05 |
APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1 | 71 | 9.26e-08 | -0.367 | 3.64e-06 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
ERYTHROCYTES TAKE UP CARBON DIOXIDE AND RELEASE OXYGEN | 10 | 1.41e-04 | -0.695000 | 1.54e-03 |
ADENYLATE CYCLASE ACTIVATING PATHWAY | 10 | 1.95e-04 | 0.680000 | 2.03e-03 |
REGULATION OF RUNX1 EXPRESSION AND ACTIVITY | 17 | 6.32e-05 | 0.560000 | 8.09e-04 |
ENDOSOMAL VACUOLAR PATHWAY | 10 | 3.88e-03 | -0.527000 | 2.56e-02 |
TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR | 11 | 2.83e-03 | -0.520000 | 1.97e-02 |
INTERACTION BETWEEN L1 AND ANKYRINS | 27 | 4.35e-06 | 0.511000 | 8.55e-05 |
RETINOID CYCLE DISEASE EVENTS | 10 | 7.39e-03 | -0.489000 | 4.22e-02 |
SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYMES | 29 | 6.40e-06 | -0.484000 | 1.13e-04 |
LGI ADAM INTERACTIONS | 14 | 2.77e-03 | 0.462000 | 1.95e-02 |
YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION | 11 | 9.97e-03 | 0.449000 | 5.37e-02 |
CLASS I PEROXISOMAL MEMBRANE PROTEIN IMPORT | 20 | 5.16e-04 | -0.448000 | 4.82e-03 |
P75NTR REGULATES AXONOGENESIS | 10 | 1.52e-02 | -0.443000 | 7.35e-02 |
THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION | 15 | 3.18e-03 | -0.440000 | 2.14e-02 |
PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING | 11 | 1.16e-02 | 0.440000 | 6.05e-02 |
DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TYPE | 20 | 1.13e-03 | 0.421000 | 9.22e-03 |
CD28 DEPENDENT VAV1 PATHWAY | 11 | 1.75e-02 | -0.414000 | 8.17e-02 |
RORA ACTIVATES GENE EXPRESSION | 18 | 2.58e-03 | 0.410000 | 1.86e-02 |
MITOCHONDRIAL TRANSLATION | 93 | 1.33e-11 | -0.406000 | 2.61e-09 |
RECEPTOR MEDIATED MITOPHAGY | 11 | 2.00e-02 | -0.405000 | 8.88e-02 |
CRISTAE FORMATION | 31 | 1.04e-04 | -0.403000 | 1.23e-03 |
BRANCHED CHAIN AMINO ACID CATABOLISM | 21 | 1.53e-03 | -0.399000 | 1.20e-02 |
PENTOSE PHOSPHATE PATHWAY | 13 | 1.30e-02 | -0.398000 | 6.52e-02 |
METABOLISM OF POLYAMINES | 58 | 1.59e-07 | -0.398000 | 6.05e-06 |
COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDING | 26 | 4.46e-04 | -0.398000 | 4.28e-03 |
NEGATIVE REGULATION OF NOTCH4 SIGNALING | 54 | 4.32e-07 | -0.398000 | 1.34e-05 |
FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC | 19 | 2.78e-03 | -0.396000 | 1.95e-02 |
ASSEMBLY OF THE PRE REPLICATIVE COMPLEX | 65 | 3.29e-08 | -0.396000 | 1.69e-06 |
SIGNALING BY LEPTIN | 10 | 3.01e-02 | 0.396000 | 1.18e-01 |
TIGHT JUNCTION INTERACTIONS | 17 | 4.74e-03 | -0.396000 | 3.04e-02 |
UNWINDING OF DNA | 12 | 1.86e-02 | -0.392000 | 8.47e-02 |
CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES | 47 | 3.49e-06 | -0.391000 | 7.49e-05 |
RESPIRATORY ELECTRON TRANSPORT | 102 | 1.02e-11 | -0.390000 | 2.41e-09 |
SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1 | 13 | 1.49e-02 | -0.390000 | 7.25e-02 |
PHOSPHORYLATION OF THE APC C | 18 | 4.69e-03 | -0.385000 | 3.03e-02 |
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12 | 20 | 2.90e-03 | -0.385000 | 2.01e-02 |
SYNAPTIC ADHESION LIKE MOLECULES | 21 | 2.31e-03 | 0.384000 | 1.70e-02 |
GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATION | 31 | 2.37e-04 | -0.381000 | 2.45e-03 |
SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE | 87 | 7.74e-10 | -0.381000 | 5.71e-08 |
METHYLATION | 11 | 2.99e-02 | -0.378000 | 1.17e-01 |
ADENYLATE CYCLASE INHIBITORY PATHWAY | 13 | 1.83e-02 | 0.378000 | 8.47e-02 |
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS | 26 | 9.17e-04 | 0.376000 | 7.66e-03 |
ORC1 REMOVAL FROM CHROMATIN | 68 | 8.69e-08 | -0.375000 | 3.63e-06 |
PCNA DEPENDENT LONG PATCH BASE EXCISION REPAIR | 20 | 3.73e-03 | -0.375000 | 2.47e-02 |
SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN | 12 | 2.50e-02 | -0.374000 | 1.04e-01 |
SCF SKP2 MEDIATED DEGRADATION OF P27 P21 | 59 | 7.83e-07 | -0.372000 | 2.20e-05 |
PROTEIN UBIQUITINATION | 70 | 7.66e-08 | -0.372000 | 3.34e-06 |
PROCESSING AND ACTIVATION OF SUMO | 10 | 4.22e-02 | -0.371000 | 1.47e-01 |
FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | 18 | 6.98e-03 | -0.367000 | 4.03e-02 |
COMPLEX I BIOGENESIS | 56 | 2.06e-06 | -0.367000 | 4.67e-05 |
APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1 | 71 | 9.26e-08 | -0.367000 | 3.64e-06 |
RHOBTB3 ATPASE CYCLE | 10 | 4.50e-02 | -0.366000 | 1.54e-01 |
SYNTHESIS OF IP3 AND IP4 IN THE CYTOSOL | 25 | 1.68e-03 | 0.363000 | 1.29e-02 |
RAB GERANYLGERANYLATION | 58 | 1.84e-06 | -0.362000 | 4.25e-05 |
E2F MEDIATED REGULATION OF DNA REPLICATION | 20 | 5.09e-03 | -0.362000 | 3.19e-02 |
CHK1 CHK2 CDS1 MEDIATED INACTIVATION OF CYCLIN B CDK1 COMPLEX | 11 | 3.78e-02 | -0.362000 | 1.36e-01 |
RECOGNITION OF DNA DAMAGE BY PCNA CONTAINING REPLICATION COMPLEX | 29 | 7.55e-04 | -0.361000 | 6.74e-03 |
ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT ESCRT | 30 | 6.13e-04 | -0.361000 | 5.60e-03 |
AUF1 HNRNP D0 BINDS AND DESTABILIZES MRNA | 54 | 4.56e-06 | -0.361000 | 8.81e-05 |
INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS | 19 | 6.59e-03 | -0.360000 | 3.87e-02 |
REGULATION OF HMOX1 EXPRESSION AND ACTIVITY | 64 | 6.91e-07 | -0.359000 | 1.99e-05 |
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS | 125 | 4.38e-12 | -0.359000 | 1.29e-09 |
GLUTATHIONE CONJUGATION | 29 | 8.68e-04 | -0.357000 | 7.42e-03 |
NOTCH HLH TRANSCRIPTION PATHWAY | 28 | 1.08e-03 | 0.357000 | 8.93e-03 |
ABERRANT REGULATION OF MITOTIC EXIT IN CANCER DUE TO RB1 DEFECTS | 19 | 7.57e-03 | -0.354000 | 4.27e-02 |
ACTIVATION OF SMO | 16 | 1.44e-02 | 0.353000 | 7.10e-02 |
MITOCHONDRIAL PROTEIN IMPORT | 63 | 1.23e-06 | -0.353000 | 3.38e-05 |
DNA REPLICATION PRE INITIATION | 80 | 5.29e-08 | -0.352000 | 2.49e-06 |
RESPONSE OF EIF2AK1 HRI TO HEME DEFICIENCY | 15 | 1.83e-02 | -0.352000 | 8.47e-02 |
ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S | 59 | 2.98e-06 | -0.352000 | 6.56e-05 |
E3 UBIQUITIN LIGASES UBIQUITINATE TARGET PROTEINS | 51 | 1.45e-05 | -0.351000 | 2.19e-04 |
TRIGLYCERIDE CATABOLISM | 14 | 2.38e-02 | -0.349000 | 1.01e-01 |
INTERLEUKIN 6 SIGNALING | 10 | 5.63e-02 | 0.349000 | 1.78e-01 |
APC C MEDIATED DEGRADATION OF CELL CYCLE PROTEINS | 83 | 4.26e-08 | -0.348000 | 2.09e-06 |
INTERLEUKIN 12 SIGNALING | 36 | 3.04e-04 | -0.348000 | 3.04e-03 |
S PHASE | 154 | 1.33e-13 | -0.346000 | 7.76e-11 |
DECTIN 1 MEDIATED NONCANONICAL NF KB SIGNALING | 60 | 3.93e-06 | -0.344000 | 8.13e-05 |
PROTEIN METHYLATION | 17 | 1.42e-02 | -0.344000 | 7.01e-02 |
TRANSFERRIN ENDOCYTOSIS AND RECYCLING | 26 | 2.42e-03 | -0.344000 | 1.78e-02 |
DNA REPLICATION | 122 | 5.78e-11 | -0.343000 | 7.23e-09 |
HIV TRANSCRIPTION INITIATION | 45 | 6.91e-05 | -0.343000 | 8.49e-04 |
GOLGI CISTERNAE PERICENTRIOLAR STACK REORGANIZATION | 13 | 3.38e-02 | -0.340000 | 1.25e-01 |
DEGRADATION OF DVL | 56 | 1.09e-05 | -0.340000 | 1.72e-04 |
INSULIN RECEPTOR RECYCLING | 20 | 8.66e-03 | -0.339000 | 4.72e-02 |
PHASE 4 RESTING MEMBRANE POTENTIAL | 14 | 2.85e-02 | -0.338000 | 1.14e-01 |
CRMPS IN SEMA3A SIGNALING | 16 | 1.95e-02 | 0.337000 | 8.68e-02 |
THE ROLE OF GTSE1 IN G2 M PROGRESSION AFTER G2 CHECKPOINT | 69 | 1.48e-06 | -0.335000 | 3.72e-05 |
MET ACTIVATES RAP1 AND RAC1 | 10 | 6.65e-02 | -0.335000 | 1.97e-01 |
DEGRADATION OF AXIN | 54 | 2.11e-05 | -0.335000 | 3.10e-04 |
G BETA GAMMA SIGNALLING THROUGH CDC42 | 19 | 1.20e-02 | -0.333000 | 6.18e-02 |
REGULATION OF RUNX3 EXPRESSION AND ACTIVITY | 53 | 2.89e-05 | -0.332000 | 4.11e-04 |
DEFECTIVE CFTR CAUSES CYSTIC FIBROSIS | 60 | 8.98e-06 | -0.331000 | 1.47e-04 |
SYNTHESIS OF IP2 IP AND INS IN THE CYTOSOL | 13 | 3.87e-02 | 0.331000 | 1.38e-01 |
PYRUVATE METABOLISM | 27 | 2.95e-03 | -0.331000 | 2.02e-02 |
NR1H3 NR1H2 REGULATE GENE EXPRESSION LINKED TO CHOLESTEROL TRANSPORT AND EFFLUX | 32 | 1.32e-03 | 0.328000 | 1.06e-02 |
MATURATION OF NUCLEOPROTEIN | 10 | 7.48e-02 | -0.325000 | 2.16e-01 |
NR1H2 AND NR1H3 MEDIATED SIGNALING | 38 | 5.20e-04 | 0.325000 | 4.82e-03 |
THE CITRIC ACID TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT | 172 | 1.97e-13 | -0.325000 | 7.76e-11 |
DEGRADATION OF GLI1 BY THE PROTEASOME | 58 | 1.99e-05 | -0.324000 | 2.97e-04 |
RAS PROCESSING | 24 | 6.10e-03 | -0.323000 | 3.63e-02 |
ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALING | 11 | 6.33e-02 | -0.323000 | 1.91e-01 |
NGF STIMULATED TRANSCRIPTION | 36 | 8.24e-04 | -0.322000 | 7.14e-03 |
PERK REGULATES GENE EXPRESSION | 28 | 3.24e-03 | -0.321000 | 2.17e-02 |
CYCLIN A CDK2 ASSOCIATED EVENTS AT S PHASE ENTRY | 84 | 3.67e-07 | -0.321000 | 1.24e-05 |
EARLY PHASE OF HIV LIFE CYCLE | 13 | 4.51e-02 | -0.321000 | 1.54e-01 |
STABILIZATION OF P53 | 55 | 4.02e-05 | -0.320000 | 5.51e-04 |
SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS | 20 | 1.37e-02 | -0.319000 | 6.82e-02 |
CYTOSOLIC SULFONATION OF SMALL MOLECULES | 15 | 3.27e-02 | -0.319000 | 1.23e-01 |
PHASE II CONJUGATION OF COMPOUNDS | 63 | 1.32e-05 | -0.317000 | 2.03e-04 |
TRANSLATION OF REPLICASE AND ASSEMBLY OF THE REPLICATION TRANSCRIPTION COMPLEX | 12 | 5.70e-02 | -0.317000 | 1.78e-01 |
SEMA3A PLEXIN REPULSION SIGNALING BY INHIBITING INTEGRIN ADHESION | 14 | 3.99e-02 | 0.317000 | 1.42e-01 |
DISEASES ASSOCIATED WITH O GLYCOSYLATION OF PROTEINS | 53 | 6.64e-05 | 0.317000 | 8.33e-04 |
INCRETIN SYNTHESIS SECRETION AND INACTIVATION | 14 | 4.11e-02 | -0.315000 | 1.44e-01 |
PROCESSING OF SMDT1 | 16 | 2.91e-02 | -0.315000 | 1.15e-01 |
REGULATION OF COMMISSURAL AXON PATHFINDING BY SLIT AND ROBO | 10 | 8.64e-02 | 0.313000 | 2.38e-01 |
DNA STRAND ELONGATION | 32 | 2.23e-03 | -0.312000 | 1.66e-02 |
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE | 27 | 4.99e-03 | 0.312000 | 3.15e-02 |
ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC | 24 | 8.21e-03 | -0.312000 | 4.54e-02 |
RUNX3 REGULATES NOTCH SIGNALING | 13 | 5.19e-02 | 0.311000 | 1.68e-01 |
O GLYCOSYLATION OF TSR DOMAIN CONTAINING PROTEINS | 36 | 1.28e-03 | 0.310000 | 1.04e-02 |
CELLULAR RESPONSE TO HYPOXIA | 73 | 4.65e-06 | -0.310000 | 8.84e-05 |
REGULATION OF RUNX2 EXPRESSION AND ACTIVITY | 69 | 8.48e-06 | -0.310000 | 1.43e-04 |
REGULATION OF BACH1 ACTIVITY | 11 | 7.58e-02 | -0.309000 | 2.18e-01 |
PKA ACTIVATION IN GLUCAGON SIGNALLING | 16 | 3.23e-02 | 0.309000 | 1.22e-01 |
EUKARYOTIC TRANSLATION INITIATION | 115 | 1.08e-08 | -0.309000 | 6.39e-07 |
INTERFERON ALPHA BETA SIGNALING | 56 | 6.86e-05 | -0.308000 | 8.49e-04 |
MITOCHONDRIAL FATTY ACID BETA OXIDATION | 33 | 2.24e-03 | -0.307000 | 1.66e-02 |
MITOTIC G1 PHASE AND G1 S TRANSITION | 141 | 3.46e-10 | -0.306000 | 2.92e-08 |
INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES | 29 | 4.42e-03 | -0.305000 | 2.89e-02 |
MET ACTIVATES PTK2 SIGNALING | 28 | 5.23e-03 | 0.305000 | 3.21e-02 |
APC CDC20 MEDIATED DEGRADATION OF NEK2A | 24 | 1.00e-02 | -0.304000 | 5.37e-02 |
TRANSLATION | 287 | 1.10e-18 | -0.303000 | 1.30e-15 |
PROTEIN LOCALIZATION | 157 | 6.13e-11 | -0.303000 | 7.23e-09 |
TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY DREAM COMPLEX | 17 | 3.09e-02 | -0.302000 | 1.20e-01 |
ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE | 17 | 3.10e-02 | 0.302000 | 1.20e-01 |
ACTIVATION OF RAC1 | 13 | 6.03e-02 | -0.301000 | 1.84e-01 |
DARPP 32 EVENTS | 23 | 1.27e-02 | -0.300000 | 6.46e-02 |
DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR | 79 | 4.15e-06 | -0.300000 | 8.44e-05 |
APOPTOSIS INDUCED DNA FRAGMENTATION | 10 | 1.01e-01 | -0.300000 | 2.57e-01 |
BBSOME MEDIATED CARGO TARGETING TO CILIUM | 23 | 1.30e-02 | -0.299000 | 6.52e-02 |
SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | 107 | 8.93e-08 | -0.299000 | 3.63e-06 |
BUDDING AND MATURATION OF HIV VIRION | 27 | 7.41e-03 | -0.298000 | 4.22e-02 |
REGULATION OF PTEN STABILITY AND ACTIVITY | 68 | 2.21e-05 | -0.298000 | 3.22e-04 |
INTERLEUKIN 37 SIGNALING | 18 | 2.95e-02 | 0.296000 | 1.16e-01 |
ACTIVATION OF THE PRE REPLICATIVE COMPLEX | 29 | 5.87e-03 | -0.296000 | 3.55e-02 |
DEGRADATION OF CYSTEINE AND HOMOCYSTEINE | 13 | 6.54e-02 | -0.295000 | 1.95e-01 |
APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B | 22 | 1.68e-02 | -0.295000 | 7.93e-02 |
OTHER SEMAPHORIN INTERACTIONS | 19 | 2.66e-02 | 0.294000 | 1.08e-01 |
KINESINS | 47 | 5.02e-04 | 0.293000 | 4.74e-03 |
INTERLEUKIN 12 FAMILY SIGNALING | 43 | 8.96e-04 | -0.293000 | 7.58e-03 |
CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE | 19 | 2.72e-02 | -0.293000 | 1.10e-01 |
REGULATION OF TLR BY ENDOGENOUS LIGAND | 14 | 5.82e-02 | -0.292000 | 1.80e-01 |
NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION | 58 | 1.27e-04 | -0.291000 | 1.41e-03 |
COOPERATION OF PDCL PHLP1 AND TRIC CCT IN G PROTEIN BETA FOLDING | 35 | 2.92e-03 | -0.291000 | 2.02e-02 |
FCERI MEDIATED NF KB ACTIVATION | 77 | 1.05e-05 | -0.290000 | 1.68e-04 |
BIOSYNTHESIS OF SPECIALIZED PRORESOLVING MEDIATORS SPMS | 12 | 8.30e-02 | -0.289000 | 2.32e-01 |
REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMENTS | 85 | 4.34e-06 | -0.288000 | 8.55e-05 |
G BETA GAMMA SIGNALLING THROUGH PI3KGAMMA | 24 | 1.46e-02 | -0.288000 | 7.13e-02 |
PHASE 2 PLATEAU PHASE | 12 | 8.41e-02 | 0.288000 | 2.35e-01 |
FOXO MEDIATED TRANSCRIPTION OF CELL CYCLE GENES | 16 | 4.74e-02 | -0.286000 | 1.58e-01 |
PYROPTOSIS | 21 | 2.34e-02 | -0.286000 | 1.00e-01 |
RNA POLYMERASE III CHAIN ELONGATION | 18 | 3.63e-02 | -0.285000 | 1.31e-01 |
RESPONSE OF EIF2AK4 GCN2 TO AMINO ACID DEFICIENCY | 96 | 1.46e-06 | -0.285000 | 3.72e-05 |
PURINE CATABOLISM | 16 | 4.89e-02 | -0.284000 | 1.61e-01 |
SIGNALING BY NOTCH1 HD DOMAIN MUTANTS IN CANCER | 15 | 5.70e-02 | 0.284000 | 1.78e-01 |
DEGRADATION OF BETA CATENIN BY THE DESTRUCTION COMPLEX | 83 | 7.90e-06 | -0.284000 | 1.35e-04 |
RESOLUTION OF AP SITES VIA THE MULTIPLE NUCLEOTIDE PATCH REPLACEMENT PATHWAY | 24 | 1.61e-02 | -0.284000 | 7.73e-02 |
SULFUR AMINO ACID METABOLISM | 23 | 1.87e-02 | -0.283000 | 8.49e-02 |
TERMINATION OF TRANSLESION DNA SYNTHESIS | 31 | 6.57e-03 | -0.282000 | 3.87e-02 |
ANTIGEN PROCESSING CROSS PRESENTATION | 99 | 1.27e-06 | -0.282000 | 3.41e-05 |
RRNA PROCESSING IN THE MITOCHONDRION | 10 | 1.23e-01 | -0.281000 | 2.95e-01 |
PROCESSIVE SYNTHESIS ON THE C STRAND OF THE TELOMERE | 19 | 3.38e-02 | -0.281000 | 1.25e-01 |
DEFECTIVE EXT2 CAUSES EXOSTOSES 2 | 14 | 6.86e-02 | 0.281000 | 2.01e-01 |
METABOLISM OF COFACTORS | 19 | 3.41e-02 | -0.281000 | 1.25e-01 |
SIGNALING BY FGFR2 IIIA TM | 19 | 3.58e-02 | -0.278000 | 1.30e-01 |
MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES | 31 | 7.36e-03 | -0.278000 | 4.22e-02 |
FORMATION OF APOPTOSOME | 10 | 1.28e-01 | -0.278000 | 3.00e-01 |
PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR | 17 | 4.81e-02 | -0.277000 | 1.60e-01 |
FORMATION OF TC NER PRE INCISION COMPLEX | 53 | 4.95e-04 | -0.277000 | 4.70e-03 |
REGULATION OF MECP2 EXPRESSION AND ACTIVITY | 30 | 9.05e-03 | 0.275000 | 4.92e-02 |
ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA | 15 | 6.48e-02 | -0.275000 | 1.94e-01 |
HEDGEHOG LIGAND BIOGENESIS | 62 | 1.78e-04 | -0.275000 | 1.91e-03 |
TRANSLESION SYNTHESIS BY POLK | 17 | 5.02e-02 | -0.274000 | 1.64e-01 |
SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 7ALPHA HYDROXYCHOLESTEROL | 13 | 8.69e-02 | 0.274000 | 2.39e-01 |
EUKARYOTIC TRANSLATION ELONGATION | 88 | 8.99e-06 | -0.274000 | 1.47e-04 |
ATF6 ATF6 ALPHA ACTIVATES CHAPERONES | 12 | 1.01e-01 | -0.273000 | 2.57e-01 |
TELOMERE C STRAND LAGGING STRAND SYNTHESIS | 33 | 6.92e-03 | -0.272000 | 4.03e-02 |
G1 S DNA DAMAGE CHECKPOINTS | 66 | 1.37e-04 | -0.272000 | 1.51e-03 |
POLYMERASE SWITCHING | 14 | 7.89e-02 | -0.271000 | 2.22e-01 |
TRANSLESION SYNTHESIS BY POLH | 19 | 4.12e-02 | -0.271000 | 1.44e-01 |
MRNA CAPPING | 29 | 1.22e-02 | -0.269000 | 6.24e-02 |
REGULATION OF RAS BY GAPS | 67 | 1.43e-04 | -0.269000 | 1.55e-03 |
HS GAG DEGRADATION | 21 | 3.35e-02 | 0.268000 | 1.25e-01 |
ATF6 ATF6 ALPHA ACTIVATES CHAPERONE GENES | 10 | 1.45e-01 | -0.266000 | 3.24e-01 |
COMMON PATHWAY OF FIBRIN CLOT FORMATION | 11 | 1.26e-01 | -0.266000 | 2.98e-01 |
NEUREXINS AND NEUROLIGINS | 54 | 7.62e-04 | 0.265000 | 6.76e-03 |
FORMATION OF INCISION COMPLEX IN GG NER | 43 | 2.67e-03 | -0.265000 | 1.90e-02 |
IRON UPTAKE AND TRANSPORT | 52 | 9.76e-04 | -0.264000 | 8.11e-03 |
LAGGING STRAND SYNTHESIS | 20 | 4.12e-02 | -0.264000 | 1.44e-01 |
HYALURONAN METABOLISM | 16 | 6.80e-02 | 0.264000 | 2.00e-01 |
INTERLEUKIN 7 SIGNALING | 19 | 4.68e-02 | 0.263000 | 1.57e-01 |
CLEC7A DECTIN 1 SIGNALING | 95 | 9.54e-06 | -0.263000 | 1.54e-04 |
GLUTATHIONE SYNTHESIS AND RECYCLING | 11 | 1.31e-01 | -0.263000 | 3.05e-01 |
DNA DAMAGE BYPASS | 47 | 1.87e-03 | -0.262000 | 1.42e-02 |
BUTYRATE RESPONSE FACTOR 1 BRF1 BINDS AND DESTABILIZES MRNA | 16 | 7.17e-02 | -0.260000 | 2.09e-01 |
FGFR2 MUTANT RECEPTOR ACTIVATION | 27 | 1.95e-02 | -0.260000 | 8.68e-02 |
NRAGE SIGNALS DEATH THROUGH JNK | 55 | 9.00e-04 | 0.259000 | 7.58e-03 |
GP1B IX V ACTIVATION SIGNALLING | 11 | 1.38e-01 | 0.259000 | 3.16e-01 |
INTERLEUKIN RECEPTOR SHC SIGNALING | 20 | 4.57e-02 | 0.258000 | 1.54e-01 |
RHOC GTPASE CYCLE | 74 | 1.25e-04 | 0.258000 | 1.41e-03 |
RNA POLYMERASE III TRANSCRIPTION TERMINATION | 23 | 3.23e-02 | -0.258000 | 1.22e-01 |
NOTCH4 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION | 20 | 4.67e-02 | 0.257000 | 1.57e-01 |
RHO GTPASES ACTIVATE WASPS AND WAVES | 36 | 7.79e-03 | -0.256000 | 4.38e-02 |
INTERLEUKIN 15 SIGNALING | 12 | 1.25e-01 | 0.256000 | 2.96e-01 |
MITOPHAGY | 29 | 1.71e-02 | -0.256000 | 8.05e-02 |
POLYMERASE SWITCHING ON THE C STRAND OF THE TELOMERE | 25 | 2.70e-02 | -0.256000 | 1.09e-01 |
RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF HSCS | 85 | 4.68e-05 | -0.256000 | 6.28e-04 |
PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE | 51 | 1.61e-03 | -0.255000 | 1.24e-02 |
RHOB GTPASE CYCLE | 68 | 2.79e-04 | 0.255000 | 2.86e-03 |
ATF4 ACTIVATES GENES IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 23 | 3.46e-02 | -0.255000 | 1.27e-01 |
TRISTETRAPROLIN TTP ZFP36 BINDS AND DESTABILIZES MRNA | 16 | 7.87e-02 | -0.254000 | 2.22e-01 |
CYTOCHROME C MEDIATED APOPTOTIC RESPONSE | 12 | 1.28e-01 | -0.254000 | 3.00e-01 |
PINK1 PRKN MEDIATED MITOPHAGY | 22 | 3.95e-02 | -0.254000 | 1.41e-01 |
HEME BIOSYNTHESIS | 13 | 1.14e-01 | -0.253000 | 2.79e-01 |
REGULATION OF EXPRESSION OF SLITS AND ROBOS | 165 | 2.24e-08 | -0.252000 | 1.20e-06 |
RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASES | 20 | 5.07e-02 | 0.252000 | 1.65e-01 |
SELENOAMINO ACID METABOLISM | 110 | 5.04e-06 | -0.252000 | 9.06e-05 |
REGULATED NECROSIS | 46 | 3.12e-03 | -0.252000 | 2.11e-02 |
DETOXIFICATION OF REACTIVE OXYGEN SPECIES | 34 | 1.11e-02 | -0.252000 | 5.84e-02 |
G2 M CHECKPOINTS | 136 | 4.10e-07 | -0.252000 | 1.31e-05 |
METABOLISM OF PORPHYRINS | 19 | 5.81e-02 | -0.251000 | 1.80e-01 |
NA CL DEPENDENT NEUROTRANSMITTER TRANSPORTERS | 15 | 9.25e-02 | 0.251000 | 2.46e-01 |
RNA POLYMERASE I PROMOTER ESCAPE | 48 | 2.65e-03 | -0.251000 | 1.89e-02 |
DERMATAN SULFATE BIOSYNTHESIS | 11 | 1.50e-01 | 0.250000 | 3.34e-01 |
CS DS DEGRADATION | 14 | 1.06e-01 | 0.250000 | 2.65e-01 |
PROTEIN PROTEIN INTERACTIONS AT SYNAPSES | 85 | 7.63e-05 | 0.248000 | 9.27e-04 |
HOST INTERACTIONS OF HIV FACTORS | 126 | 1.54e-06 | -0.248000 | 3.78e-05 |
ENOS ACTIVATION | 11 | 1.54e-01 | -0.248000 | 3.39e-01 |
CELLULAR RESPONSE TO STARVATION | 147 | 2.30e-07 | -0.247000 | 8.22e-06 |
TELOMERE C STRAND SYNTHESIS INITIATION | 13 | 1.23e-01 | -0.247000 | 2.94e-01 |
GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR GG NER | 83 | 1.10e-04 | -0.246000 | 1.28e-03 |
ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS | 33 | 1.47e-02 | -0.245000 | 7.19e-02 |
PROCESSIVE SYNTHESIS ON THE LAGGING STRAND | 15 | 1.00e-01 | -0.245000 | 2.57e-01 |
VOLTAGE GATED POTASSIUM CHANNELS | 39 | 8.06e-03 | 0.245000 | 4.50e-02 |
ERKS ARE INACTIVATED | 13 | 1.26e-01 | -0.245000 | 2.97e-01 |
REGULATION OF GENE EXPRESSION IN LATE STAGE BRANCHING MORPHOGENESIS PANCREATIC BUD PRECURSOR CELLS | 15 | 1.01e-01 | 0.245000 | 2.57e-01 |
ACTIVATION OF THE AP 1 FAMILY OF TRANSCRIPTION FACTORS | 10 | 1.80e-01 | -0.245000 | 3.76e-01 |
ASYMMETRIC LOCALIZATION OF PCP PROTEINS | 63 | 7.99e-04 | -0.244000 | 7.00e-03 |
ANCHORING FIBRIL FORMATION | 14 | 1.16e-01 | 0.243000 | 2.81e-01 |
METABOLISM OF NITRIC OXIDE NOS3 ACTIVATION AND REGULATION | 15 | 1.04e-01 | -0.243000 | 2.62e-01 |
DUAL INCISION IN TC NER | 64 | 8.02e-04 | -0.242000 | 7.00e-03 |
C TYPE LECTIN RECEPTORS CLRS | 116 | 6.82e-06 | -0.242000 | 1.18e-04 |
CITRIC ACID CYCLE TCA CYCLE | 22 | 4.96e-02 | -0.242000 | 1.63e-01 |
GAP FILLING DNA REPAIR SYNTHESIS AND LIGATION IN GG NER | 24 | 4.04e-02 | -0.242000 | 1.43e-01 |
CYCLIN D ASSOCIATED EVENTS IN G1 | 45 | 5.16e-03 | -0.241000 | 3.20e-02 |
SEMA4D INDUCED CELL MIGRATION AND GROWTH CONE COLLAPSE | 20 | 6.31e-02 | 0.240000 | 1.91e-01 |
TNFR2 NON CANONICAL NF KB PATHWAY | 82 | 1.80e-04 | -0.239000 | 1.92e-03 |
CONDENSATION OF PROPHASE CHROMOSOMES | 29 | 2.60e-02 | -0.239000 | 1.07e-01 |
TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR TC NER | 77 | 2.98e-04 | -0.238000 | 3.01e-03 |
SIGNALING BY NTRK3 TRKC | 17 | 8.94e-02 | 0.238000 | 2.42e-01 |
MITOCHONDRIAL IRON SULFUR CLUSTER BIOGENESIS | 13 | 1.41e-01 | -0.236000 | 3.20e-01 |
PEROXISOMAL PROTEIN IMPORT | 58 | 1.92e-03 | -0.236000 | 1.45e-02 |
INHIBITION OF DNA RECOMBINATION AT TELOMERE | 36 | 1.45e-02 | -0.236000 | 7.11e-02 |
PHASE 0 RAPID DEPOLARISATION | 28 | 3.22e-02 | 0.234000 | 1.22e-01 |
BILE ACID AND BILE SALT METABOLISM | 25 | 4.31e-02 | 0.234000 | 1.49e-01 |
SUPPRESSION OF PHAGOSOMAL MATURATION | 12 | 1.62e-01 | -0.233000 | 3.51e-01 |
SIGNALING BY THE B CELL RECEPTOR BCR | 104 | 4.22e-05 | -0.232000 | 5.72e-04 |
TETRAHYDROBIOPTERIN BH4 SYNTHESIS RECYCLING SALVAGE AND REGULATION | 10 | 2.03e-01 | -0.232000 | 4.07e-01 |
CDC42 GTPASE CYCLE | 154 | 6.78e-07 | 0.232000 | 1.99e-05 |
FGFR1 LIGAND BINDING AND ACTIVATION | 10 | 2.05e-01 | -0.232000 | 4.07e-01 |
HIV INFECTION | 222 | 2.88e-09 | -0.231000 | 2.00e-07 |
SEPARATION OF SISTER CHROMATIDS | 166 | 2.71e-07 | -0.231000 | 9.40e-06 |
ECM PROTEOGLYCANS | 66 | 1.17e-03 | 0.231000 | 9.48e-03 |
TICAM1 RIP1 MEDIATED IKK COMPLEX RECRUITMENT | 18 | 8.97e-02 | -0.231000 | 2.43e-01 |
FERTILIZATION | 13 | 1.50e-01 | 0.231000 | 3.34e-01 |
THE NLRP3 INFLAMMASOME | 14 | 1.36e-01 | -0.230000 | 3.14e-01 |
TRIGLYCERIDE METABOLISM | 24 | 5.21e-02 | -0.229000 | 1.68e-01 |
INTERFERON GAMMA SIGNALING | 79 | 4.36e-04 | -0.229000 | 4.21e-03 |
SIGNALING BY NOTCH4 | 83 | 3.47e-04 | -0.227000 | 3.41e-03 |
MITOCHONDRIAL CALCIUM ION TRANSPORT | 23 | 6.00e-02 | -0.227000 | 1.84e-01 |
TRANSLESION SYNTHESIS BY Y FAMILY DNA POLYMERASES BYPASSES LESIONS ON DNA TEMPLATE | 38 | 1.57e-02 | -0.227000 | 7.54e-02 |
SEROTONIN NEUROTRANSMITTER RELEASE CYCLE | 18 | 9.65e-02 | 0.226000 | 2.51e-01 |
MAPK6 MAPK4 SIGNALING | 85 | 3.14e-04 | -0.226000 | 3.11e-03 |
CELLULAR RESPONSE TO CHEMICAL STRESS | 152 | 1.77e-06 | -0.225000 | 4.18e-05 |
STAT5 ACTIVATION DOWNSTREAM OF FLT3 ITD MUTANTS | 10 | 2.20e-01 | 0.224000 | 4.25e-01 |
FORMATION OF FIBRIN CLOT CLOTTING CASCADE | 21 | 7.62e-02 | -0.224000 | 2.19e-01 |
RIPK1 MEDIATED REGULATED NECROSIS | 25 | 5.37e-02 | -0.223000 | 1.71e-01 |
SIGNALING BY FGFR2 IN DISEASE | 37 | 1.92e-02 | -0.222000 | 8.63e-02 |
METALLOPROTEASE DUBS | 25 | 5.44e-02 | -0.222000 | 1.73e-01 |
DOPAMINE NEUROTRANSMITTER RELEASE CYCLE | 23 | 6.61e-02 | 0.221000 | 1.96e-01 |
CYTOPROTECTION BY HMOX1 | 119 | 3.13e-05 | -0.221000 | 4.39e-04 |
NONSENSE MEDIATED DECAY NMD | 110 | 6.31e-05 | -0.221000 | 8.09e-04 |
MISMATCH REPAIR | 14 | 1.53e-01 | -0.221000 | 3.36e-01 |
GLYOXYLATE METABOLISM AND GLYCINE DEGRADATION | 26 | 5.16e-02 | -0.221000 | 1.67e-01 |
INFLUENZA INFECTION | 146 | 4.88e-06 | -0.219000 | 9.06e-05 |
MITOTIC METAPHASE AND ANAPHASE | 208 | 5.59e-08 | -0.219000 | 2.53e-06 |
DISEASES OF MITOTIC CELL CYCLE | 37 | 2.15e-02 | -0.218000 | 9.36e-02 |
ASPARTATE AND ASPARAGINE METABOLISM | 11 | 2.10e-01 | -0.218000 | 4.11e-01 |
NICOTINAMIDE SALVAGING | 15 | 1.44e-01 | -0.218000 | 3.24e-01 |
CHOLESTEROL BIOSYNTHESIS | 24 | 6.59e-02 | -0.217000 | 1.96e-01 |
NEUROTOXICITY OF CLOSTRIDIUM TOXINS | 10 | 2.35e-01 | 0.217000 | 4.44e-01 |
NCAM1 INTERACTIONS | 41 | 1.63e-02 | 0.217000 | 7.76e-02 |
METABOLISM OF AMINO ACIDS AND DERIVATIVES | 320 | 2.92e-11 | -0.217000 | 4.92e-09 |
NUCLEOTIDE EXCISION REPAIR | 109 | 1.02e-04 | -0.216000 | 1.21e-03 |
OLFACTORY SIGNALING PATHWAY | 33 | 3.28e-02 | 0.215000 | 1.23e-01 |
BLOOD GROUP SYSTEMS BIOSYNTHESIS | 14 | 1.67e-01 | -0.214000 | 3.59e-01 |
SIRT1 NEGATIVELY REGULATES RRNA EXPRESSION | 25 | 6.46e-02 | -0.214000 | 1.94e-01 |
ION TRANSPORT BY P TYPE ATPASES | 51 | 8.42e-03 | 0.213000 | 4.64e-02 |
EFFECTS OF PIP2 HYDROLYSIS | 27 | 5.55e-02 | 0.213000 | 1.76e-01 |
NEPHRIN FAMILY INTERACTIONS | 23 | 7.72e-02 | 0.213000 | 2.20e-01 |
GLYCOGEN SYNTHESIS | 14 | 1.70e-01 | -0.212000 | 3.61e-01 |
SYNTHESIS OF BILE ACIDS AND BILE SALTS | 22 | 8.54e-02 | 0.212000 | 2.37e-01 |
CELL CYCLE CHECKPOINTS | 244 | 1.32e-08 | -0.211000 | 7.41e-07 |
BIOSYNTHESIS OF THE N GLYCAN PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND TRANSFER TO A NASCENT PROTEIN | 76 | 1.45e-03 | -0.211000 | 1.15e-02 |
PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS | 12 | 2.05e-01 | -0.211000 | 4.07e-01 |
SYNTHESIS OF PROSTAGLANDINS PG AND THROMBOXANES TX | 13 | 1.88e-01 | -0.211000 | 3.85e-01 |
ERK MAPK TARGETS | 22 | 8.71e-02 | -0.211000 | 2.39e-01 |
REGULATION OF TP53 ACTIVITY THROUGH ASSOCIATION WITH CO FACTORS | 14 | 1.74e-01 | 0.210000 | 3.67e-01 |
FC EPSILON RECEPTOR FCERI SIGNALING | 124 | 5.57e-05 | -0.210000 | 7.30e-04 |
PKA MEDIATED PHOSPHORYLATION OF CREB | 19 | 1.14e-01 | 0.210000 | 2.79e-01 |
ACTIVATION OF GENE EXPRESSION BY SREBF SREBP | 43 | 1.75e-02 | 0.209000 | 8.17e-02 |
HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE | 40 | 2.20e-02 | -0.209000 | 9.45e-02 |
PRE NOTCH PROCESSING IN GOLGI | 18 | 1.25e-01 | 0.209000 | 2.96e-01 |
INSERTION OF TAIL ANCHORED PROTEINS INTO THE ENDOPLASMIC RETICULUM MEMBRANE | 22 | 9.02e-02 | -0.209000 | 2.43e-01 |
G PROTEIN BETA GAMMA SIGNALLING | 31 | 4.49e-02 | -0.208000 | 1.54e-01 |
RRNA PROCESSING | 195 | 5.69e-07 | -0.208000 | 1.72e-05 |
TCR SIGNALING | 102 | 2.96e-04 | -0.207000 | 3.01e-03 |
DEPOLYMERISATION OF THE NUCLEAR LAMINA | 14 | 1.82e-01 | -0.206000 | 3.77e-01 |
APOPTOTIC FACTOR MEDIATED RESPONSE | 18 | 1.30e-01 | -0.206000 | 3.03e-01 |
DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN METABOLISM | 39 | 2.61e-02 | 0.206000 | 1.07e-01 |
NRIF SIGNALS CELL DEATH FROM THE NUCLEUS | 17 | 1.43e-01 | -0.205000 | 3.22e-01 |
SYNTHESIS OF SUBSTRATES IN N GLYCAN BIOSYTHESIS | 62 | 5.26e-03 | -0.205000 | 3.21e-02 |
METABOLISM OF ANGIOTENSINOGEN TO ANGIOTENSINS | 10 | 2.62e-01 | -0.205000 | 4.75e-01 |
ROLE OF PHOSPHOLIPIDS IN PHAGOCYTOSIS | 22 | 9.80e-02 | 0.204000 | 2.54e-01 |
SHC MEDIATED CASCADE FGFR1 | 16 | 1.58e-01 | -0.204000 | 3.46e-01 |
G0 AND EARLY G1 | 25 | 7.80e-02 | -0.204000 | 2.21e-01 |
INITIATION OF NUCLEAR ENVELOPE NE REFORMATION | 18 | 1.38e-01 | -0.202000 | 3.16e-01 |
DUAL INCISION IN GG NER | 40 | 2.74e-02 | -0.202000 | 1.10e-01 |
INTERLEUKIN 2 FAMILY SIGNALING | 32 | 4.88e-02 | 0.201000 | 1.61e-01 |
COPII MEDIATED VESICLE TRANSPORT | 66 | 4.83e-03 | -0.201000 | 3.08e-02 |
SARS COV 1 INFECTION | 48 | 1.68e-02 | -0.199000 | 7.93e-02 |
NOTCH2 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION | 11 | 2.54e-01 | 0.199000 | 4.66e-01 |
INTERLEUKIN 1 SIGNALING | 96 | 8.60e-04 | -0.197000 | 7.40e-03 |
CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM | 48 | 1.90e-02 | 0.196000 | 8.57e-02 |
INOSITOL PHOSPHATE METABOLISM | 46 | 2.20e-02 | 0.195000 | 9.45e-02 |
FCERI MEDIATED MAPK ACTIVATION | 28 | 7.38e-02 | -0.195000 | 2.14e-01 |
UCH PROTEINASES | 90 | 1.38e-03 | -0.195000 | 1.10e-02 |
TRANSCRIPTION OF THE HIV GENOME | 67 | 5.96e-03 | -0.194000 | 3.58e-02 |
FATTY ACID METABOLISM | 146 | 5.12e-05 | -0.194000 | 6.78e-04 |
NEGATIVE EPIGENETIC REGULATION OF RRNA EXPRESSION | 66 | 6.36e-03 | -0.194000 | 3.77e-02 |
ABC TRANSPORTER DISORDERS | 71 | 4.70e-03 | -0.194000 | 3.03e-02 |
SIGNALING BY ROBO RECEPTORS | 210 | 1.31e-06 | -0.194000 | 3.43e-05 |
PROGRAMMED CELL DEATH | 188 | 5.07e-06 | -0.193000 | 9.06e-05 |
MTORC1 MEDIATED SIGNALLING | 24 | 1.02e-01 | -0.193000 | 2.59e-01 |
EXTRA NUCLEAR ESTROGEN SIGNALING | 68 | 6.05e-03 | -0.193000 | 3.62e-02 |
REGULATION OF GENE EXPRESSION BY HYPOXIA INDUCIBLE FACTOR | 10 | 2.93e-01 | 0.192000 | 5.10e-01 |
DNA DAMAGE RECOGNITION IN GG NER | 38 | 4.06e-02 | -0.192000 | 1.43e-01 |
CHONDROITIN SULFATE BIOSYNTHESIS | 18 | 1.59e-01 | 0.192000 | 3.46e-01 |
RAF ACTIVATION | 34 | 5.30e-02 | -0.192000 | 1.70e-01 |
PKMTS METHYLATE HISTONE LYSINES | 49 | 2.10e-02 | 0.191000 | 9.24e-02 |
SIALIC ACID METABOLISM | 32 | 6.29e-02 | -0.190000 | 1.91e-01 |
FATTY ACYL COA BIOSYNTHESIS | 32 | 6.32e-02 | -0.190000 | 1.91e-01 |
PEROXISOMAL LIPID METABOLISM | 26 | 9.40e-02 | -0.190000 | 2.47e-01 |
INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1 | 13 | 2.36e-01 | -0.190000 | 4.46e-01 |
IRF3 MEDIATED INDUCTION OF TYPE I IFN | 11 | 2.77e-01 | 0.189000 | 4.92e-01 |
PIWI INTERACTING RNA PIRNA BIOGENESIS | 19 | 1.53e-01 | -0.189000 | 3.37e-01 |
ZINC INFLUX INTO CELLS BY THE SLC39 GENE FAMILY | 10 | 3.02e-01 | 0.189000 | 5.19e-01 |
INTERFERON SIGNALING | 167 | 2.75e-05 | -0.188000 | 3.95e-04 |
ANTIMICROBIAL PEPTIDES | 17 | 1.79e-01 | -0.188000 | 3.75e-01 |
MRNA DECAY BY 3 TO 5 EXORIBONUCLEASE | 15 | 2.07e-01 | -0.188000 | 4.09e-01 |
COSTIMULATION BY THE CD28 FAMILY | 50 | 2.15e-02 | -0.188000 | 9.36e-02 |
CYCLIN A B1 B2 ASSOCIATED EVENTS DURING G2 M TRANSITION | 23 | 1.22e-01 | -0.186000 | 2.94e-01 |
RHOA GTPASE CYCLE | 143 | 1.25e-04 | 0.186000 | 1.41e-03 |
RUNX2 REGULATES BONE DEVELOPMENT | 29 | 8.47e-02 | 0.185000 | 2.36e-01 |
ARACHIDONIC ACID METABOLISM | 40 | 4.34e-02 | -0.185000 | 1.50e-01 |
IRE1ALPHA ACTIVATES CHAPERONES | 50 | 2.40e-02 | 0.185000 | 1.01e-01 |
PCP CE PATHWAY | 90 | 2.53e-03 | -0.184000 | 1.83e-02 |
INFECTION WITH MYCOBACTERIUM TUBERCULOSIS | 24 | 1.19e-01 | -0.184000 | 2.87e-01 |
N GLYCAN ANTENNAE ELONGATION | 15 | 2.18e-01 | -0.184000 | 4.22e-01 |
DAG AND IP3 SIGNALING | 40 | 4.48e-02 | 0.183000 | 1.54e-01 |
REGULATION OF GENE EXPRESSION IN BETA CELLS | 12 | 2.71e-01 | -0.183000 | 4.86e-01 |
NUCLEOBASE BIOSYNTHESIS | 15 | 2.21e-01 | -0.182000 | 4.26e-01 |
RND2 GTPASE CYCLE | 39 | 4.99e-02 | 0.182000 | 1.64e-01 |
G2 M DNA DAMAGE CHECKPOINT | 67 | 1.04e-02 | -0.181000 | 5.55e-02 |
SARS COV 2 INFECTION | 65 | 1.17e-02 | -0.181000 | 6.11e-02 |
SEMA4D IN SEMAPHORIN SIGNALING | 24 | 1.26e-01 | 0.181000 | 2.97e-01 |
INTERLEUKIN 20 FAMILY SIGNALING | 14 | 2.42e-01 | 0.180000 | 4.53e-01 |
CYTOSOLIC IRON SULFUR CLUSTER ASSEMBLY | 13 | 2.60e-01 | 0.180000 | 4.74e-01 |
SEALING OF THE NUCLEAR ENVELOPE NE BY ESCRT III | 23 | 1.35e-01 | -0.180000 | 3.11e-01 |
SYNTHESIS OF PA | 29 | 9.33e-02 | 0.180000 | 2.46e-01 |
APOPTOSIS | 166 | 6.55e-05 | -0.180000 | 8.30e-04 |
BIOLOGICAL OXIDATIONS | 125 | 5.38e-04 | -0.179000 | 4.96e-03 |
SIGNALING BY CTNNB1 PHOSPHO SITE MUTANTS | 15 | 2.29e-01 | -0.179000 | 4.36e-01 |
DISEASES OF PROGRAMMED CELL DEATH | 55 | 2.17e-02 | -0.179000 | 9.39e-02 |
ELEVATION OF CYTOSOLIC CA2 LEVELS | 14 | 2.47e-01 | 0.179000 | 4.58e-01 |
LAMININ INTERACTIONS | 28 | 1.03e-01 | 0.178000 | 2.61e-01 |
REGULATION OF TP53 ACTIVITY THROUGH ACETYLATION | 30 | 9.20e-02 | 0.178000 | 2.45e-01 |
RNA POLYMERASE I TRANSCRIPTION TERMINATION | 31 | 8.76e-02 | -0.177000 | 2.40e-01 |
G1 S SPECIFIC TRANSCRIPTION | 27 | 1.11e-01 | -0.177000 | 2.74e-01 |
CHROMOSOME MAINTENANCE | 102 | 2.03e-03 | -0.177000 | 1.52e-02 |
PTK6 REGULATES RHO GTPASES RAS GTPASE AND MAP KINASES | 13 | 2.72e-01 | -0.176000 | 4.86e-01 |
CHAPERONE MEDIATED AUTOPHAGY | 21 | 1.65e-01 | -0.175000 | 3.57e-01 |
RECOGNITION AND ASSOCIATION OF DNA GLYCOSYLASE WITH SITE CONTAINING AN AFFECTED PURINE | 23 | 1.46e-01 | -0.175000 | 3.27e-01 |
AMINO ACIDS REGULATE MTORC1 | 51 | 3.10e-02 | -0.175000 | 1.20e-01 |
NCAM SIGNALING FOR NEURITE OUT GROWTH | 61 | 1.86e-02 | 0.174000 | 8.47e-02 |
TRAFFICKING OF AMPA RECEPTORS | 31 | 9.36e-02 | 0.174000 | 2.46e-01 |
DEPOSITION OF NEW CENPA CONTAINING NUCLEOSOMES AT THE CENTROMERE | 38 | 6.38e-02 | -0.174000 | 1.92e-01 |
CASPASE ACTIVATION VIA DEATH RECEPTORS IN THE PRESENCE OF LIGAND | 14 | 2.61e-01 | -0.174000 | 4.74e-01 |
ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS | 32 | 9.02e-02 | 0.173000 | 2.43e-01 |
HIV LIFE CYCLE | 142 | 3.78e-04 | -0.173000 | 3.68e-03 |
CASPASE MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS | 12 | 3.00e-01 | 0.173000 | 5.19e-01 |
SIGNALING BY CYTOSOLIC FGFR1 FUSION MUTANTS | 18 | 2.05e-01 | 0.173000 | 4.07e-01 |
MITOTIC PROPHASE | 96 | 3.56e-03 | -0.172000 | 2.37e-02 |
TELOMERE MAINTENANCE | 79 | 8.20e-03 | -0.172000 | 4.54e-02 |
TNFR1 INDUCED NFKAPPAB SIGNALING PATHWAY | 29 | 1.09e-01 | 0.172000 | 2.70e-01 |
TRANSCRIPTIONAL REGULATION OF PLURIPOTENT STEM CELLS | 18 | 2.07e-01 | 0.172000 | 4.09e-01 |
TP53 REGULATES TRANSCRIPTION OF ADDITIONAL CELL CYCLE GENES WHOSE EXACT ROLE IN THE P53 PATHWAY REMAIN UNCERTAIN | 20 | 1.84e-01 | -0.172000 | 3.80e-01 |
SENSORY PROCESSING OF SOUND BY OUTER HAIR CELLS OF THE COCHLEA | 41 | 5.78e-02 | 0.171000 | 1.80e-01 |
MET PROMOTES CELL MOTILITY | 38 | 6.80e-02 | 0.171000 | 2.00e-01 |
NEDDYLATION | 221 | 1.21e-05 | -0.171000 | 1.88e-04 |
REGULATION OF FOXO TRANSCRIPTIONAL ACTIVITY BY ACETYLATION | 10 | 3.50e-01 | -0.171000 | 5.66e-01 |
BETA CATENIN PHOSPHORYLATION CASCADE | 16 | 2.38e-01 | -0.171000 | 4.47e-01 |
SEMAPHORIN INTERACTIONS | 64 | 1.85e-02 | 0.170000 | 8.47e-02 |
RHO GTPASES ACTIVATE KTN1 | 11 | 3.30e-01 | -0.169000 | 5.44e-01 |
LATE ENDOSOMAL MICROAUTOPHAGY | 32 | 9.81e-02 | -0.169000 | 2.54e-01 |
GAMMA CARBOXYLATION HYPUSINE FORMATION AND ARYLSULFATASE ACTIVATION | 30 | 1.09e-01 | -0.169000 | 2.70e-01 |
ZBP1 DAI MEDIATED INDUCTION OF TYPE I IFNS | 18 | 2.15e-01 | 0.169000 | 4.18e-01 |
INTRINSIC PATHWAY OF FIBRIN CLOT FORMATION | 13 | 2.92e-01 | -0.169000 | 5.10e-01 |
NEGATIVE REGULATORS OF DDX58 IFIH1 SIGNALING | 34 | 8.91e-02 | -0.169000 | 2.42e-01 |
CARGO CONCENTRATION IN THE ER | 31 | 1.05e-01 | -0.168000 | 2.65e-01 |
MECP2 REGULATES NEURONAL RECEPTORS AND CHANNELS | 18 | 2.17e-01 | 0.168000 | 4.20e-01 |
CROSSLINKING OF COLLAGEN FIBRILS | 16 | 2.45e-01 | 0.168000 | 4.57e-01 |
DOWNREGULATION OF TGF BETA RECEPTOR SIGNALING | 26 | 1.39e-01 | -0.168000 | 3.18e-01 |
CLASS C 3 METABOTROPIC GLUTAMATE PHEROMONE RECEPTORS | 12 | 3.16e-01 | 0.167000 | 5.31e-01 |
CONSTITUTIVE SIGNALING BY OVEREXPRESSED ERBB2 | 11 | 3.38e-01 | -0.167000 | 5.52e-01 |
GLUCAGON TYPE LIGAND RECEPTORS | 26 | 1.41e-01 | -0.167000 | 3.20e-01 |
FGFRL1 MODULATION OF FGFR1 SIGNALING | 10 | 3.61e-01 | -0.167000 | 5.73e-01 |
RAC1 GTPASE CYCLE | 179 | 1.22e-04 | 0.167000 | 1.40e-03 |
INFLAMMASOMES | 18 | 2.21e-01 | -0.167000 | 4.26e-01 |
SHC1 EVENTS IN EGFR SIGNALING | 11 | 3.40e-01 | -0.166000 | 5.54e-01 |
MITOTIC SPINDLE CHECKPOINT | 96 | 4.99e-03 | -0.166000 | 3.15e-02 |
NF KB IS ACTIVATED AND SIGNALS SURVIVAL | 13 | 3.01e-01 | 0.166000 | 5.19e-01 |
INITIAL TRIGGERING OF COMPLEMENT | 13 | 3.05e-01 | 0.164000 | 5.21e-01 |
PI 3K CASCADE FGFR2 | 17 | 2.41e-01 | -0.164000 | 4.51e-01 |
GOLGI ASSOCIATED VESICLE BIOGENESIS | 55 | 3.53e-02 | -0.164000 | 1.29e-01 |
FGFR2 LIGAND BINDING AND ACTIVATION | 13 | 3.06e-01 | -0.164000 | 5.22e-01 |
G ALPHA 12 13 SIGNALLING EVENTS | 75 | 1.41e-02 | 0.164000 | 7.01e-02 |
CD28 CO STIMULATION | 31 | 1.15e-01 | -0.164000 | 2.79e-01 |
TRANSCRIPTIONAL REGULATION BY RUNX2 | 110 | 3.08e-03 | -0.163000 | 2.10e-02 |
RESOLUTION OF D LOOP STRUCTURES THROUGH SYNTHESIS DEPENDENT STRAND ANNEALING SDSA | 24 | 1.66e-01 | -0.163000 | 3.59e-01 |
ESTROGEN DEPENDENT NUCLEAR EVENTS DOWNSTREAM OF ESR MEMBRANE SIGNALING | 21 | 1.96e-01 | -0.163000 | 3.98e-01 |
DEADENYLATION OF MRNA | 25 | 1.59e-01 | -0.163000 | 3.46e-01 |
DAP12 INTERACTIONS | 30 | 1.23e-01 | -0.163000 | 2.94e-01 |
FORMATION OF THE EARLY ELONGATION COMPLEX | 33 | 1.06e-01 | -0.163000 | 2.65e-01 |
COLLAGEN BIOSYNTHESIS AND MODIFYING ENZYMES | 64 | 2.53e-02 | 0.162000 | 1.05e-01 |
CYTOSOLIC TRNA AMINOACYLATION | 24 | 1.71e-01 | -0.162000 | 3.62e-01 |
TICAM1 TRAF6 DEPENDENT INDUCTION OF TAK1 COMPLEX | 11 | 3.54e-01 | -0.161000 | 5.69e-01 |
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G1 CELL CYCLE ARREST | 13 | 3.14e-01 | 0.161000 | 5.31e-01 |
HDMS DEMETHYLATE HISTONES | 28 | 1.41e-01 | 0.161000 | 3.20e-01 |
TRANSPORT OF INORGANIC CATIONS ANIONS AND AMINO ACIDS OLIGOPEPTIDES | 87 | 9.70e-03 | 0.160000 | 5.25e-02 |
SIGNALING BY INSULIN RECEPTOR | 64 | 2.66e-02 | -0.160000 | 1.08e-01 |
NUCLEAR ENVELOPE NE REASSEMBLY | 65 | 2.55e-02 | -0.160000 | 1.06e-01 |
TRANSCRIPTIONAL REGULATION BY MECP2 | 60 | 3.21e-02 | 0.160000 | 1.22e-01 |
SCAVENGING OF HEME FROM PLASMA | 11 | 3.59e-01 | -0.160000 | 5.70e-01 |
CTLA4 INHIBITORY SIGNALING | 20 | 2.17e-01 | -0.160000 | 4.20e-01 |
SENSORY PROCESSING OF SOUND | 61 | 3.17e-02 | 0.159000 | 1.22e-01 |
RND3 GTPASE CYCLE | 38 | 9.17e-02 | 0.158000 | 2.45e-01 |
UNBLOCKING OF NMDA RECEPTORS GLUTAMATE BINDING AND ACTIVATION | 21 | 2.10e-01 | 0.158000 | 4.11e-01 |
SLBP DEPENDENT PROCESSING OF REPLICATION DEPENDENT HISTONE PRE MRNAS | 11 | 3.65e-01 | -0.158000 | 5.76e-01 |
TP53 REGULATES TRANSCRIPTION OF CELL DEATH GENES | 37 | 9.71e-02 | -0.158000 | 2.52e-01 |
REGULATION OF TP53 ACTIVITY THROUGH METHYLATION | 18 | 2.47e-01 | 0.158000 | 4.59e-01 |
SPHINGOLIPID DE NOVO BIOSYNTHESIS | 41 | 8.14e-02 | -0.157000 | 2.29e-01 |
P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS | 12 | 3.46e-01 | 0.157000 | 5.60e-01 |
SPHINGOLIPID METABOLISM | 79 | 1.62e-02 | -0.156000 | 7.75e-02 |
CELL CYCLE MITOTIC | 476 | 5.41e-09 | -0.156000 | 3.36e-07 |
PI 3K CASCADE FGFR1 | 16 | 2.80e-01 | -0.156000 | 4.96e-01 |
DISEASES OF GLYCOSYLATION | 126 | 2.49e-03 | 0.156000 | 1.81e-02 |
ASSEMBLY AND CELL SURFACE PRESENTATION OF NMDA RECEPTORS | 36 | 1.05e-01 | 0.156000 | 2.65e-01 |
STING MEDIATED INDUCTION OF HOST IMMUNE RESPONSES | 14 | 3.15e-01 | 0.155000 | 5.31e-01 |
BASE EXCISION REPAIR | 57 | 4.29e-02 | -0.155000 | 1.49e-01 |
NOREPINEPHRINE NEUROTRANSMITTER RELEASE CYCLE | 17 | 2.69e-01 | 0.155000 | 4.83e-01 |
GLYCOSPHINGOLIPID METABOLISM | 38 | 9.86e-02 | -0.155000 | 2.54e-01 |
DISEASES ASSOCIATED WITH N GLYCOSYLATION OF PROTEINS | 17 | 2.71e-01 | -0.154000 | 4.86e-01 |
G PROTEIN MEDIATED EVENTS | 51 | 5.75e-02 | 0.154000 | 1.79e-01 |
PLATELET SENSITIZATION BY LDL | 15 | 3.03e-01 | -0.154000 | 5.20e-01 |
NEUTROPHIL DEGRANULATION | 393 | 1.82e-07 | -0.154000 | 6.71e-06 |
FRS MEDIATED FGFR2 SIGNALING | 19 | 2.47e-01 | -0.154000 | 4.58e-01 |
METABOLISM OF RNA | 646 | 3.85e-11 | -0.153000 | 5.68e-09 |
HDR THROUGH HOMOLOGOUS RECOMBINATION HRR | 62 | 3.82e-02 | -0.152000 | 1.37e-01 |
SYNTHESIS OF PE | 13 | 3.42e-01 | 0.152000 | 5.57e-01 |
CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF ADENYLATE CYCLASE | 11 | 3.83e-01 | -0.152000 | 5.94e-01 |
TRANSPORT OF CONNEXONS TO THE PLASMA MEMBRANE | 13 | 3.43e-01 | -0.152000 | 5.57e-01 |
N GLYCAN ANTENNAE ELONGATION IN THE MEDIAL TRANS GOLGI | 24 | 1.98e-01 | -0.152000 | 4.02e-01 |
GPVI MEDIATED ACTIVATION CASCADE | 31 | 1.45e-01 | -0.151000 | 3.24e-01 |
FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION | 119 | 4.49e-03 | 0.151000 | 2.92e-02 |
ABC FAMILY PROTEINS MEDIATED TRANSPORT | 96 | 1.07e-02 | -0.151000 | 5.70e-02 |
M PHASE | 342 | 1.75e-06 | -0.151000 | 4.18e-05 |
RHOBTB2 GTPASE CYCLE | 23 | 2.11e-01 | -0.151000 | 4.12e-01 |
THE ROLE OF NEF IN HIV 1 REPLICATION AND DISEASE PATHOGENESIS | 27 | 1.76e-01 | -0.150000 | 3.69e-01 |
CELLULAR RESPONSES TO EXTERNAL STIMULI | 607 | 3.18e-10 | -0.150000 | 2.88e-08 |
METABOLISM OF NUCLEOTIDES | 92 | 1.30e-02 | -0.150000 | 6.52e-02 |
FCGR3A MEDIATED IL10 SYNTHESIS | 32 | 1.42e-01 | 0.150000 | 3.22e-01 |
INLB MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CELL | 15 | 3.15e-01 | -0.150000 | 5.31e-01 |
MUCOPOLYSACCHARIDOSES | 11 | 3.91e-01 | 0.150000 | 6.00e-01 |
RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER | 28 | 1.72e-01 | -0.149000 | 3.64e-01 |
HIV TRANSCRIPTION ELONGATION | 42 | 9.51e-02 | -0.149000 | 2.49e-01 |
PRE NOTCH EXPRESSION AND PROCESSING | 65 | 3.80e-02 | 0.149000 | 1.37e-01 |
GAP JUNCTION ASSEMBLY | 21 | 2.39e-01 | -0.148000 | 4.49e-01 |
DOWNREGULATION OF ERBB2 ERBB3 SIGNALING | 13 | 3.58e-01 | 0.147000 | 5.70e-01 |
NEGATIVE REGULATION OF MAPK PATHWAY | 42 | 9.88e-02 | -0.147000 | 2.54e-01 |
TRNA PROCESSING IN THE NUCLEUS | 56 | 5.69e-02 | -0.147000 | 1.78e-01 |
NICOTINATE METABOLISM | 25 | 2.03e-01 | -0.147000 | 4.07e-01 |
RA BIOSYNTHESIS PATHWAY | 15 | 3.25e-01 | -0.147000 | 5.38e-01 |
HSF1 ACTIVATION | 26 | 1.95e-01 | -0.147000 | 3.98e-01 |
GASTRIN CREB SIGNALLING PATHWAY VIA PKC AND MAPK | 16 | 3.10e-01 | -0.146000 | 5.26e-01 |
PURINE SALVAGE | 12 | 3.81e-01 | -0.146000 | 5.93e-01 |
CHROMATIN MODIFYING ENZYMES | 221 | 1.86e-04 | 0.146000 | 1.96e-03 |
FRS MEDIATED FGFR1 SIGNALING | 18 | 2.84e-01 | -0.146000 | 5.01e-01 |
CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION | 352 | 3.01e-06 | -0.145000 | 6.56e-05 |
RMTS METHYLATE HISTONE ARGININES | 44 | 9.59e-02 | 0.145000 | 2.50e-01 |
RUNX1 INTERACTS WITH CO FACTORS WHOSE PRECISE EFFECT ON RUNX1 TARGETS IS NOT KNOWN | 37 | 1.27e-01 | 0.145000 | 3.00e-01 |
FLT3 SIGNALING IN DISEASE | 28 | 1.88e-01 | 0.144000 | 3.85e-01 |
REGULATION OF PYRUVATE DEHYDROGENASE PDH COMPLEX | 15 | 3.35e-01 | -0.144000 | 5.51e-01 |
DISEASES ASSOCIATED WITH GLYCOSYLATION PRECURSOR BIOSYNTHESIS | 18 | 2.91e-01 | -0.144000 | 5.08e-01 |
TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY P107 RBL1 AND P130 RBL2 IN COMPLEX WITH HDAC1 | 16 | 3.20e-01 | -0.144000 | 5.33e-01 |
HSP90 CHAPERONE CYCLE FOR STEROID HORMONE RECEPTORS SHR | 48 | 8.64e-02 | -0.143000 | 2.38e-01 |
INTERLEUKIN 6 FAMILY SIGNALING | 20 | 2.69e-01 | 0.143000 | 4.83e-01 |
RET SIGNALING | 37 | 1.33e-01 | 0.143000 | 3.08e-01 |
SIGNALING BY FGFR4 IN DISEASE | 11 | 4.14e-01 | -0.142000 | 6.24e-01 |
CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE | 73 | 3.58e-02 | 0.142000 | 1.30e-01 |
REGULATION OF IFNG SIGNALING | 13 | 3.76e-01 | -0.142000 | 5.89e-01 |
ASPARAGINE N LINKED GLYCOSYLATION | 285 | 3.97e-05 | -0.142000 | 5.50e-04 |
COLLAGEN FORMATION | 81 | 2.83e-02 | 0.141000 | 1.13e-01 |
CELL CYCLE | 594 | 5.02e-09 | -0.141000 | 3.29e-07 |
NEGATIVE REGULATION OF NMDA RECEPTOR MEDIATED NEURONAL TRANSMISSION | 21 | 2.64e-01 | 0.141000 | 4.78e-01 |
TRANSLATION OF SARS COV 2 STRUCTURAL PROTEINS | 44 | 1.07e-01 | -0.141000 | 2.65e-01 |
NEUROTRANSMITTER RELEASE CYCLE | 49 | 8.89e-02 | 0.141000 | 2.42e-01 |
ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK EPSILON | 17 | 3.18e-01 | 0.140000 | 5.31e-01 |
RESOLUTION OF ABASIC SITES AP SITES | 37 | 1.43e-01 | -0.139000 | 3.22e-01 |
IRAK4 DEFICIENCY TLR2 4 | 15 | 3.53e-01 | -0.139000 | 5.68e-01 |
SYNTHESIS OF PIPS AT THE GOLGI MEMBRANE | 15 | 3.56e-01 | 0.138000 | 5.69e-01 |
TRANS GOLGI NETWORK VESICLE BUDDING | 70 | 4.67e-02 | -0.138000 | 1.57e-01 |
ABERRANT REGULATION OF MITOTIC G1 S TRANSITION IN CANCER DUE TO RB1 DEFECTS | 17 | 3.28e-01 | -0.137000 | 5.40e-01 |
REGULATION OF CHOLESTEROL BIOSYNTHESIS BY SREBP SREBF | 56 | 7.71e-02 | 0.137000 | 2.20e-01 |
TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES | 32 | 1.81e-01 | -0.137000 | 3.77e-01 |
ACTIVATION OF MATRIX METALLOPROTEINASES | 14 | 3.76e-01 | -0.137000 | 5.89e-01 |
COPI INDEPENDENT GOLGI TO ER RETROGRADE TRAFFIC | 44 | 1.17e-01 | -0.136000 | 2.85e-01 |
RNA POLYMERASE I TRANSCRIPTION | 68 | 5.23e-02 | -0.136000 | 1.68e-01 |
LONG TERM POTENTIATION | 23 | 2.59e-01 | 0.136000 | 4.74e-01 |
HCMV LATE EVENTS | 66 | 5.64e-02 | -0.136000 | 1.78e-01 |
EXTENSION OF TELOMERES | 49 | 1.01e-01 | -0.135000 | 2.57e-01 |
CD209 DC SIGN SIGNALING | 18 | 3.22e-01 | -0.135000 | 5.34e-01 |
RHOV GTPASE CYCLE | 33 | 1.80e-01 | 0.135000 | 3.76e-01 |
BIOTIN TRANSPORT AND METABOLISM | 11 | 4.39e-01 | 0.135000 | 6.50e-01 |
PHOSPHOLIPASE C MEDIATED CASCADE FGFR2 | 12 | 4.19e-01 | -0.135000 | 6.30e-01 |
RESOLUTION OF SISTER CHROMATID COHESION | 102 | 1.90e-02 | -0.135000 | 8.57e-02 |
RHOU GTPASE CYCLE | 34 | 1.75e-01 | 0.134000 | 3.68e-01 |
MRNA SPLICING MINOR PATHWAY | 52 | 9.37e-02 | -0.134000 | 2.46e-01 |
ROS AND RNS PRODUCTION IN PHAGOCYTES | 29 | 2.11e-01 | -0.134000 | 4.12e-01 |
INNATE IMMUNE SYSTEM | 792 | 1.73e-10 | -0.134000 | 1.85e-08 |
INFECTIOUS DISEASE | 737 | 7.05e-10 | -0.134000 | 5.54e-08 |
NOTCH3 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION | 23 | 2.68e-01 | 0.133000 | 4.83e-01 |
PROTEIN FOLDING | 89 | 2.99e-02 | -0.133000 | 1.17e-01 |
ANTIVIRAL MECHANISM BY IFN STIMULATED GENES | 74 | 4.79e-02 | -0.133000 | 1.59e-01 |
INTEGRIN SIGNALING | 24 | 2.59e-01 | 0.133000 | 4.74e-01 |
PROCESSING OF DNA DOUBLE STRAND BREAK ENDS | 71 | 5.35e-02 | -0.133000 | 1.71e-01 |
TP53 REGULATES METABOLIC GENES | 87 | 3.35e-02 | -0.132000 | 1.25e-01 |
ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION | 290 | 1.17e-04 | -0.132000 | 1.35e-03 |
PRESYNAPTIC FUNCTION OF KAINATE RECEPTORS | 20 | 3.08e-01 | -0.132000 | 5.24e-01 |
DEADENYLATION DEPENDENT MRNA DECAY | 55 | 9.13e-02 | -0.132000 | 2.45e-01 |
EPHB MEDIATED FORWARD SIGNALING | 42 | 1.41e-01 | -0.131000 | 3.20e-01 |
NEF MEDIATED DOWNREGULATION OF MHC CLASS I COMPLEX CELL SURFACE EXPRESSION | 13 | 4.13e-01 | -0.131000 | 6.23e-01 |
SUMOYLATION OF TRANSCRIPTION FACTORS | 18 | 3.36e-01 | -0.131000 | 5.51e-01 |
BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN GENE EXPRESSION | 26 | 2.48e-01 | 0.131000 | 4.59e-01 |
PROLONGED ERK ACTIVATION EVENTS | 14 | 3.97e-01 | -0.131000 | 6.09e-01 |
AMYLOID FIBER FORMATION | 58 | 8.54e-02 | -0.131000 | 2.37e-01 |
TOLL LIKE RECEPTOR CASCADES | 141 | 7.48e-03 | -0.131000 | 4.24e-02 |
ONCOGENE INDUCED SENESCENCE | 32 | 2.02e-01 | 0.130000 | 4.07e-01 |
ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING | 29 | 2.28e-01 | -0.129000 | 4.35e-01 |
INTERLEUKIN 3 INTERLEUKIN 5 AND GM CSF SIGNALING | 41 | 1.52e-01 | 0.129000 | 3.36e-01 |
STIMULI SENSING CHANNELS | 76 | 5.15e-02 | 0.129000 | 1.67e-01 |
TNFR1 INDUCED PROAPOPTOTIC SIGNALING | 12 | 4.41e-01 | 0.129000 | 6.51e-01 |
ACETYLCHOLINE BINDING AND DOWNSTREAM EVENTS | 10 | 4.82e-01 | 0.129000 | 6.87e-01 |
HIGHLY CALCIUM PERMEABLE POSTSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS | 10 | 4.82e-01 | 0.129000 | 6.87e-01 |
DEGRADATION OF THE EXTRACELLULAR MATRIX | 108 | 2.13e-02 | 0.128000 | 9.34e-02 |
PLATELET CALCIUM HOMEOSTASIS | 26 | 2.60e-01 | 0.128000 | 4.74e-01 |
METABOLISM OF FAT SOLUBLE VITAMINS | 33 | 2.05e-01 | 0.127000 | 4.07e-01 |
MEIOTIC RECOMBINATION | 39 | 1.69e-01 | -0.127000 | 3.61e-01 |
CYTOKINE SIGNALING IN IMMUNE SYSTEM | 553 | 3.83e-07 | -0.127000 | 1.25e-05 |
NON INTEGRIN MEMBRANE ECM INTERACTIONS | 56 | 1.01e-01 | 0.127000 | 2.57e-01 |
FOXO MEDIATED TRANSCRIPTION | 59 | 9.28e-02 | -0.127000 | 2.46e-01 |
L1CAM INTERACTIONS | 107 | 2.39e-02 | 0.126000 | 1.01e-01 |
REGULATION OF TNFR1 SIGNALING | 34 | 2.02e-01 | 0.126000 | 4.07e-01 |
RHO GTPASES ACTIVATE NADPH OXIDASES | 22 | 3.07e-01 | -0.126000 | 5.23e-01 |
SNRNP ASSEMBLY | 51 | 1.20e-01 | -0.126000 | 2.90e-01 |
EXTRACELLULAR MATRIX ORGANIZATION | 247 | 6.90e-04 | 0.126000 | 6.21e-03 |
LOSS OF FUNCTION OF MECP2 IN RETT SYNDROME | 13 | 4.34e-01 | 0.125000 | 6.45e-01 |
PEXOPHAGY | 11 | 4.73e-01 | 0.125000 | 6.82e-01 |
ACTIVATED PKN1 STIMULATES TRANSCRIPTION OF AR ANDROGEN RECEPTOR REGULATED GENES KLK2 AND KLK3 | 22 | 3.11e-01 | -0.125000 | 5.26e-01 |
METABOLISM OF AMINE DERIVED HORMONES | 10 | 4.95e-01 | 0.125000 | 6.96e-01 |
NEGATIVE REGULATION OF FGFR2 SIGNALING | 28 | 2.54e-01 | -0.125000 | 4.66e-01 |
B WICH COMPLEX POSITIVELY REGULATES RRNA EXPRESSION | 48 | 1.36e-01 | -0.125000 | 3.13e-01 |
RHO GTPASES ACTIVATE IQGAPS | 24 | 2.91e-01 | -0.125000 | 5.08e-01 |
EPHA MEDIATED GROWTH CONE COLLAPSE | 29 | 2.47e-01 | 0.124000 | 4.58e-01 |
PRC2 METHYLATES HISTONES AND DNA | 30 | 2.40e-01 | -0.124000 | 4.49e-01 |
HDR THROUGH SINGLE STRAND ANNEALING SSA | 36 | 1.99e-01 | -0.124000 | 4.03e-01 |
GLUCONEOGENESIS | 27 | 2.67e-01 | -0.124000 | 4.81e-01 |
ABC TRANSPORTERS IN LIPID HOMEOSTASIS | 14 | 4.24e-01 | 0.123000 | 6.34e-01 |
AUTOPHAGY | 140 | 1.20e-02 | -0.123000 | 6.18e-02 |
TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATION | 171 | 5.58e-03 | -0.123000 | 3.39e-02 |
INWARDLY RECTIFYING K CHANNELS | 32 | 2.31e-01 | -0.122000 | 4.37e-01 |
SIGNALING BY FLT3 FUSION PROTEINS | 19 | 3.58e-01 | 0.122000 | 5.70e-01 |
SIGNALING BY FGFR3 FUSIONS IN CANCER | 10 | 5.06e-01 | -0.121000 | 7.02e-01 |
SUMOYLATION OF INTRACELLULAR RECEPTORS | 26 | 2.84e-01 | -0.121000 | 5.01e-01 |
METABOLISM OF STEROID HORMONES | 21 | 3.37e-01 | -0.121000 | 5.51e-01 |
TCF DEPENDENT SIGNALING IN RESPONSE TO WNT | 179 | 5.24e-03 | -0.121000 | 3.21e-02 |
RESPONSE OF MTB TO PHAGOCYTOSIS | 21 | 3.39e-01 | -0.121000 | 5.52e-01 |
SENESCENCE ASSOCIATED SECRETORY PHENOTYPE SASP | 64 | 9.55e-02 | -0.121000 | 2.50e-01 |
RHO GTPASES ACTIVATE PKNS | 48 | 1.51e-01 | -0.120000 | 3.35e-01 |
TRANSLATION OF SARS COV 1 STRUCTURAL PROTEINS | 28 | 2.73e-01 | -0.120000 | 4.86e-01 |
TRANSCRIPTIONAL ACTIVATION OF MITOCHONDRIAL BIOGENESIS | 54 | 1.28e-01 | 0.120000 | 3.00e-01 |
SUMOYLATION OF DNA DAMAGE RESPONSE AND REPAIR PROTEINS | 73 | 7.78e-02 | -0.119000 | 2.21e-01 |
TRANSCRIPTIONAL REGULATION BY RUNX3 | 94 | 4.56e-02 | -0.119000 | 1.54e-01 |
P75NTR SIGNALS VIA NF KB | 16 | 4.09e-01 | 0.119000 | 6.20e-01 |
RRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL | 59 | 1.13e-01 | -0.119000 | 2.78e-01 |
HEPARAN SULFATE HEPARIN HS GAG METABOLISM | 53 | 1.34e-01 | 0.119000 | 3.11e-01 |
WNT LIGAND BIOGENESIS AND TRAFFICKING | 21 | 3.46e-01 | -0.119000 | 5.60e-01 |
MITOTIC G2 G2 M PHASES | 187 | 5.12e-03 | -0.119000 | 3.19e-02 |
MTOR SIGNALLING | 41 | 1.90e-01 | -0.118000 | 3.87e-01 |
SIGNALING BY NOTCH1 | 75 | 7.64e-02 | 0.118000 | 2.19e-01 |
NEGATIVE REGULATION OF FGFR1 SIGNALING | 27 | 2.87e-01 | -0.118000 | 5.05e-01 |
SENSORY PERCEPTION | 153 | 1.20e-02 | 0.118000 | 6.18e-02 |
POST TRANSLATIONAL MODIFICATION SYNTHESIS OF GPI ANCHORED PROTEINS | 62 | 1.09e-01 | -0.118000 | 2.70e-01 |
SIGNALING BY RETINOIC ACID | 35 | 2.28e-01 | -0.118000 | 4.35e-01 |
INTERLEUKIN 17 SIGNALING | 68 | 9.34e-02 | -0.118000 | 2.46e-01 |
INTRINSIC PATHWAY FOR APOPTOSIS | 52 | 1.42e-01 | -0.118000 | 3.22e-01 |
NEURONAL SYSTEM | 373 | 1.01e-04 | 0.117000 | 1.21e-03 |
REGULATION OF LOCALIZATION OF FOXO TRANSCRIPTION FACTORS | 12 | 4.82e-01 | -0.117000 | 6.87e-01 |
INTERLEUKIN 1 FAMILY SIGNALING | 123 | 2.48e-02 | -0.117000 | 1.04e-01 |
HEME SIGNALING | 46 | 1.69e-01 | 0.117000 | 3.61e-01 |
REGULATION OF IFNA SIGNALING | 12 | 4.82e-01 | 0.117000 | 6.87e-01 |
GENERATION OF SECOND MESSENGER MOLECULES | 19 | 3.79e-01 | -0.117000 | 5.92e-01 |
RHO GTPASES ACTIVATE PAKS | 21 | 3.56e-01 | 0.116000 | 5.69e-01 |
TGF BETA RECEPTOR SIGNALING ACTIVATES SMADS | 32 | 2.55e-01 | -0.116000 | 4.67e-01 |
INTERLEUKIN 10 SIGNALING | 19 | 3.81e-01 | -0.116000 | 5.93e-01 |
TRAF3 DEPENDENT IRF ACTIVATION PATHWAY | 13 | 4.70e-01 | 0.116000 | 6.80e-01 |
ROLE OF SECOND MESSENGERS IN NETRIN 1 SIGNALING | 10 | 5.28e-01 | 0.115000 | 7.22e-01 |
NEGATIVE REGULATION OF FLT3 | 14 | 4.57e-01 | 0.115000 | 6.68e-01 |
SIGNAL AMPLIFICATION | 30 | 2.80e-01 | -0.114000 | 4.96e-01 |
DNA METHYLATION | 21 | 3.66e-01 | -0.114000 | 5.78e-01 |
NEF MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS | 21 | 3.68e-01 | -0.113000 | 5.79e-01 |
RHO GTPASES ACTIVATE FORMINS | 118 | 3.36e-02 | -0.113000 | 1.25e-01 |
NOTCH4 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS | 12 | 4.97e-01 | -0.113000 | 6.98e-01 |
MOLECULES ASSOCIATED WITH ELASTIC FIBRES | 32 | 2.68e-01 | 0.113000 | 4.83e-01 |
TNF SIGNALING | 43 | 2.00e-01 | 0.113000 | 4.05e-01 |
GRB2 SOS PROVIDES LINKAGE TO MAPK SIGNALING FOR INTEGRINS | 12 | 5.00e-01 | 0.112000 | 7.00e-01 |
MYD88 INDEPENDENT TLR4 CASCADE | 94 | 5.96e-02 | -0.112000 | 1.84e-01 |
ER TO GOLGI ANTEROGRADE TRANSPORT | 142 | 2.09e-02 | -0.112000 | 9.24e-02 |
RIP MEDIATED NFKB ACTIVATION VIA ZBP1 | 15 | 4.52e-01 | 0.112000 | 6.65e-01 |
TBC RABGAPS | 43 | 2.04e-01 | -0.112000 | 4.07e-01 |
GLYCOGEN BREAKDOWN GLYCOGENOLYSIS | 14 | 4.68e-01 | 0.112000 | 6.79e-01 |
TIE2 SIGNALING | 17 | 4.24e-01 | -0.112000 | 6.34e-01 |
DCC MEDIATED ATTRACTIVE SIGNALING | 14 | 4.68e-01 | 0.112000 | 6.79e-01 |
TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTORS | 17 | 4.25e-01 | 0.112000 | 6.34e-01 |
GABA SYNTHESIS RELEASE REUPTAKE AND DEGRADATION | 19 | 4.00e-01 | 0.112000 | 6.10e-01 |
CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE | 31 | 2.83e-01 | 0.111000 | 5.00e-01 |
O LINKED GLYCOSYLATION | 88 | 7.13e-02 | 0.111000 | 2.09e-01 |
DISASSEMBLY OF THE DESTRUCTION COMPLEX AND RECRUITMENT OF AXIN TO THE MEMBRANE | 27 | 3.17e-01 | 0.111000 | 5.31e-01 |
G ALPHA Z SIGNALLING EVENTS | 44 | 2.04e-01 | -0.111000 | 4.07e-01 |
ANCHORING OF THE BASAL BODY TO THE PLASMA MEMBRANE | 97 | 5.96e-02 | 0.111000 | 1.84e-01 |
SHC1 EVENTS IN ERBB4 SIGNALING | 13 | 4.89e-01 | -0.111000 | 6.93e-01 |
COHESIN LOADING ONTO CHROMATIN | 10 | 5.45e-01 | -0.111000 | 7.38e-01 |
ADAPTIVE IMMUNE SYSTEM | 614 | 3.69e-06 | -0.110000 | 7.78e-05 |
ACYL CHAIN REMODELLING OF PS | 14 | 4.78e-01 | -0.110000 | 6.87e-01 |
IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL | 53 | 1.68e-01 | -0.110000 | 3.60e-01 |
POST TRANSLATIONAL PROTEIN MODIFICATION | 1230 | 1.90e-10 | -0.109000 | 1.87e-08 |
GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE | 23 | 3.67e-01 | 0.109000 | 5.78e-01 |
DNA REPAIR | 292 | 1.47e-03 | -0.108000 | 1.15e-02 |
ASSEMBLY OF THE HIV VIRION | 16 | 4.55e-01 | -0.108000 | 6.67e-01 |
LYSINE CATABOLISM | 11 | 5.37e-01 | 0.107000 | 7.32e-01 |
INTEGRATION OF ENERGY METABOLISM | 99 | 6.50e-02 | 0.107000 | 1.94e-01 |
KSRP KHSRP BINDS AND DESTABILIZES MRNA | 16 | 4.58e-01 | -0.107000 | 6.70e-01 |
BETA CATENIN INDEPENDENT WNT SIGNALING | 140 | 2.89e-02 | -0.107000 | 1.15e-01 |
ION HOMEOSTASIS | 51 | 1.87e-01 | 0.107000 | 3.84e-01 |
GLUTAMATE AND GLUTAMINE METABOLISM | 13 | 5.06e-01 | 0.107000 | 7.02e-01 |
TRNA PROCESSING | 105 | 6.03e-02 | -0.106000 | 1.84e-01 |
RHOH GTPASE CYCLE | 37 | 2.64e-01 | -0.106000 | 4.78e-01 |
ION CHANNEL TRANSPORT | 144 | 2.83e-02 | 0.106000 | 1.13e-01 |
PURINERGIC SIGNALING IN LEISHMANIASIS INFECTION | 22 | 3.92e-01 | -0.105000 | 6.02e-01 |
DISEASES OF METABOLISM | 200 | 1.10e-02 | 0.104000 | 5.81e-02 |
TERMINATION OF O GLYCAN BIOSYNTHESIS | 11 | 5.50e-01 | 0.104000 | 7.40e-01 |
BASE EXCISION REPAIR AP SITE FORMATION | 30 | 3.23e-01 | -0.104000 | 5.36e-01 |
PEPTIDE HORMONE METABOLISM | 60 | 1.67e-01 | -0.103000 | 3.59e-01 |
LYSOSOME VESICLE BIOGENESIS | 33 | 3.07e-01 | -0.103000 | 5.23e-01 |
TRANSLOCATION OF SLC2A4 GLUT4 TO THE PLASMA MEMBRANE | 64 | 1.55e-01 | -0.103000 | 3.39e-01 |
FLT3 SIGNALING | 36 | 2.88e-01 | 0.102000 | 5.05e-01 |
TNFS BIND THEIR PHYSIOLOGICAL RECEPTORS | 13 | 5.23e-01 | 0.102000 | 7.16e-01 |
SMOOTH MUSCLE CONTRACTION | 33 | 3.09e-01 | 0.102000 | 5.26e-01 |
RAS ACTIVATION UPON CA2 INFLUX THROUGH NMDA RECEPTOR | 20 | 4.30e-01 | 0.102000 | 6.39e-01 |
GRB2 EVENTS IN ERBB2 SIGNALING | 15 | 4.94e-01 | -0.102000 | 6.96e-01 |
PLATELET AGGREGATION PLUG FORMATION | 32 | 3.19e-01 | 0.102000 | 5.32e-01 |
AQUAPORIN MEDIATED TRANSPORT | 42 | 2.56e-01 | -0.101000 | 4.68e-01 |
MITOCHONDRIAL TRNA AMINOACYLATION | 21 | 4.22e-01 | 0.101000 | 6.32e-01 |
DISEASES OF DNA REPAIR | 11 | 5.61e-01 | 0.101000 | 7.51e-01 |
CARGO TRAFFICKING TO THE PERICILIARY MEMBRANE | 49 | 2.25e-01 | -0.100000 | 4.30e-01 |
UB SPECIFIC PROCESSING PROTEASES | 169 | 2.48e-02 | -0.100000 | 1.04e-01 |
ACTIVATION OF AMPK DOWNSTREAM OF NMDARS | 21 | 4.27e-01 | -0.100000 | 6.36e-01 |
HOMOLOGY DIRECTED REPAIR | 107 | 7.43e-02 | -0.099900 | 2.15e-01 |
CA DEPENDENT EVENTS | 36 | 3.01e-01 | 0.099600 | 5.19e-01 |
PTEN REGULATION | 136 | 4.56e-02 | -0.099400 | 1.54e-01 |
NETRIN 1 SIGNALING | 50 | 2.25e-01 | 0.099300 | 4.30e-01 |
COLLAGEN CHAIN TRIMERIZATION | 41 | 2.73e-01 | 0.099000 | 4.86e-01 |
POST CHAPERONIN TUBULIN FOLDING PATHWAY | 17 | 4.80e-01 | -0.098900 | 6.87e-01 |
PARASITE INFECTION | 54 | 2.10e-01 | -0.098600 | 4.11e-01 |
HEDGEHOG ON STATE | 83 | 1.22e-01 | -0.098300 | 2.93e-01 |
DDX58 IFIH1 MEDIATED INDUCTION OF INTERFERON ALPHA BETA | 64 | 1.74e-01 | -0.098300 | 3.67e-01 |
SIGNALING BY INTERLEUKINS | 353 | 1.55e-03 | -0.098300 | 1.20e-02 |
P38MAPK EVENTS | 13 | 5.41e-01 | -0.098000 | 7.35e-01 |
RUNX1 REGULATES GENES INVOLVED IN MEGAKARYOCYTE DIFFERENTIATION AND PLATELET FUNCTION | 51 | 2.27e-01 | 0.097800 | 4.34e-01 |
MEIOSIS | 66 | 1.71e-01 | -0.097500 | 3.62e-01 |
ACYL CHAIN REMODELLING OF PC | 17 | 4.87e-01 | 0.097300 | 6.90e-01 |
RHO GTPASE CYCLE | 426 | 6.19e-04 | 0.096900 | 5.61e-03 |
THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS PARS | 27 | 3.84e-01 | -0.096800 | 5.94e-01 |
INACTIVATION OF CSF3 G CSF SIGNALING | 24 | 4.12e-01 | -0.096700 | 6.23e-01 |
P75 NTR RECEPTOR MEDIATED SIGNALLING | 94 | 1.06e-01 | 0.096500 | 2.65e-01 |
ELASTIC FIBRE FORMATION | 38 | 3.05e-01 | 0.096300 | 5.21e-01 |
TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7 8 OR 9 SIGNALING | 13 | 5.48e-01 | -0.096100 | 7.40e-01 |
ESR MEDIATED SIGNALING | 168 | 3.18e-02 | -0.096100 | 1.22e-01 |
REGULATION OF LIPID METABOLISM BY PPARALPHA | 108 | 8.70e-02 | 0.095400 | 2.39e-01 |
BETA OXIDATION OF VERY LONG CHAIN FATTY ACIDS | 11 | 5.85e-01 | 0.095200 | 7.69e-01 |
PLASMA LIPOPROTEIN CLEARANCE | 28 | 3.84e-01 | 0.095200 | 5.94e-01 |
REGULATION OF INSULIN SECRETION | 71 | 1.69e-01 | 0.094400 | 3.61e-01 |
MRNA SPLICING | 188 | 2.63e-02 | -0.094100 | 1.07e-01 |
RHO GTPASES ACTIVATE CIT | 18 | 4.91e-01 | 0.093700 | 6.94e-01 |
GLYCEROPHOSPHOLIPID BIOSYNTHESIS | 109 | 9.14e-02 | 0.093600 | 2.45e-01 |
SIGNALING BY WNT | 270 | 8.50e-03 | -0.093200 | 4.66e-02 |
DEUBIQUITINATION | 243 | 1.29e-02 | -0.092800 | 6.52e-02 |
ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK | 29 | 3.88e-01 | -0.092700 | 5.98e-01 |
DEREGULATED CDK5 TRIGGERS MULTIPLE NEURODEGENERATIVE PATHWAYS IN ALZHEIMER S DISEASE MODELS | 19 | 4.86e-01 | -0.092300 | 6.90e-01 |
RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 1 PROMOTER | 28 | 3.99e-01 | -0.092100 | 6.10e-01 |
SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER | 59 | 2.22e-01 | 0.091900 | 4.27e-01 |
REGULATION OF HSF1 MEDIATED HEAT SHOCK RESPONSE | 76 | 1.67e-01 | -0.091800 | 3.59e-01 |
SIGNAL TRANSDUCTION BY L1 | 21 | 4.71e-01 | -0.090900 | 6.80e-01 |
TOLL LIKE RECEPTOR TLR1 TLR2 CASCADE | 95 | 1.28e-01 | -0.090300 | 3.00e-01 |
ALPHA LINOLENIC OMEGA3 AND LINOLEIC OMEGA6 ACID METABOLISM | 12 | 5.90e-01 | 0.089900 | 7.72e-01 |
APOPTOTIC EXECUTION PHASE | 45 | 2.98e-01 | -0.089800 | 5.17e-01 |
NONHOMOLOGOUS END JOINING NHEJ | 44 | 3.04e-01 | -0.089500 | 5.21e-01 |
TOLL LIKE RECEPTOR 9 TLR9 CASCADE | 92 | 1.40e-01 | -0.089100 | 3.19e-01 |
KERATAN SULFATE BIOSYNTHESIS | 24 | 4.52e-01 | -0.088700 | 6.65e-01 |
ACTIVATION OF BH3 ONLY PROTEINS | 30 | 4.01e-01 | -0.088500 | 6.10e-01 |
GAP JUNCTION TRAFFICKING AND REGULATION | 33 | 3.79e-01 | -0.088400 | 5.92e-01 |
LYSOSPHINGOLIPID AND LPA RECEPTORS | 13 | 5.82e-01 | -0.088200 | 7.68e-01 |
SYNTHESIS OF PIPS AT THE EARLY ENDOSOME MEMBRANE | 16 | 5.42e-01 | -0.088100 | 7.35e-01 |
SARS COV INFECTIONS | 141 | 7.15e-02 | -0.088000 | 2.09e-01 |
RAB GEFS EXCHANGE GTP FOR GDP ON RABS | 87 | 1.57e-01 | -0.087800 | 3.44e-01 |
SIGNALING BY FGFR1 | 44 | 3.14e-01 | -0.087700 | 5.31e-01 |
MEIOTIC SYNAPSIS | 42 | 3.26e-01 | -0.087600 | 5.39e-01 |
SIGNALING BY PDGFRA TRANSMEMBRANE JUXTAMEMBRANE AND KINASE DOMAIN MUTANTS | 12 | 6.00e-01 | -0.087500 | 7.80e-01 |
TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION | 74 | 1.96e-01 | 0.086900 | 3.99e-01 |
SIGNALING BY ERBB2 ECD MUTANTS | 16 | 5.48e-01 | -0.086700 | 7.40e-01 |
PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA | 237 | 2.22e-02 | -0.086400 | 9.50e-02 |
SIGNALING BY MET | 74 | 2.04e-01 | 0.085400 | 4.07e-01 |
SELECTIVE AUTOPHAGY | 73 | 2.08e-01 | -0.085300 | 4.09e-01 |
DAP12 SIGNALING | 24 | 4.71e-01 | -0.085100 | 6.80e-01 |
FGFR2 ALTERNATIVE SPLICING | 25 | 4.62e-01 | -0.085000 | 6.73e-01 |
RHO GTPASES ACTIVATE ROCKS | 19 | 5.23e-01 | 0.084700 | 7.16e-01 |
TRANSCRIPTIONAL REGULATION BY TP53 | 346 | 6.94e-03 | -0.084600 | 4.03e-02 |
HYALURONAN UPTAKE AND DEGRADATION | 12 | 6.13e-01 | 0.084300 | 7.85e-01 |
IRS MEDIATED SIGNALLING | 40 | 3.58e-01 | -0.084000 | 5.70e-01 |
DISORDERS OF TRANSMEMBRANE TRANSPORTERS | 148 | 7.81e-02 | -0.084000 | 2.21e-01 |
METABOLISM OF FOLATE AND PTERINES | 15 | 5.74e-01 | 0.083900 | 7.62e-01 |
NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION | 48 | 3.16e-01 | 0.083700 | 5.31e-01 |
ASSOCIATION OF TRIC CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS | 38 | 3.74e-01 | -0.083400 | 5.86e-01 |
TP53 REGULATES TRANSCRIPTION OF SEVERAL ADDITIONAL CELL DEATH GENES WHOSE SPECIFIC ROLES IN P53 DEPENDENT APOPTOSIS REMAIN UNCERTAIN | 12 | 6.18e-01 | -0.083100 | 7.87e-01 |
SIGNALING BY FGFR IN DISEASE | 57 | 2.78e-01 | -0.083100 | 4.94e-01 |
CASPASE ACTIVATION VIA EXTRINSIC APOPTOTIC SIGNALLING PATHWAY | 24 | 4.82e-01 | -0.082900 | 6.87e-01 |
RUNX2 REGULATES OSTEOBLAST DIFFERENTIATION | 23 | 4.92e-01 | 0.082800 | 6.94e-01 |
RNA POLYMERASE I TRANSCRIPTION INITIATION | 47 | 3.27e-01 | -0.082700 | 5.39e-01 |
THROMBOXANE SIGNALLING THROUGH TP RECEPTOR | 22 | 5.03e-01 | -0.082400 | 7.01e-01 |
NUCLEOTIDE LIKE PURINERGIC RECEPTORS | 13 | 6.07e-01 | -0.082400 | 7.82e-01 |
RNA POLYMERASE II TRANSCRIPTION | 1100 | 4.94e-06 | -0.082100 | 9.06e-05 |
PLASMA LIPOPROTEIN ASSEMBLY REMODELING AND CLEARANCE | 49 | 3.20e-01 | 0.082100 | 5.33e-01 |
SIGNALING BY NTRKS | 130 | 1.07e-01 | -0.082000 | 2.65e-01 |
PECAM1 INTERACTIONS | 12 | 6.24e-01 | 0.081700 | 7.92e-01 |
DOWNSTREAM SIGNAL TRANSDUCTION | 29 | 4.47e-01 | 0.081600 | 6.59e-01 |
FORMATION OF RNA POL II ELONGATION COMPLEX | 57 | 2.89e-01 | -0.081200 | 5.07e-01 |
HDACS DEACETYLATE HISTONES | 47 | 3.36e-01 | 0.081100 | 5.51e-01 |
COPI MEDIATED ANTEROGRADE TRANSPORT | 91 | 1.82e-01 | -0.081000 | 3.77e-01 |
RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 | 106 | 1.50e-01 | -0.081000 | 3.34e-01 |
DEATH RECEPTOR SIGNALLING | 133 | 1.07e-01 | 0.080900 | 2.67e-01 |
IKK COMPLEX RECRUITMENT MEDIATED BY RIP1 | 22 | 5.13e-01 | -0.080500 | 7.09e-01 |
SIGNALING BY ERBB2 | 48 | 3.37e-01 | -0.080100 | 5.52e-01 |
IRAK1 RECRUITS IKK COMPLEX | 14 | 6.05e-01 | 0.079800 | 7.82e-01 |
ERBB2 ACTIVATES PTK6 SIGNALING | 11 | 6.47e-01 | 0.079700 | 8.11e-01 |
TRANSMISSION ACROSS CHEMICAL SYNAPSES | 245 | 3.22e-02 | 0.079600 | 1.22e-01 |
NEGATIVE REGULATION OF TCF DEPENDENT SIGNALING BY WNT LIGAND ANTAGONISTS | 11 | 6.49e-01 | 0.079200 | 8.11e-01 |
REGULATION OF TP53 ACTIVITY THROUGH PHOSPHORYLATION | 88 | 2.01e-01 | -0.078900 | 4.05e-01 |
AKT PHOSPHORYLATES TARGETS IN THE NUCLEUS | 10 | 6.66e-01 | -0.078800 | 8.19e-01 |
DEACTIVATION OF THE BETA CATENIN TRANSACTIVATING COMPLEX | 41 | 3.84e-01 | 0.078600 | 5.94e-01 |
DNA DAMAGE TELOMERE STRESS INDUCED SENESCENCE | 45 | 3.63e-01 | -0.078400 | 5.74e-01 |
SIGNALING BY NOTCH3 | 48 | 3.48e-01 | 0.078300 | 5.63e-01 |
NEGATIVE REGULATION OF THE PI3K AKT NETWORK | 96 | 1.86e-01 | -0.078100 | 3.84e-01 |
SIGNALING BY TGF BETA RECEPTOR COMPLEX | 72 | 2.53e-01 | -0.078000 | 4.65e-01 |
HCMV INFECTION | 104 | 1.70e-01 | -0.077900 | 3.61e-01 |
METAL ION SLC TRANSPORTERS | 25 | 5.01e-01 | 0.077800 | 7.00e-01 |
POLO LIKE KINASE MEDIATED EVENTS | 14 | 6.16e-01 | -0.077400 | 7.86e-01 |
SIGNALING BY EGFR | 47 | 3.59e-01 | 0.077300 | 5.70e-01 |
MYOGENESIS | 25 | 5.04e-01 | 0.077200 | 7.01e-01 |
DOWNSTREAM SIGNALING OF ACTIVATED FGFR2 | 24 | 5.15e-01 | -0.076800 | 7.09e-01 |
MHC CLASS II ANTIGEN PRESENTATION | 101 | 1.83e-01 | -0.076800 | 3.79e-01 |
CELL CELL JUNCTION ORGANIZATION | 49 | 3.53e-01 | -0.076800 | 5.68e-01 |
KERATAN SULFATE DEGRADATION | 11 | 6.60e-01 | 0.076600 | 8.18e-01 |
G ALPHA S SIGNALLING EVENTS | 108 | 1.69e-01 | 0.076600 | 3.61e-01 |
SYNTHESIS OF LEUKOTRIENES LT AND EOXINS EX | 12 | 6.47e-01 | -0.076400 | 8.11e-01 |
N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCLE | 35 | 4.37e-01 | -0.075900 | 6.48e-01 |
CARGO RECOGNITION FOR CLATHRIN MEDIATED ENDOCYTOSIS | 93 | 2.08e-01 | -0.075700 | 4.09e-01 |
SIGNALING BY NODAL | 15 | 6.12e-01 | -0.075500 | 7.85e-01 |
SHC MEDIATED CASCADE FGFR4 | 12 | 6.51e-01 | -0.075300 | 8.12e-01 |
NITRIC OXIDE STIMULATES GUANYLATE CYCLASE | 20 | 5.64e-01 | 0.074600 | 7.53e-01 |
COMPLEMENT CASCADE | 27 | 5.04e-01 | 0.074300 | 7.01e-01 |
SIGNALING BY TGFB FAMILY MEMBERS | 97 | 2.09e-01 | -0.073900 | 4.10e-01 |
KILLING MECHANISMS | 11 | 6.72e-01 | 0.073700 | 8.25e-01 |
ABORTIVE ELONGATION OF HIV 1 TRANSCRIPT IN THE ABSENCE OF TAT | 23 | 5.44e-01 | -0.073100 | 7.37e-01 |
FGFR1 MUTANT RECEPTOR ACTIVATION | 26 | 5.20e-01 | 0.072900 | 7.14e-01 |
SIGNALLING TO ERKS | 34 | 4.63e-01 | -0.072800 | 6.74e-01 |
ADRENALINE NORADRENALINE INHIBITS INSULIN SECRETION | 27 | 5.13e-01 | -0.072700 | 7.09e-01 |
RHOBTB GTPASE CYCLE | 35 | 4.59e-01 | -0.072300 | 6.70e-01 |
PYRIMIDINE SALVAGE | 10 | 6.93e-01 | 0.072200 | 8.36e-01 |
ACTIVATION OF PPARGC1A PGC 1ALPHA BY PHOSPHORYLATION | 10 | 6.93e-01 | 0.072100 | 8.36e-01 |
RHOJ GTPASE CYCLE | 55 | 3.56e-01 | 0.071900 | 5.69e-01 |
HSF1 DEPENDENT TRANSACTIVATION | 34 | 4.72e-01 | 0.071200 | 6.82e-01 |
RAB REGULATION OF TRAFFICKING | 118 | 1.84e-01 | -0.070800 | 3.80e-01 |
MUSCLE CONTRACTION | 164 | 1.18e-01 | 0.070800 | 2.86e-01 |
SLC MEDIATED TRANSMEMBRANE TRANSPORT | 195 | 8.91e-02 | 0.070700 | 2.42e-01 |
PROLACTIN RECEPTOR SIGNALING | 11 | 6.85e-01 | -0.070600 | 8.32e-01 |
DEFECTS IN COBALAMIN B12 METABOLISM | 13 | 6.60e-01 | -0.070500 | 8.18e-01 |
CELLULAR RESPONSE TO HEAT STRESS | 95 | 2.35e-01 | -0.070500 | 4.44e-01 |
OTHER INTERLEUKIN SIGNALING | 20 | 5.86e-01 | 0.070400 | 7.69e-01 |
SIGNALING BY EGFR IN CANCER | 22 | 5.68e-01 | -0.070300 | 7.58e-01 |
VEGFR2 MEDIATED VASCULAR PERMEABILITY | 27 | 5.34e-01 | -0.069200 | 7.29e-01 |
VLDLR INTERNALISATION AND DEGRADATION | 12 | 6.79e-01 | 0.069000 | 8.28e-01 |
SIGNALING BY NUCLEAR RECEPTORS | 227 | 7.38e-02 | -0.069000 | 2.14e-01 |
ENDOGENOUS STEROLS | 20 | 5.95e-01 | 0.068600 | 7.76e-01 |
LISTERIA MONOCYTOGENES ENTRY INTO HOST CELLS | 20 | 5.96e-01 | -0.068500 | 7.76e-01 |
GAP JUNCTION DEGRADATION | 11 | 6.95e-01 | -0.068200 | 8.38e-01 |
RAP1 SIGNALLING | 15 | 6.48e-01 | -0.068000 | 8.11e-01 |
COLLAGEN DEGRADATION | 51 | 4.01e-01 | 0.068000 | 6.10e-01 |
TICAM1 DEPENDENT ACTIVATION OF IRF3 IRF7 | 12 | 6.84e-01 | -0.067900 | 8.31e-01 |
INTERLEUKIN 4 AND INTERLEUKIN 13 SIGNALING | 79 | 2.98e-01 | -0.067800 | 5.18e-01 |
PROCESSING OF CAPPED INTRONLESS PRE MRNA | 28 | 5.35e-01 | -0.067700 | 7.29e-01 |
CARBOXYTERMINAL POST TRANSLATIONAL MODIFICATIONS OF TUBULIN | 36 | 4.82e-01 | 0.067700 | 6.87e-01 |
REDUCTION OF CYTOSOLIC CA LEVELS | 12 | 6.86e-01 | 0.067500 | 8.32e-01 |
RHO GTPASE EFFECTORS | 252 | 6.81e-02 | -0.066800 | 2.00e-01 |
SIGNALING BY FGFR | 75 | 3.19e-01 | -0.066600 | 5.32e-01 |
SIGNALING BY NOTCH2 | 33 | 5.08e-01 | 0.066600 | 7.04e-01 |
SUMOYLATION OF TRANSCRIPTION COFACTORS | 42 | 4.55e-01 | 0.066600 | 6.67e-01 |
INSULIN RECEPTOR SIGNALLING CASCADE | 45 | 4.40e-01 | -0.066600 | 6.51e-01 |
VXPX CARGO TARGETING TO CILIUM | 19 | 6.16e-01 | 0.066400 | 7.86e-01 |
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1 | 23 | 5.82e-01 | -0.066300 | 7.68e-01 |
CILIUM ASSEMBLY | 193 | 1.14e-01 | 0.066100 | 2.79e-01 |
DOWNSTREAM SIGNALING OF ACTIVATED FGFR3 | 20 | 6.10e-01 | 0.066000 | 7.85e-01 |
TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION | 16 | 6.51e-01 | -0.065400 | 8.12e-01 |
TRP CHANNELS | 20 | 6.13e-01 | 0.065300 | 7.85e-01 |
FORMATION OF SENESCENCE ASSOCIATED HETEROCHROMATIN FOCI SAHF | 14 | 6.73e-01 | 0.065100 | 8.25e-01 |
SUMOYLATION OF RNA BINDING PROTEINS | 45 | 4.53e-01 | -0.064700 | 6.65e-01 |
SIGNALING BY FGFR2 | 64 | 3.71e-01 | -0.064600 | 5.83e-01 |
RHOBTB1 GTPASE CYCLE | 23 | 5.92e-01 | -0.064600 | 7.73e-01 |
NOTCH3 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS | 26 | 5.70e-01 | 0.064400 | 7.59e-01 |
MATURATION OF SARS COV 2 SPIKE PROTEIN | 29 | 5.54e-01 | -0.063400 | 7.44e-01 |
ROLE OF LAT2 NTAL LAB ON CALCIUM MOBILIZATION | 14 | 6.82e-01 | 0.063200 | 8.31e-01 |
POTASSIUM CHANNELS | 91 | 2.98e-01 | 0.063100 | 5.18e-01 |
TP53 REGULATES TRANSCRIPTION OF CASPASE ACTIVATORS AND CASPASES | 11 | 7.19e-01 | -0.062700 | 8.54e-01 |
CONSTITUTIVE SIGNALING BY AKT1 E17K IN CANCER | 26 | 5.81e-01 | 0.062600 | 7.68e-01 |
ER QUALITY CONTROL COMPARTMENT ERQC | 21 | 6.22e-01 | -0.062200 | 7.91e-01 |
SIGNALING BY KIT IN DISEASE | 20 | 6.31e-01 | -0.062100 | 7.96e-01 |
OVARIAN TUMOR DOMAIN PROTEASES | 37 | 5.15e-01 | -0.061900 | 7.09e-01 |
GLYCOSAMINOGLYCAN METABOLISM | 115 | 2.52e-01 | 0.061800 | 4.65e-01 |
TRIGLYCERIDE BIOSYNTHESIS | 10 | 7.39e-01 | -0.060900 | 8.66e-01 |
PHOSPHOLIPID METABOLISM | 187 | 1.52e-01 | 0.060800 | 3.36e-01 |
VIRAL MESSENGER RNA SYNTHESIS | 42 | 4.96e-01 | -0.060700 | 6.97e-01 |
SIGNALING BY PDGF | 57 | 4.28e-01 | 0.060700 | 6.38e-01 |
REGULATION OF INNATE IMMUNE RESPONSES TO CYTOSOLIC DNA | 13 | 7.06e-01 | 0.060500 | 8.45e-01 |
RHOQ GTPASE CYCLE | 59 | 4.22e-01 | 0.060500 | 6.32e-01 |
CLATHRIN MEDIATED ENDOCYTOSIS | 133 | 2.29e-01 | -0.060400 | 4.36e-01 |
REGULATION OF KIT SIGNALING | 16 | 6.76e-01 | 0.060400 | 8.26e-01 |
TRANSCRIPTIONAL REGULATION BY SMALL RNAS | 62 | 4.13e-01 | -0.060200 | 6.23e-01 |
SIGNALING BY BMP | 25 | 6.03e-01 | -0.060100 | 7.80e-01 |
GAB1 SIGNALOSOME | 14 | 6.97e-01 | 0.060000 | 8.39e-01 |
REGULATED PROTEOLYSIS OF P75NTR | 12 | 7.19e-01 | 0.059900 | 8.54e-01 |
PLATELET ACTIVATION SIGNALING AND AGGREGATION | 222 | 1.25e-01 | -0.059900 | 2.96e-01 |
SIGNALING BY GPCR | 486 | 2.43e-02 | 0.059800 | 1.02e-01 |
ONCOGENIC MAPK SIGNALING | 76 | 3.68e-01 | 0.059800 | 5.79e-01 |
VITAMIN B5 PANTOTHENATE METABOLISM | 15 | 6.91e-01 | -0.059300 | 8.35e-01 |
ALPHA PROTEIN KINASE 1 SIGNALING PATHWAY | 11 | 7.34e-01 | -0.059200 | 8.63e-01 |
KERATAN SULFATE KERATIN METABOLISM | 30 | 5.75e-01 | -0.059200 | 7.62e-01 |
POSITIVE EPIGENETIC REGULATION OF RRNA EXPRESSION | 63 | 4.17e-01 | -0.059100 | 6.27e-01 |
DOWNSTREAM SIGNALING OF ACTIVATED FGFR1 | 26 | 6.02e-01 | -0.059100 | 7.80e-01 |
ATTENUATION PHASE | 24 | 6.17e-01 | 0.059100 | 7.86e-01 |
RETROGRADE TRANSPORT AT THE TRANS GOLGI NETWORK | 48 | 4.81e-01 | -0.058800 | 6.87e-01 |
INTRAFLAGELLAR TRANSPORT | 52 | 4.65e-01 | 0.058600 | 6.76e-01 |
INTERACTIONS OF REV WITH HOST CELLULAR PROTEINS | 35 | 5.50e-01 | -0.058300 | 7.40e-01 |
TRANSPORT OF BILE SALTS AND ORGANIC ACIDS METAL IONS AND AMINE COMPOUNDS | 70 | 4.00e-01 | 0.058200 | 6.10e-01 |
MITOTIC PROMETAPHASE | 177 | 1.84e-01 | -0.057900 | 3.80e-01 |
CARDIAC CONDUCTION | 109 | 3.01e-01 | 0.057400 | 5.19e-01 |
DNA DOUBLE STRAND BREAK REPAIR | 136 | 2.52e-01 | -0.056900 | 4.65e-01 |
SIGNALING BY NTRK2 TRKB | 24 | 6.30e-01 | 0.056700 | 7.96e-01 |
SPRY REGULATION OF FGF SIGNALING | 16 | 6.97e-01 | -0.056100 | 8.39e-01 |
MICRORNA MIRNA BIOGENESIS | 24 | 6.36e-01 | 0.055900 | 7.99e-01 |
TRANSCRIPTIONAL REGULATION BY THE AP 2 TFAP2 FAMILY OF TRANSCRIPTION FACTORS | 32 | 5.85e-01 | -0.055800 | 7.69e-01 |
METABOLISM OF LIPIDS | 616 | 1.86e-02 | -0.055800 | 8.47e-02 |
METABOLIC DISORDERS OF BIOLOGICAL OXIDATION ENZYMES | 20 | 6.67e-01 | -0.055700 | 8.19e-01 |
POSTMITOTIC NUCLEAR PORE COMPLEX NPC REFORMATION | 26 | 6.24e-01 | -0.055600 | 7.92e-01 |
VEGFR2 MEDIATED CELL PROLIFERATION | 19 | 6.75e-01 | -0.055600 | 8.26e-01 |
AMINE LIGAND BINDING RECEPTORS | 28 | 6.11e-01 | 0.055600 | 7.85e-01 |
TFAP2 AP 2 FAMILY REGULATES TRANSCRIPTION OF GROWTH FACTORS AND THEIR RECEPTORS | 11 | 7.50e-01 | 0.055500 | 8.74e-01 |
SYNDECAN INTERACTIONS | 26 | 6.25e-01 | 0.055500 | 7.92e-01 |
RNA POLYMERASE III TRANSCRIPTION | 41 | 5.41e-01 | -0.055200 | 7.35e-01 |
PYRIMIDINE CATABOLISM | 10 | 7.64e-01 | -0.054900 | 8.83e-01 |
DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVITY | 23 | 6.50e-01 | -0.054700 | 8.11e-01 |
BASIGIN INTERACTIONS | 22 | 6.58e-01 | -0.054600 | 8.17e-01 |
CELL EXTRACELLULAR MATRIX INTERACTIONS | 18 | 6.91e-01 | -0.054100 | 8.35e-01 |
VASOPRESSIN REGULATES RENAL WATER HOMEOSTASIS VIA AQUAPORINS | 38 | 5.64e-01 | -0.054100 | 7.53e-01 |
JNK C JUN KINASES PHOSPHORYLATION AND ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1 | 22 | 6.63e-01 | -0.053700 | 8.19e-01 |
SIGNALING BY FLT3 ITD AND TKD MUTANTS | 16 | 7.12e-01 | 0.053400 | 8.50e-01 |
ESTROGEN DEPENDENT GENE EXPRESSION | 104 | 3.52e-01 | -0.052900 | 5.68e-01 |
P75NTR RECRUITS SIGNALLING COMPLEXES | 13 | 7.42e-01 | 0.052800 | 8.67e-01 |
MEMBRANE TRAFFICKING | 581 | 3.20e-02 | -0.052200 | 1.22e-01 |
TRAF6 MEDIATED INDUCTION OF TAK1 COMPLEX WITHIN TLR4 COMPLEX | 16 | 7.20e-01 | 0.051700 | 8.54e-01 |
INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS | 34 | 6.02e-01 | -0.051700 | 7.80e-01 |
CHEMOKINE RECEPTORS BIND CHEMOKINES | 18 | 7.06e-01 | -0.051400 | 8.45e-01 |
HATS ACETYLATE HISTONES | 94 | 3.90e-01 | 0.051300 | 6.00e-01 |
MITOCHONDRIAL BIOGENESIS | 93 | 4.02e-01 | -0.050300 | 6.10e-01 |
TRANSCRIPTIONAL REGULATION BY VENTX | 35 | 6.06e-01 | 0.050300 | 7.82e-01 |
METABOLISM OF STEROIDS | 115 | 3.55e-01 | 0.049900 | 5.69e-01 |
TP53 REGULATES TRANSCRIPTION OF DNA REPAIR GENES | 61 | 5.02e-01 | -0.049700 | 7.01e-01 |
ANTIGEN ACTIVATES B CELL RECEPTOR BCR LEADING TO GENERATION OF SECOND MESSENGERS | 26 | 6.64e-01 | -0.049300 | 8.19e-01 |
CALNEXIN CALRETICULIN CYCLE | 26 | 6.64e-01 | -0.049200 | 8.19e-01 |
VESICLE MEDIATED TRANSPORT | 614 | 4.16e-02 | -0.048300 | 1.45e-01 |
IONOTROPIC ACTIVITY OF KAINATE RECEPTORS | 10 | 7.92e-01 | -0.048100 | 9.01e-01 |
EPIGENETIC REGULATION OF GENE EXPRESSION | 104 | 3.99e-01 | -0.047900 | 6.10e-01 |
FOXO MEDIATED TRANSCRIPTION OF OXIDATIVE STRESS METABOLIC AND NEURONAL GENES | 25 | 6.84e-01 | 0.047000 | 8.31e-01 |
IL 6 TYPE CYTOKINE RECEPTOR LIGAND INTERACTIONS | 14 | 7.61e-01 | 0.046900 | 8.83e-01 |
ASSEMBLY OF COLLAGEN FIBRILS AND OTHER MULTIMERIC STRUCTURES | 53 | 5.56e-01 | 0.046800 | 7.45e-01 |
ACTIVATION OF ANTERIOR HOX GENES IN HINDBRAIN DEVELOPMENT DURING EARLY EMBRYOGENESIS | 76 | 4.85e-01 | -0.046300 | 6.89e-01 |
NEGATIVE REGULATION OF MET ACTIVITY | 20 | 7.20e-01 | -0.046300 | 8.54e-01 |
RESOLUTION OF D LOOP STRUCTURES | 30 | 6.63e-01 | -0.045900 | 8.19e-01 |
SIGNALING BY RHO GTPASES MIRO GTPASES AND RHOBTB3 | 630 | 5.06e-02 | 0.045800 | 1.65e-01 |
NEUROTRANSMITTER RECEPTORS AND POSTSYNAPTIC SIGNAL TRANSMISSION | 183 | 2.87e-01 | 0.045700 | 5.04e-01 |
PLASMA LIPOPROTEIN REMODELING | 14 | 7.67e-01 | 0.045700 | 8.83e-01 |
TRANSPORT OF MATURE MRNAS DERIVED FROM INTRONLESS TRANSCRIPTS | 41 | 6.16e-01 | 0.045300 | 7.86e-01 |
NUCLEAR ENVELOPE BREAKDOWN | 50 | 5.79e-01 | -0.045300 | 7.67e-01 |
G PROTEIN ACTIVATION | 22 | 7.15e-01 | -0.045000 | 8.52e-01 |
RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES | 79 | 4.91e-01 | 0.044800 | 6.94e-01 |
SIGNALING BY CSF3 G CSF | 29 | 6.77e-01 | -0.044600 | 8.27e-01 |
ACTIVATION OF NMDA RECEPTORS AND POSTSYNAPTIC EVENTS | 85 | 4.78e-01 | 0.044500 | 6.87e-01 |
RNA POLYMERASE II TRANSCRIBES SNRNA GENES | 74 | 5.09e-01 | -0.044400 | 7.04e-01 |
NF KB ACTIVATION THROUGH FADD RIP 1 PATHWAY MEDIATED BY CASPASE 8 AND 10 | 11 | 7.99e-01 | -0.044300 | 9.03e-01 |
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G2 CELL CYCLE ARREST | 16 | 7.59e-01 | 0.044200 | 8.82e-01 |
CASPASE ACTIVATION VIA DEPENDENCE RECEPTORS IN THE ABSENCE OF LIGAND | 10 | 8.09e-01 | 0.044200 | 9.07e-01 |
ERYTHROPOIETIN ACTIVATES PHOSPHOINOSITIDE 3 KINASE PI3K | 11 | 8.02e-01 | -0.043600 | 9.04e-01 |
ERYTHROPOIETIN ACTIVATES RAS | 13 | 7.85e-01 | -0.043600 | 8.96e-01 |
NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR NLR SIGNALING PATHWAYS | 52 | 5.87e-01 | -0.043600 | 7.70e-01 |
REPRODUCTION | 79 | 5.05e-01 | -0.043500 | 7.01e-01 |
CA2 PATHWAY | 58 | 5.74e-01 | 0.042700 | 7.62e-01 |
O LINKED GLYCOSYLATION OF MUCINS | 42 | 6.33e-01 | -0.042700 | 7.98e-01 |
RAC3 GTPASE CYCLE | 91 | 4.83e-01 | 0.042600 | 6.87e-01 |
CELLULAR HEXOSE TRANSPORT | 11 | 8.07e-01 | 0.042500 | 9.07e-01 |
PLATELET ADHESION TO EXPOSED COLLAGEN | 12 | 7.99e-01 | 0.042400 | 9.03e-01 |
DOWNSTREAM SIGNALING OF ACTIVATED FGFR4 | 19 | 7.49e-01 | 0.042400 | 8.74e-01 |
MAPK FAMILY SIGNALING CASCADES | 290 | 2.15e-01 | -0.042400 | 4.18e-01 |
ACYL CHAIN REMODELLING OF PE | 17 | 7.67e-01 | -0.041600 | 8.83e-01 |
MAP2K AND MAPK ACTIVATION | 36 | 6.69e-01 | 0.041200 | 8.21e-01 |
RND1 GTPASE CYCLE | 38 | 6.62e-01 | 0.041000 | 8.19e-01 |
INTRACELLULAR SIGNALING BY SECOND MESSENGERS | 286 | 2.39e-01 | -0.040500 | 4.49e-01 |
PREGNENOLONE BIOSYNTHESIS | 12 | 8.09e-01 | -0.040400 | 9.07e-01 |
PLASMA LIPOPROTEIN ASSEMBLY | 12 | 8.09e-01 | 0.040300 | 9.07e-01 |
SUMOYLATION OF DNA METHYLATION PROTEINS | 16 | 7.81e-01 | 0.040200 | 8.95e-01 |
DNA DOUBLE STRAND BREAK RESPONSE | 53 | 6.13e-01 | 0.040200 | 7.85e-01 |
TRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL | 43 | 6.53e-01 | -0.039700 | 8.13e-01 |
ORGANIC CATION ANION ZWITTERION TRANSPORT | 11 | 8.21e-01 | 0.039400 | 9.11e-01 |
GLYCOGEN METABOLISM | 25 | 7.34e-01 | 0.039300 | 8.63e-01 |
RNA POLYMERASE II TRANSCRIPTION TERMINATION | 65 | 5.86e-01 | -0.039100 | 7.69e-01 |
SIGNALLING TO RAS | 20 | 7.62e-01 | 0.039100 | 8.83e-01 |
ADHERENS JUNCTIONS INTERACTIONS | 30 | 7.12e-01 | 0.038900 | 8.50e-01 |
EGFR DOWNREGULATION | 28 | 7.22e-01 | -0.038900 | 8.54e-01 |
RAC2 GTPASE CYCLE | 88 | 5.29e-01 | 0.038900 | 7.22e-01 |
IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX | 10 | 8.33e-01 | -0.038500 | 9.17e-01 |
TRANSCRIPTIONAL REGULATION OF GRANULOPOIESIS | 45 | 6.55e-01 | 0.038500 | 8.15e-01 |
JOSEPHIN DOMAIN DUBS | 11 | 8.25e-01 | -0.038500 | 9.12e-01 |
SIGNALING BY FGFR1 IN DISEASE | 33 | 7.04e-01 | 0.038300 | 8.44e-01 |
RHOD GTPASE CYCLE | 51 | 6.39e-01 | 0.038000 | 8.02e-01 |
REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN | 29 | 7.26e-01 | 0.037600 | 8.58e-01 |
COPI DEPENDENT GOLGI TO ER RETROGRADE TRAFFIC | 86 | 5.49e-01 | 0.037400 | 7.40e-01 |
TRANSCRIPTIONAL REGULATION BY RUNX1 | 181 | 3.87e-01 | -0.037300 | 5.98e-01 |
ERCC6 CSB AND EHMT2 G9A POSITIVELY REGULATE RRNA EXPRESSION | 33 | 7.11e-01 | -0.037300 | 8.50e-01 |
RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES | 86 | 5.51e-01 | 0.037200 | 7.40e-01 |
RETROGRADE NEUROTROPHIN SIGNALLING | 14 | 8.10e-01 | 0.037200 | 9.07e-01 |
UPTAKE AND ACTIONS OF BACTERIAL TOXINS | 28 | 7.35e-01 | 0.037000 | 8.64e-01 |
SIGNALING BY VEGF | 104 | 5.15e-01 | -0.037000 | 7.09e-01 |
AURKA ACTIVATION BY TPX2 | 72 | 5.88e-01 | 0.037000 | 7.70e-01 |
SODIUM CALCIUM EXCHANGERS | 10 | 8.41e-01 | -0.036700 | 9.20e-01 |
FORMATION OF THE BETA CATENIN TCF TRANSACTIVATING COMPLEX | 47 | 6.65e-01 | 0.036500 | 8.19e-01 |
NEGATIVE REGULATION OF FGFR4 SIGNALING | 23 | 7.62e-01 | -0.036400 | 8.83e-01 |
INTERLEUKIN 27 SIGNALING | 10 | 8.42e-01 | 0.036400 | 9.20e-01 |
SCAVENGING BY CLASS A RECEPTORS | 15 | 8.09e-01 | -0.036100 | 9.07e-01 |
TELOMERE EXTENSION BY TELOMERASE | 22 | 7.70e-01 | 0.036100 | 8.85e-01 |
REGULATION OF GLYCOLYSIS BY FRUCTOSE 2 6 BISPHOSPHATE METABOLISM | 11 | 8.37e-01 | -0.035900 | 9.18e-01 |
SIGNALING BY BRAF AND RAF FUSIONS | 60 | 6.34e-01 | 0.035500 | 7.98e-01 |
PROCESSING OF INTRONLESS PRE MRNAS | 19 | 7.92e-01 | -0.035000 | 9.01e-01 |
FCGAMMA RECEPTOR FCGR DEPENDENT PHAGOCYTOSIS | 81 | 5.90e-01 | -0.034600 | 7.72e-01 |
CLASS A 1 RHODOPSIN LIKE RECEPTORS | 188 | 4.16e-01 | 0.034400 | 6.27e-01 |
SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R | 46 | 6.87e-01 | -0.034400 | 8.32e-01 |
UPTAKE AND FUNCTION OF ANTHRAX TOXINS | 11 | 8.45e-01 | 0.034100 | 9.21e-01 |
SIGNAL REGULATORY PROTEIN FAMILY INTERACTIONS | 11 | 8.45e-01 | -0.034000 | 9.21e-01 |
GROWTH HORMONE RECEPTOR SIGNALING | 20 | 7.94e-01 | -0.033800 | 9.02e-01 |
MAP3K8 TPL2 DEPENDENT MAPK1 3 ACTIVATION | 16 | 8.16e-01 | 0.033700 | 9.08e-01 |
GLUCOSE METABOLISM | 81 | 6.03e-01 | -0.033500 | 7.80e-01 |
SIGNALING BY HEDGEHOG | 142 | 5.00e-01 | 0.032800 | 7.00e-01 |
GABA RECEPTOR ACTIVATION | 55 | 6.76e-01 | -0.032600 | 8.26e-01 |
SIGNALING BY SCF KIT | 41 | 7.20e-01 | 0.032300 | 8.54e-01 |
NOTCH2 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS | 23 | 7.90e-01 | 0.032100 | 9.00e-01 |
METABOLISM OF WATER SOLUBLE VITAMINS AND COFACTORS | 103 | 5.73e-01 | -0.032100 | 7.62e-01 |
DISEASES OF CARBOHYDRATE METABOLISM | 29 | 7.65e-01 | 0.032100 | 8.83e-01 |
SIGNALING BY ERBB2 IN CANCER | 25 | 7.81e-01 | -0.032100 | 8.95e-01 |
REPRESSION OF WNT TARGET GENES | 14 | 8.36e-01 | 0.032000 | 9.18e-01 |
FANCONI ANEMIA PATHWAY | 36 | 7.42e-01 | -0.031700 | 8.67e-01 |
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN CYTOCHROME C RELEASE | 19 | 8.13e-01 | -0.031300 | 9.08e-01 |
SIGNALING BY HIPPO | 20 | 8.11e-01 | 0.030900 | 9.07e-01 |
EGR2 AND SOX10 MEDIATED INITIATION OF SCHWANN CELL MYELINATION | 27 | 7.82e-01 | 0.030800 | 8.95e-01 |
SUMOYLATION OF DNA REPLICATION PROTEINS | 42 | 7.31e-01 | -0.030700 | 8.62e-01 |
DISEASES OF SIGNAL TRANSDUCTION BY GROWTH FACTOR RECEPTORS AND SECOND MESSENGERS | 368 | 3.17e-01 | -0.030400 | 5.31e-01 |
THE PHOTOTRANSDUCTION CASCADE | 21 | 8.11e-01 | 0.030200 | 9.07e-01 |
SHC MEDIATED CASCADE FGFR3 | 13 | 8.51e-01 | -0.030100 | 9.23e-01 |
SUMOYLATION | 164 | 5.21e-01 | -0.029100 | 7.14e-01 |
EPH EPHRIN SIGNALING | 92 | 6.31e-01 | -0.029000 | 7.96e-01 |
TRAF6 MEDIATED IRF7 ACTIVATION | 15 | 8.46e-01 | -0.028900 | 9.21e-01 |
TP53 REGULATES TRANSCRIPTION OF CELL CYCLE GENES | 46 | 7.36e-01 | -0.028800 | 8.64e-01 |
PI 3K CASCADE FGFR3 | 13 | 8.59e-01 | 0.028500 | 9.26e-01 |
SHC1 EVENTS IN ERBB2 SIGNALING | 21 | 8.22e-01 | -0.028400 | 9.11e-01 |
ORGANELLE BIOGENESIS AND MAINTENANCE | 286 | 4.11e-01 | 0.028300 | 6.23e-01 |
SIGNALING BY ERYTHROPOIETIN | 24 | 8.14e-01 | 0.027700 | 9.08e-01 |
GLUCAGON SIGNALING IN METABOLIC REGULATION | 30 | 7.97e-01 | 0.027100 | 9.03e-01 |
INSULIN PROCESSING | 24 | 8.18e-01 | -0.027100 | 9.10e-01 |
SYNTHESIS OF PIPS AT THE LATE ENDOSOME MEMBRANE | 11 | 8.77e-01 | 0.027000 | 9.41e-01 |
GPCR LIGAND BINDING | 271 | 4.47e-01 | 0.026900 | 6.59e-01 |
AGGREPHAGY | 35 | 7.91e-01 | 0.025900 | 9.01e-01 |
SURFACTANT METABOLISM | 16 | 8.59e-01 | -0.025700 | 9.26e-01 |
CELL JUNCTION ORGANIZATION | 74 | 7.04e-01 | -0.025600 | 8.44e-01 |
TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER | 43 | 7.72e-01 | -0.025500 | 8.87e-01 |
REGULATION OF PTEN GENE TRANSCRIPTION | 59 | 7.39e-01 | -0.025100 | 8.66e-01 |
CIRCADIAN CLOCK | 68 | 7.21e-01 | 0.025100 | 8.54e-01 |
RHOF GTPASE CYCLE | 41 | 7.83e-01 | -0.024800 | 8.96e-01 |
ZINC TRANSPORTERS | 16 | 8.64e-01 | 0.024800 | 9.30e-01 |
LEISHMANIA INFECTION | 199 | 5.51e-01 | -0.024600 | 7.40e-01 |
METABOLISM OF VITAMINS AND COFACTORS | 154 | 6.00e-01 | -0.024500 | 7.80e-01 |
DOWNREGULATION OF ERBB2 SIGNALING | 28 | 8.24e-01 | -0.024300 | 9.12e-01 |
ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION | 23 | 8.41e-01 | 0.024200 | 9.20e-01 |
CAMK IV MEDIATED PHOSPHORYLATION OF CREB | 10 | 8.98e-01 | -0.023500 | 9.51e-01 |
NUCLEAR IMPORT OF REV PROTEIN | 32 | 8.19e-01 | -0.023400 | 9.10e-01 |
SIGNALING BY ACTIVIN | 12 | 8.89e-01 | -0.023300 | 9.45e-01 |
SIGNALING BY RECEPTOR TYROSINE KINASES | 467 | 3.91e-01 | -0.023200 | 6.00e-01 |
HDR THROUGH MMEJ ALT NHEJ | 10 | 9.01e-01 | -0.022700 | 9.51e-01 |
G ALPHA Q SIGNALLING EVENTS | 157 | 6.25e-01 | 0.022600 | 7.92e-01 |
AKT PHOSPHORYLATES TARGETS IN THE CYTOSOL | 14 | 8.84e-01 | 0.022400 | 9.44e-01 |
SUMOYLATION OF UBIQUITINYLATION PROTEINS | 37 | 8.14e-01 | -0.022300 | 9.08e-01 |
RHOG GTPASE CYCLE | 74 | 7.40e-01 | 0.022300 | 8.67e-01 |
MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE | 15 | 8.82e-01 | -0.022200 | 9.43e-01 |
REGULATION OF INSULIN LIKE GROWTH FACTOR IGF TRANSPORT AND UPTAKE BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS | 91 | 7.16e-01 | -0.022100 | 8.53e-01 |
VISUAL PHOTOTRANSDUCTION | 61 | 7.67e-01 | 0.021900 | 8.83e-01 |
STRIATED MUSCLE CONTRACTION | 28 | 8.41e-01 | 0.021900 | 9.20e-01 |
NUCLEOBASE CATABOLISM | 31 | 8.34e-01 | -0.021800 | 9.17e-01 |
CONSTITUTIVE SIGNALING BY ABERRANT PI3K IN CANCER | 63 | 7.66e-01 | -0.021700 | 8.83e-01 |
CD28 DEPENDENT PI3K AKT SIGNALING | 21 | 8.65e-01 | 0.021500 | 9.30e-01 |
PEPTIDE LIGAND BINDING RECEPTORS | 112 | 6.98e-01 | 0.021200 | 8.39e-01 |
G ALPHA I SIGNALLING EVENTS | 205 | 6.05e-01 | 0.021000 | 7.82e-01 |
CELL SURFACE INTERACTIONS AT THE VASCULAR WALL | 93 | 7.27e-01 | -0.020900 | 8.58e-01 |
PLATELET HOMEOSTASIS | 78 | 7.53e-01 | -0.020600 | 8.76e-01 |
GABA B RECEPTOR ACTIVATION | 40 | 8.22e-01 | 0.020500 | 9.11e-01 |
REGULATION OF TP53 EXPRESSION AND DEGRADATION | 36 | 8.32e-01 | -0.020500 | 9.16e-01 |
SIGNALING BY NOTCH | 190 | 6.34e-01 | -0.020100 | 7.98e-01 |
RECYCLING PATHWAY OF L1 | 40 | 8.28e-01 | -0.019900 | 9.14e-01 |
SUMOYLATION OF SUMOYLATION PROTEINS | 33 | 8.45e-01 | -0.019600 | 9.21e-01 |
FRS MEDIATED FGFR4 SIGNALING | 14 | 9.01e-01 | -0.019200 | 9.51e-01 |
TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX | 30 | 8.57e-01 | 0.019000 | 9.26e-01 |
APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS | 34 | 8.50e-01 | 0.018800 | 9.23e-01 |
NUCLEOTIDE SALVAGE | 21 | 8.82e-01 | -0.018700 | 9.43e-01 |
SLC TRANSPORTER DISORDERS | 77 | 7.82e-01 | 0.018300 | 8.95e-01 |
DEFECTS IN VITAMIN AND COFACTOR METABOLISM | 21 | 8.87e-01 | -0.017900 | 9.44e-01 |
CLASS B 2 SECRETIN FAMILY RECEPTORS | 71 | 7.98e-01 | -0.017500 | 9.03e-01 |
TNF RECEPTOR SUPERFAMILY TNFSF MEMBERS MEDIATING NON CANONICAL NF KB PATHWAY | 13 | 9.14e-01 | -0.017300 | 9.56e-01 |
CELL CELL COMMUNICATION | 107 | 7.58e-01 | 0.017300 | 8.81e-01 |
WNT5A DEPENDENT INTERNALIZATION OF FZD2 FZD5 AND ROR2 | 13 | 9.15e-01 | 0.017100 | 9.56e-01 |
FOXO MEDIATED TRANSCRIPTION OF CELL DEATH GENES | 15 | 9.09e-01 | 0.017100 | 9.53e-01 |
ANTI INFLAMMATORY RESPONSE FAVOURING LEISHMANIA PARASITE INFECTION | 120 | 7.47e-01 | 0.017000 | 8.72e-01 |
SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL GPI | 18 | 9.02e-01 | -0.016800 | 9.51e-01 |
SIGNALING BY MODERATE KINASE ACTIVITY BRAF MUTANTS | 41 | 8.56e-01 | 0.016400 | 9.26e-01 |
ACYL CHAIN REMODELLING OF PG | 10 | 9.29e-01 | -0.016300 | 9.64e-01 |
FRS MEDIATED FGFR3 SIGNALING | 15 | 9.13e-01 | 0.016300 | 9.56e-01 |
REGULATION OF PLK1 ACTIVITY AT G2 M TRANSITION | 86 | 7.96e-01 | 0.016100 | 9.03e-01 |
REGULATION OF BETA CELL DEVELOPMENT | 29 | 8.81e-01 | 0.016100 | 9.43e-01 |
PHASE I FUNCTIONALIZATION OF COMPOUNDS | 59 | 8.32e-01 | -0.016000 | 9.16e-01 |
CONSTITUTIVE SIGNALING BY LIGAND RESPONSIVE EGFR CANCER VARIANTS | 19 | 9.04e-01 | -0.015900 | 9.51e-01 |
DSCAM INTERACTIONS | 11 | 9.29e-01 | 0.015500 | 9.64e-01 |
NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY | 45 | 8.58e-01 | 0.015400 | 9.26e-01 |
TRNA AMINOACYLATION | 42 | 8.64e-01 | -0.015300 | 9.30e-01 |
PI METABOLISM | 79 | 8.15e-01 | 0.015200 | 9.08e-01 |
RAF INDEPENDENT MAPK1 3 ACTIVATION | 21 | 9.04e-01 | -0.015200 | 9.51e-01 |
REGULATION OF SIGNALING BY CBL | 22 | 9.03e-01 | 0.015100 | 9.51e-01 |
NS1 MEDIATED EFFECTS ON HOST PATHWAYS | 37 | 8.75e-01 | -0.015000 | 9.39e-01 |
EXPORT OF VIRAL RIBONUCLEOPROTEINS FROM NUCLEUS | 31 | 8.85e-01 | -0.015000 | 9.44e-01 |
SIGNALING BY FGFR4 | 33 | 8.82e-01 | -0.014900 | 9.43e-01 |
CLEC7A DECTIN 1 INDUCES NFAT ACTIVATION | 11 | 9.33e-01 | -0.014700 | 9.66e-01 |
TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM | 79 | 8.26e-01 | 0.014300 | 9.12e-01 |
COBALAMIN CBL VITAMIN B12 TRANSPORT AND METABOLISM | 14 | 9.26e-01 | -0.014300 | 9.63e-01 |
SIGNALING BY FGFR3 | 35 | 8.84e-01 | 0.014200 | 9.44e-01 |
HEDGEHOG OFF STATE | 107 | 8.02e-01 | -0.014000 | 9.04e-01 |
GLYCOGEN STORAGE DISEASES | 12 | 9.35e-01 | -0.013700 | 9.67e-01 |
NEGATIVE REGULATION OF FGFR3 SIGNALING | 24 | 9.09e-01 | -0.013500 | 9.53e-01 |
SEMA3A PAK DEPENDENT AXON REPULSION | 16 | 9.26e-01 | -0.013400 | 9.63e-01 |
CELLULAR SENESCENCE | 143 | 7.84e-01 | -0.013300 | 8.96e-01 |
HS GAG BIOSYNTHESIS | 30 | 9.02e-01 | 0.013000 | 9.51e-01 |
SUMOYLATION OF IMMUNE RESPONSE PROTEINS | 11 | 9.42e-01 | -0.012800 | 9.71e-01 |
SMAD2 SMAD3 SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION | 31 | 9.04e-01 | 0.012500 | 9.51e-01 |
DECTIN 2 FAMILY | 10 | 9.47e-01 | -0.012200 | 9.73e-01 |
HCMV EARLY EVENTS | 81 | 8.50e-01 | 0.012100 | 9.23e-01 |
PI 3K CASCADE FGFR4 | 12 | 9.43e-01 | -0.011900 | 9.72e-01 |
DEVELOPMENTAL BIOLOGY | 832 | 5.77e-01 | 0.011400 | 7.65e-01 |
INTRA GOLGI AND RETROGRADE GOLGI TO ER TRAFFIC | 185 | 7.95e-01 | -0.011100 | 9.02e-01 |
GOLGI TO ER RETROGRADE TRANSPORT | 119 | 8.39e-01 | -0.010800 | 9.20e-01 |
NUCLEAR PORE COMPLEX NPC DISASSEMBLY | 33 | 9.16e-01 | 0.010600 | 9.56e-01 |
HIV ELONGATION ARREST AND RECOVERY | 32 | 9.18e-01 | -0.010500 | 9.57e-01 |
SIGNALING BY PTK6 | 50 | 9.00e-01 | -0.010300 | 9.51e-01 |
OXIDATIVE STRESS INDUCED SENESCENCE | 79 | 8.86e-01 | 0.009300 | 9.44e-01 |
SIGNALING BY ERBB4 | 57 | 9.05e-01 | -0.009170 | 9.51e-01 |
PI3K EVENTS IN ERBB2 SIGNALING | 15 | 9.52e-01 | -0.008960 | 9.75e-01 |
REGULATION OF TP53 ACTIVITY | 154 | 8.53e-01 | -0.008680 | 9.24e-01 |
REGULATION OF FZD BY UBIQUITINATION | 19 | 9.48e-01 | 0.008580 | 9.73e-01 |
SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE | 52 | 9.15e-01 | 0.008520 | 9.56e-01 |
GLYCOLYSIS | 67 | 9.04e-01 | -0.008510 | 9.51e-01 |
SIGNALING BY WNT IN CANCER | 31 | 9.36e-01 | 0.008380 | 9.67e-01 |
SUMOYLATION OF CHROMATIN ORGANIZATION PROTEINS | 58 | 9.13e-01 | -0.008340 | 9.56e-01 |
CARNITINE METABOLISM | 14 | 9.57e-01 | -0.008240 | 9.76e-01 |
TRAF6 MEDIATED NF KB ACTIVATION | 22 | 9.48e-01 | 0.008000 | 9.73e-01 |
GENE SILENCING BY RNA | 83 | 9.02e-01 | 0.007790 | 9.51e-01 |
FCERI MEDIATED CA 2 MOBILIZATION | 26 | 9.46e-01 | -0.007680 | 9.73e-01 |
CGMP EFFECTS | 15 | 9.60e-01 | 0.007490 | 9.77e-01 |
EPHRIN SIGNALING | 19 | 9.55e-01 | 0.007460 | 9.75e-01 |
CREB1 PHOSPHORYLATION THROUGH NMDA RECEPTOR MEDIATED ACTIVATION OF RAS SIGNALING | 28 | 9.49e-01 | -0.006930 | 9.73e-01 |
EPH EPHRIN MEDIATED REPULSION OF CELLS | 51 | 9.32e-01 | -0.006890 | 9.66e-01 |
METABOLISM OF CARBOHYDRATES | 261 | 8.51e-01 | 0.006770 | 9.23e-01 |
FORMATION OF THE CORNIFIED ENVELOPE | 27 | 9.54e-01 | 0.006470 | 9.75e-01 |
KERATINIZATION | 27 | 9.54e-01 | 0.006470 | 9.75e-01 |
MISCELLANEOUS TRANSPORT AND BINDING EVENTS | 20 | 9.63e-01 | -0.005960 | 9.79e-01 |
UNFOLDED PROTEIN RESPONSE UPR | 85 | 9.26e-01 | -0.005850 | 9.63e-01 |
NUCLEAR SIGNALING BY ERBB4 | 31 | 9.59e-01 | 0.005370 | 9.77e-01 |
GLUCAGON LIKE PEPTIDE 1 GLP1 REGULATES INSULIN SECRETION | 39 | 9.54e-01 | 0.005340 | 9.75e-01 |
INTEGRIN CELL SURFACE INTERACTIONS | 74 | 9.38e-01 | -0.005190 | 9.69e-01 |
PI3K AKT SIGNALING IN CANCER | 90 | 9.33e-01 | -0.005150 | 9.66e-01 |
ERBB2 REGULATES CELL MOTILITY | 14 | 9.74e-01 | -0.004940 | 9.88e-01 |
TRANSPORT OF SMALL MOLECULES | 590 | 8.70e-01 | -0.003960 | 9.35e-01 |
CYTOSOLIC SENSORS OF PATHOGEN ASSOCIATED DNA | 59 | 9.61e-01 | -0.003650 | 9.78e-01 |
MITOTIC TELOPHASE CYTOKINESIS | 13 | 9.83e-01 | 0.003380 | 9.92e-01 |
SIGNALING BY PDGFR IN DISEASE | 20 | 9.80e-01 | -0.003280 | 9.91e-01 |
WNT5A DEPENDENT INTERNALIZATION OF FZD4 | 15 | 9.83e-01 | 0.003200 | 9.92e-01 |
INTRA GOLGI TRAFFIC | 43 | 9.72e-01 | -0.003120 | 9.87e-01 |
BINDING AND UPTAKE OF LIGANDS BY SCAVENGER RECEPTORS | 35 | 9.76e-01 | 0.002970 | 9.88e-01 |
TRANSCRIPTIONAL REGULATION BY E2F6 | 34 | 9.80e-01 | -0.002550 | 9.91e-01 |
LDL CLEARANCE | 16 | 9.88e-01 | -0.002220 | 9.93e-01 |
ACTIVATED NTRK2 SIGNALS THROUGH FRS2 AND FRS3 | 10 | 9.91e-01 | -0.002030 | 9.95e-01 |
OPIOID SIGNALLING | 86 | 9.74e-01 | 0.002020 | 9.88e-01 |
HEMOSTASIS | 475 | 9.45e-01 | 0.001850 | 9.73e-01 |
TRANSPORT OF THE SLBP DEPENDANT MATURE MRNA | 34 | 9.85e-01 | 0.001810 | 9.92e-01 |
SYNTHESIS OF PC | 27 | 9.88e-01 | -0.001680 | 9.93e-01 |
POTENTIAL THERAPEUTICS FOR SARS | 78 | 9.85e-01 | -0.001240 | 9.92e-01 |
CONSTITUTIVE SIGNALING BY EGFRVIII | 15 | 9.95e-01 | -0.001030 | 9.96e-01 |
SYNTHESIS OF PYROPHOSPHATES IN THE CYTOSOL | 10 | 9.96e-01 | -0.001020 | 9.96e-01 |
NOD1 2 SIGNALING PATHWAY | 35 | 9.94e-01 | 0.000765 | 9.96e-01 |
ADORA2B MEDIATED ANTI INFLAMMATORY CYTOKINES PRODUCTION | 95 | 9.90e-01 | 0.000742 | 9.94e-01 |
NERVOUS SYSTEM DEVELOPMENT | 554 | 9.82e-01 | 0.000549 | 9.92e-01 |
DISEASES OF IMMUNE SYSTEM | 27 | 9.96e-01 | -0.000495 | 9.96e-01 |
ERYTHROCYTES TAKE UP CARBON DIOXIDE AND RELEASE OXYGEN
299 | |
---|---|
set | ERYTHROCYTES TAKE UP CARBON DIOXIDE AND RELEASE OXYGEN |
setSize | 10 |
pANOVA | 0.000141 |
s.dist | -0.695 |
p.adjustANOVA | 0.00154 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Aqp1 | -8402 |
Hbb-bt | -8023 |
Cyb5r4 | -7594 |
Car4 | -6819 |
Hba-a1 | -6349 |
Cyb5r2 | -6138 |
Cyb5r1 | -5444 |
Hba-a2 | -5283 |
Car2 | -4736 |
Cyb5rl | 1429 |
GeneID | Gene Rank |
---|---|
Aqp1 | -8402 |
Hbb-bt | -8023 |
Cyb5r4 | -7594 |
Car4 | -6819 |
Hba-a1 | -6349 |
Cyb5r2 | -6138 |
Cyb5r1 | -5444 |
Hba-a2 | -5283 |
Car2 | -4736 |
Cyb5rl | 1429 |
ADENYLATE CYCLASE ACTIVATING PATHWAY
35 | |
---|---|
set | ADENYLATE CYCLASE ACTIVATING PATHWAY |
setSize | 10 |
pANOVA | 0.000195 |
s.dist | 0.68 |
p.adjustANOVA | 0.00203 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Adcy6 | 8807 |
Adcy4 | 8795 |
Adcy5 | 7460 |
Adcy8 | 7205 |
Adcy2 | 6106 |
Adcy9 | 5535 |
Adcy3 | 5523 |
Adcy7 | 5402 |
Gnal | 4616 |
Adcy1 | 3287 |
GeneID | Gene Rank |
---|---|
Adcy6 | 8807 |
Adcy4 | 8795 |
Adcy5 | 7460 |
Adcy8 | 7205 |
Adcy2 | 6106 |
Adcy9 | 5535 |
Adcy3 | 5523 |
Adcy7 | 5402 |
Gnal | 4616 |
Adcy1 | 3287 |
REGULATION OF RUNX1 EXPRESSION AND ACTIVITY
817 | |
---|---|
set | REGULATION OF RUNX1 EXPRESSION AND ACTIVITY |
setSize | 17 |
pANOVA | 6.32e-05 |
s.dist | 0.56 |
p.adjustANOVA | 0.000809 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ago3 | 8738 |
Tnrc6b | 8726 |
Ago2 | 8313 |
Tnrc6a | 8107 |
Ptpn11 | 7387 |
Mov10 | 7384 |
Ago1 | 6862 |
Pml | 6835 |
Cdk6 | 6627 |
Ago4 | 5781 |
Runx1 | 5573 |
Src | 5451 |
Tnrc6c | 5157 |
Ccnd2 | 3372 |
Ccnd3 | 2218 |
Cbfb | -2842 |
Ccnd1 | -4876 |
GeneID | Gene Rank |
---|---|
Ago3 | 8738 |
Tnrc6b | 8726 |
Ago2 | 8313 |
Tnrc6a | 8107 |
Ptpn11 | 7387 |
Mov10 | 7384 |
Ago1 | 6862 |
Pml | 6835 |
Cdk6 | 6627 |
Ago4 | 5781 |
Runx1 | 5573 |
Src | 5451 |
Tnrc6c | 5157 |
Ccnd2 | 3372 |
Ccnd3 | 2218 |
Cbfb | -2842 |
Ccnd1 | -4876 |
ENDOSOMAL VACUOLAR PATHWAY
283 | |
---|---|
set | ENDOSOMAL VACUOLAR PATHWAY |
setSize | 10 |
pANOVA | 0.00388 |
s.dist | -0.527 |
p.adjustANOVA | 0.0256 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2-T23 | -7996 |
B2m | -7326 |
H2-M3 | -6895 |
Ctsl | -6233 |
Ctss | -5908 |
H2-D1 | -5834 |
H2-Q7 | -4557 |
H2-Q2 | -3151 |
H2-Q10 | 705 |
Lnpep | 4487 |
GeneID | Gene Rank |
---|---|
H2-T23 | -7996 |
B2m | -7326 |
H2-M3 | -6895 |
Ctsl | -6233 |
Ctss | -5908 |
H2-D1 | -5834 |
H2-Q7 | -4557 |
H2-Q2 | -3151 |
H2-Q10 | 705 |
Lnpep | 4487 |
TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR
1106 | |
---|---|
set | TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR |
setSize | 11 |
pANOVA | 0.00283 |
s.dist | -0.52 |
p.adjustANOVA | 0.0197 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Tlr3 | -7487 |
Hsp90b1 | -6977 |
Lgmn | -6719 |
Ctsl | -6233 |
Ctss | -5908 |
Ctsb | -5445 |
Tlr7 | -3907 |
Cnpy3 | -3425 |
Ctsk | -2446 |
Unc93b1 | -991 |
Tlr9 | 3276 |
GeneID | Gene Rank |
---|---|
Tlr3 | -7487 |
Hsp90b1 | -6977 |
Lgmn | -6719 |
Ctsl | -6233 |
Ctss | -5908 |
Ctsb | -5445 |
Tlr7 | -3907 |
Cnpy3 | -3425 |
Ctsk | -2446 |
Unc93b1 | -991 |
Tlr9 | 3276 |
INTERACTION BETWEEN L1 AND ANKYRINS
461 | |
---|---|
set | INTERACTION BETWEEN L1 AND ANKYRINS |
setSize | 27 |
pANOVA | 4.35e-06 |
s.dist | 0.511 |
p.adjustANOVA | 8.55e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Sptbn4 | 9031 |
Nfasc | 8962 |
Kcnq2 | 8536 |
Sptbn5 | 8498 |
Ank2 | 8454 |
Scn8a | 8237 |
Ank3 | 7702 |
Sptb | 6944 |
Sptan1 | 6803 |
Sptbn2 | 6783 |
Ank1 | 6709 |
Sptbn1 | 6657 |
L1cam | 6559 |
Scn5a | 6452 |
Scn2b | 6181 |
Scn9a | 5418 |
Scn7a | 3987 |
Nrcam | 3474 |
Scn4b | 3458 |
Scn3a | 3400 |
GeneID | Gene Rank |
---|---|
Sptbn4 | 9031 |
Nfasc | 8962 |
Kcnq2 | 8536 |
Sptbn5 | 8498 |
Ank2 | 8454 |
Scn8a | 8237 |
Ank3 | 7702 |
Sptb | 6944 |
Sptan1 | 6803 |
Sptbn2 | 6783 |
Ank1 | 6709 |
Sptbn1 | 6657 |
L1cam | 6559 |
Scn5a | 6452 |
Scn2b | 6181 |
Scn9a | 5418 |
Scn7a | 3987 |
Nrcam | 3474 |
Scn4b | 3458 |
Scn3a | 3400 |
Scn2a | 2477 |
Scn3b | 2230 |
Kcnq3 | 2109 |
Scn1a | 1587 |
Scn1b | -2545 |
Actb | -2632 |
Actg1 | -6189 |
RETINOID CYCLE DISEASE EVENTS
843 | |
---|---|
set | RETINOID CYCLE DISEASE EVENTS |
setSize | 10 |
pANOVA | 0.00739 |
s.dist | -0.489 |
p.adjustANOVA | 0.0422 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Stra6 | -8225 |
Abca4 | -8163 |
Ttr | -7408 |
Rdh5 | -6237 |
Napepld | -5214 |
Rdh12 | -5021 |
Rbp1 | -3616 |
Lrat | 787 |
Rlbp1 | 1485 |
Rbp4 | 2232 |
GeneID | Gene Rank |
---|---|
Stra6 | -8225 |
Abca4 | -8163 |
Ttr | -7408 |
Rdh5 | -6237 |
Napepld | -5214 |
Rdh12 | -5021 |
Rbp1 | -3616 |
Lrat | 787 |
Rlbp1 | 1485 |
Rbp4 | 2232 |
SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYMES
1035 | |
---|---|
set | SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYMES |
setSize | 29 |
pANOVA | 6.4e-06 |
s.dist | -0.484 |
p.adjustANOVA | 0.000113 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ube2w | -8355 |
Ube2e3 | -8352 |
Ube2g1 | -8298 |
Ube2d1 | -8221 |
Ube2q2 | -8178 |
Uchl3 | -8038 |
Ube2e1 | -7973 |
Ube2b | -7942 |
Ube2a | -7921 |
Ube2l3 | -7831 |
Ube2k | -7805 |
Ube2d2a | -7701 |
Ube2r2 | -5535 |
Ube2s | -4651 |
Otulin | -4523 |
Cdc34 | -4472 |
Ubb | -4221 |
Rps27a | -4124 |
Ube2t | -3528 |
Uba6 | -3395 |
GeneID | Gene Rank |
---|---|
Ube2w | -8355 |
Ube2e3 | -8352 |
Ube2g1 | -8298 |
Ube2d1 | -8221 |
Ube2q2 | -8178 |
Uchl3 | -8038 |
Ube2e1 | -7973 |
Ube2b | -7942 |
Ube2a | -7921 |
Ube2l3 | -7831 |
Ube2k | -7805 |
Ube2d2a | -7701 |
Ube2r2 | -5535 |
Ube2s | -4651 |
Otulin | -4523 |
Cdc34 | -4472 |
Ubb | -4221 |
Rps27a | -4124 |
Ube2t | -3528 |
Uba6 | -3395 |
Usp9x | -2427 |
Ube2z | -1185 |
Usp5 | 2235 |
Ube2h | 2263 |
Ube2g2 | 2747 |
Usp7 | 2984 |
Ubc | 3480 |
Uba52 | 3691 |
Uba1 | 4503 |
LGI ADAM INTERACTIONS
518 | |
---|---|
set | LGI ADAM INTERACTIONS |
setSize | 14 |
pANOVA | 0.00277 |
s.dist | 0.462 |
p.adjustANOVA | 0.0195 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Adam22 | 8016 |
Cacng8 | 7874 |
Stx1b | 7703 |
Adam11 | 7573 |
Lgi2 | 7207 |
Stx1a | 6798 |
Cacng4 | 6480 |
Dlg4 | 6247 |
Cacng3 | 5233 |
Lgi3 | 4265 |
Cacng2 | 3168 |
Adam23 | 1641 |
Lgi4 | -4756 |
Lgi1 | -6342 |
GeneID | Gene Rank |
---|---|
Adam22 | 8016 |
Cacng8 | 7874 |
Stx1b | 7703 |
Adam11 | 7573 |
Lgi2 | 7207 |
Stx1a | 6798 |
Cacng4 | 6480 |
Dlg4 | 6247 |
Cacng3 | 5233 |
Lgi3 | 4265 |
Cacng2 | 3168 |
Adam23 | 1641 |
Lgi4 | -4756 |
Lgi1 | -6342 |
YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION
1176 | |
---|---|
set | YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION |
setSize | 11 |
pANOVA | 0.00997 |
s.dist | 0.449 |
p.adjustANOVA | 0.0537 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Hipk2 | 8826 |
Tead2 | 8492 |
Tead3 | 8233 |
Hipk1 | 7691 |
Tead1 | 7226 |
Yap1 | 6637 |
Runx2 | 6579 |
Tead4 | 1791 |
Ccn2 | 1407 |
Wwtr1 | -2220 |
Kat2b | -7901 |
GeneID | Gene Rank |
---|---|
Hipk2 | 8826 |
Tead2 | 8492 |
Tead3 | 8233 |
Hipk1 | 7691 |
Tead1 | 7226 |
Yap1 | 6637 |
Runx2 | 6579 |
Tead4 | 1791 |
Ccn2 | 1407 |
Wwtr1 | -2220 |
Kat2b | -7901 |
CLASS I PEROXISOMAL MEMBRANE PROTEIN IMPORT
158 | |
---|---|
set | CLASS I PEROXISOMAL MEMBRANE PROTEIN IMPORT |
setSize | 20 |
pANOVA | 0.000516 |
s.dist | -0.448 |
p.adjustANOVA | 0.00482 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Atad1 | -8342 |
Pex3 | -8048 |
Slc25a17 | -7800 |
Acbd5 | -7619 |
Pex13 | -7516 |
Abcd2 | -7513 |
Pex2 | -7320 |
Gdap1 | -6703 |
Pex11b | -6362 |
Abcd3 | -3434 |
Aldh3a2 | -3312 |
Pex19 | -2655 |
Pex14 | -2364 |
Fis1 | -2131 |
Pxmp4 | -1092 |
Pxmp2 | -1007 |
Pex12 | 172 |
Pex16 | 962 |
Pex26 | 2534 |
Abcd1 | 7955 |
GeneID | Gene Rank |
---|---|
Atad1 | -8342 |
Pex3 | -8048 |
Slc25a17 | -7800 |
Acbd5 | -7619 |
Pex13 | -7516 |
Abcd2 | -7513 |
Pex2 | -7320 |
Gdap1 | -6703 |
Pex11b | -6362 |
Abcd3 | -3434 |
Aldh3a2 | -3312 |
Pex19 | -2655 |
Pex14 | -2364 |
Fis1 | -2131 |
Pxmp4 | -1092 |
Pxmp2 | -1007 |
Pex12 | 172 |
Pex16 | 962 |
Pex26 | 2534 |
Abcd1 | 7955 |
P75NTR REGULATES AXONOGENESIS
679 | |
---|---|
set | P75NTR REGULATES AXONOGENESIS |
setSize | 10 |
pANOVA | 0.0152 |
s.dist | -0.443 |
p.adjustANOVA | 0.0735 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Omg | -7628 |
Rhoa | -7527 |
Mcf2 | -7459 |
Rtn4 | -6580 |
Rtn4r | -6460 |
Ngf | -5442 |
Mag | -1769 |
Lingo1 | -243 |
Arhgdia | 2865 |
Ngfr | 4875 |
GeneID | Gene Rank |
---|---|
Omg | -7628 |
Rhoa | -7527 |
Mcf2 | -7459 |
Rtn4 | -6580 |
Rtn4r | -6460 |
Ngf | -5442 |
Mag | -1769 |
Lingo1 | -243 |
Arhgdia | 2865 |
Ngfr | 4875 |
THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION
1069 | |
---|---|
set | THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION |
setSize | 15 |
pANOVA | 0.00318 |
s.dist | -0.44 |
p.adjustANOVA | 0.0214 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Stra6 | -8225 |
Abca4 | -8163 |
Ttr | -7408 |
Rdh11 | -6941 |
Cyp4v3 | -6543 |
Rdh5 | -6237 |
Napepld | -5214 |
Rdh12 | -5021 |
Rbp1 | -3616 |
Rdh10 | -2641 |
Rdh1 | -349 |
Lrat | 787 |
Rlbp1 | 1485 |
Rbp4 | 2232 |
Myo7a | 3260 |
GeneID | Gene Rank |
---|---|
Stra6 | -8225 |
Abca4 | -8163 |
Ttr | -7408 |
Rdh11 | -6941 |
Cyp4v3 | -6543 |
Rdh5 | -6237 |
Napepld | -5214 |
Rdh12 | -5021 |
Rbp1 | -3616 |
Rdh10 | -2641 |
Rdh1 | -349 |
Lrat | 787 |
Rlbp1 | 1485 |
Rbp4 | 2232 |
Myo7a | 3260 |
PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING
736 | |
---|---|
set | PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING |
setSize | 11 |
pANOVA | 0.0116 |
s.dist | 0.44 |
p.adjustANOVA | 0.0605 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cacna1b | 8238 |
Cacna1e | 7552 |
Cacna1a | 6707 |
Cacnb3 | 6681 |
Cacng4 | 6480 |
Cacnb1 | 6153 |
Cacna2d2 | 5810 |
Cacng2 | 3168 |
Cacnb2 | 927 |
Cacna2d3 | 424 |
Cacnb4 | -6238 |
GeneID | Gene Rank |
---|---|
Cacna1b | 8238 |
Cacna1e | 7552 |
Cacna1a | 6707 |
Cacnb3 | 6681 |
Cacng4 | 6480 |
Cacnb1 | 6153 |
Cacna2d2 | 5810 |
Cacng2 | 3168 |
Cacnb2 | 927 |
Cacna2d3 | 424 |
Cacnb4 | -6238 |
DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TYPE
216 | |
---|---|
set | DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TYPE |
setSize | 20 |
pANOVA | 0.00113 |
s.dist | 0.421 |
p.adjustANOVA | 0.00922 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cspg4 | 8443 |
Ncan | 8140 |
Gpc2 | 8054 |
Sdc4 | 7950 |
Agrn | 7772 |
Bcan | 7329 |
Gpc4 | 6870 |
Gpc3 | 5369 |
Sdc3 | 4437 |
Hspg2 | 4411 |
Gpc1 | 4370 |
Bgn | 4058 |
Vcan | 4052 |
B4galt7 | 3013 |
Gpc6 | 1263 |
Dcn | 238 |
Sdc1 | -59 |
Gpc5 | -316 |
Cspg5 | -584 |
Sdc2 | -4724 |
GeneID | Gene Rank |
---|---|
Cspg4 | 8443 |
Ncan | 8140 |
Gpc2 | 8054 |
Sdc4 | 7950 |
Agrn | 7772 |
Bcan | 7329 |
Gpc4 | 6870 |
Gpc3 | 5369 |
Sdc3 | 4437 |
Hspg2 | 4411 |
Gpc1 | 4370 |
Bgn | 4058 |
Vcan | 4052 |
B4galt7 | 3013 |
Gpc6 | 1263 |
Dcn | 238 |
Sdc1 | -59 |
Gpc5 | -316 |
Cspg5 | -584 |
Sdc2 | -4724 |
CD28 DEPENDENT VAV1 PATHWAY
124 | |
---|---|
set | CD28 DEPENDENT VAV1 PATHWAY |
setSize | 11 |
pANOVA | 0.0175 |
s.dist | -0.414 |
p.adjustANOVA | 0.0817 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cdc42 | -8020 |
Rac1 | -7231 |
Pak1 | -7056 |
Cd86 | -6182 |
Pak2 | -4849 |
Pak3 | -3900 |
Vav1 | -3338 |
Grb2 | -3243 |
Fyn | -777 |
Lck | 2493 |
Cd80 | 6041 |
GeneID | Gene Rank |
---|---|
Cdc42 | -8020 |
Rac1 | -7231 |
Pak1 | -7056 |
Cd86 | -6182 |
Pak2 | -4849 |
Pak3 | -3900 |
Vav1 | -3338 |
Grb2 | -3243 |
Fyn | -777 |
Lck | 2493 |
Cd80 | 6041 |
RORA ACTIVATES GENE EXPRESSION
893 | |
---|---|
set | RORA ACTIVATES GENE EXPRESSION |
setSize | 18 |
pANOVA | 0.00258 |
s.dist | 0.41 |
p.adjustANOVA | 0.0186 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Crebbp | 8604 |
Rxra | 8088 |
Srebf1 | 7993 |
Chd9 | 7486 |
Med1 | 6809 |
Helz2 | 6449 |
Carm1 | 6318 |
Ncoa6 | 5920 |
Ep300 | 4550 |
Ncoa1 | 4445 |
Ppara | 4345 |
Cpt1a | 2881 |
Ncoa2 | 2549 |
Smarcd3 | 1704 |
Tbl1x | 329 |
Tgs1 | -1318 |
Rora | -2366 |
Tbl1xr1 | -4334 |
GeneID | Gene Rank |
---|---|
Crebbp | 8604 |
Rxra | 8088 |
Srebf1 | 7993 |
Chd9 | 7486 |
Med1 | 6809 |
Helz2 | 6449 |
Carm1 | 6318 |
Ncoa6 | 5920 |
Ep300 | 4550 |
Ncoa1 | 4445 |
Ppara | 4345 |
Cpt1a | 2881 |
Ncoa2 | 2549 |
Smarcd3 | 1704 |
Tbl1x | 329 |
Tgs1 | -1318 |
Rora | -2366 |
Tbl1xr1 | -4334 |
MITOCHONDRIAL TRANSLATION
571 | |
---|---|
set | MITOCHONDRIAL TRANSLATION |
setSize | 93 |
pANOVA | 1.33e-11 |
s.dist | -0.406 |
p.adjustANOVA | 2.61e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Mrpl1 | -8372 |
Mrpl50 | -8312 |
Mrpl16 | -8170 |
Mrps30 | -8052 |
Mrps31 | -7987 |
Mrpl10 | -7856 |
Mrpl40 | -7781 |
Mrps22 | -7548 |
Mrpl3 | -7511 |
Mrpl32 | -7226 |
Mrps23 | -7168 |
Mrpl47 | -7048 |
Mrpl22 | -6888 |
Mrps2 | -6767 |
Mrps14 | -6370 |
Mrpl17 | -6224 |
Mrpl15 | -5891 |
Mrpl13 | -5815 |
Mrpl34 | -5625 |
Ptcd3 | -5530 |
GeneID | Gene Rank |
---|---|
Mrpl1 | -8372 |
Mrpl50 | -8312 |
Mrpl16 | -8170 |
Mrps30 | -8052 |
Mrps31 | -7987 |
Mrpl10 | -7856 |
Mrpl40 | -7781 |
Mrps22 | -7548 |
Mrpl3 | -7511 |
Mrpl32 | -7226 |
Mrps23 | -7168 |
Mrpl47 | -7048 |
Mrpl22 | -6888 |
Mrps2 | -6767 |
Mrps14 | -6370 |
Mrpl17 | -6224 |
Mrpl15 | -5891 |
Mrpl13 | -5815 |
Mrpl34 | -5625 |
Ptcd3 | -5530 |
Mrpl30 | -5476 |
Mrpl49 | -5416 |
Mrpl27 | -5405 |
Mrpl57 | -5306 |
Chchd1 | -5288 |
Mrpl42 | -5157 |
Mrps18c | -5113 |
Mrpl48 | -5075 |
Mrpl33 | -5053 |
Mrpl39 | -5003 |
Mrpl11 | -4959 |
Mrpl9 | -4954 |
Mtif2 | -4873 |
Mrpl46 | -4657 |
Mrps36 | -4593 |
Mrps17 | -4525 |
Oxa1l | -4513 |
Mrrf | -4421 |
Tsfm | -4308 |
Mrps33 | -4133 |
Mrps27 | -3957 |
Mrps18b | -3859 |
Mrpl44 | -3828 |
Mtif3 | -3813 |
Mrpl18 | -3701 |
Gadd45gip1 | -3617 |
Mrpl54 | -3558 |
Mrps26 | -3547 |
Mrps10 | -3545 |
Mrps28 | -3440 |
Mrpl28 | -3315 |
Mrpl43 | -3304 |
Mrps18a | -3226 |
Mrpl12 | -3216 |
Mrpl20 | -3205 |
Mrpl19 | -3155 |
Mrps16 | -3110 |
Mrpl51 | -3044 |
Mrps25 | -3036 |
Mrpl21 | -2960 |
Mrps15 | -2949 |
Mrpl52 | -2883 |
Mrpl35 | -2863 |
Mrps12 | -2693 |
Mrpl2 | -2584 |
Mrps7 | -2517 |
Mrps9 | -2491 |
Mrps24 | -2225 |
Mrpl23 | -2048 |
Mrpl41 | -1998 |
Mrpl53 | -1939 |
Mrpl55 | -1656 |
Mrpl58 | -1627 |
Mrpl24 | -1572 |
Mrpl36 | -1429 |
Mrps21 | -804 |
Mrpl14 | -667 |
Mrps5 | -163 |
Mrps11 | -100 |
Mrps34 | 384 |
Aurkaip1 | 385 |
Mrpl37 | 403 |
Mrps6 | 685 |
Mrps35 | 1577 |
Mrpl38 | 2985 |
Eral1 | 3185 |
Gfm1 | 3942 |
Tufm | 4206 |
Mtfmt | 5091 |
Dap3 | 5540 |
Mtrf1l | 5671 |
Mrpl4 | 5960 |
Gfm2 | 7012 |
RECEPTOR MEDIATED MITOPHAGY
778 | |
---|---|
set | RECEPTOR MEDIATED MITOPHAGY |
setSize | 11 |
pANOVA | 0.02 |
s.dist | -0.405 |
p.adjustANOVA | 0.0888 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Atg12 | -8205 |
Fundc1 | -8009 |
Atg5 | -7837 |
Pgam5 | -6808 |
Csnk2a2 | -5327 |
Map1lc3b | -4660 |
Csnk2b | -4346 |
Csnk2a1 | -2182 |
Map1lc3a | -854 |
Src | 5451 |
Ulk1 | 7554 |
GeneID | Gene Rank |
---|---|
Atg12 | -8205 |
Fundc1 | -8009 |
Atg5 | -7837 |
Pgam5 | -6808 |
Csnk2a2 | -5327 |
Map1lc3b | -4660 |
Csnk2b | -4346 |
Csnk2a1 | -2182 |
Map1lc3a | -854 |
Src | 5451 |
Ulk1 | 7554 |
CRISTAE FORMATION
187 | |
---|---|
set | CRISTAE FORMATION |
setSize | 31 |
pANOVA | 0.000104 |
s.dist | -0.403 |
p.adjustANOVA | 0.00123 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Apoo | -8139 |
Atp5c1 | -8076 |
Mtx2 | -8034 |
Atp5pb | -7499 |
Dmac2l | -7278 |
Mtx1 | -5733 |
Apool | -5527 |
mt-Atp6 | -5071 |
Atp5b | -4886 |
Atp5h | -4812 |
Atp5o | -4698 |
Atp5l | -4684 |
Chchd3 | -4637 |
Atp5a1 | -4502 |
Atp5g3 | -4458 |
Immt | -3534 |
Tmem11 | -3471 |
Hspa9 | -3340 |
Chchd6 | -3296 |
Micos10 | -3146 |
GeneID | Gene Rank |
---|---|
Apoo | -8139 |
Atp5c1 | -8076 |
Mtx2 | -8034 |
Atp5pb | -7499 |
Dmac2l | -7278 |
Mtx1 | -5733 |
Apool | -5527 |
mt-Atp6 | -5071 |
Atp5b | -4886 |
Atp5h | -4812 |
Atp5o | -4698 |
Atp5l | -4684 |
Chchd3 | -4637 |
Atp5a1 | -4502 |
Atp5g3 | -4458 |
Immt | -3534 |
Tmem11 | -3471 |
Hspa9 | -3340 |
Chchd6 | -3296 |
Micos10 | -3146 |
Atp5g2 | -3059 |
Micos13 | -2576 |
Atp5j2 | -1520 |
Atp5e | -1120 |
Atp5j | -1104 |
Atp5d | 320 |
Samm50 | 900 |
Atp5g1 | 1349 |
Atp5k | 2050 |
Dnajc11 | 3708 |
mt-Atp8 | 7353 |
BRANCHED CHAIN AMINO ACID CATABOLISM
103 | |
---|---|
set | BRANCHED CHAIN AMINO ACID CATABOLISM |
setSize | 21 |
pANOVA | 0.00153 |
s.dist | -0.399 |
p.adjustANOVA | 0.012 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Dld | -8190 |
Acat1 | -7989 |
Hibadh | -7679 |
Acad8 | -7620 |
Mccc2 | -6938 |
Bckdhb | -6748 |
Echs1 | -6634 |
Aldh6a1 | -6447 |
Hibch | -5886 |
Acadsb | -5537 |
Ppm1k | -5382 |
Auh | -5364 |
Dbt | -4509 |
Hsd17b10 | -4464 |
Bckdk | -4353 |
Bckdha | 779 |
Slc25a44 | 3735 |
Bcat1 | 5066 |
Bcat2 | 5464 |
Ivd | 5519 |
GeneID | Gene Rank |
---|---|
Dld | -8190 |
Acat1 | -7989 |
Hibadh | -7679 |
Acad8 | -7620 |
Mccc2 | -6938 |
Bckdhb | -6748 |
Echs1 | -6634 |
Aldh6a1 | -6447 |
Hibch | -5886 |
Acadsb | -5537 |
Ppm1k | -5382 |
Auh | -5364 |
Dbt | -4509 |
Hsd17b10 | -4464 |
Bckdk | -4353 |
Bckdha | 779 |
Slc25a44 | 3735 |
Bcat1 | 5066 |
Bcat2 | 5464 |
Ivd | 5519 |
Mccc1 | 6999 |
PENTOSE PHOSPHATE PATHWAY
685 | |
---|---|
set | PENTOSE PHOSPHATE PATHWAY |
setSize | 13 |
pANOVA | 0.013 |
s.dist | -0.398 |
p.adjustANOVA | 0.0652 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Prps2 | -8270 |
Rpe | -7876 |
Rbks | -7612 |
Taldo1 | -6865 |
Pgm2 | -6624 |
Prps1 | -4907 |
Shpk | -2539 |
G6pdx | -1632 |
Tkt | -961 |
Pgls | -216 |
Dera | 1612 |
Pgd | 1849 |
Rpia | 3207 |
GeneID | Gene Rank |
---|---|
Prps2 | -8270 |
Rpe | -7876 |
Rbks | -7612 |
Taldo1 | -6865 |
Pgm2 | -6624 |
Prps1 | -4907 |
Shpk | -2539 |
G6pdx | -1632 |
Tkt | -961 |
Pgls | -216 |
Dera | 1612 |
Pgd | 1849 |
Rpia | 3207 |
METABOLISM OF POLYAMINES
552 | |
---|---|
set | METABOLISM OF POLYAMINES |
setSize | 58 |
pANOVA | 1.59e-07 |
s.dist | -0.398 |
p.adjustANOVA | 6.05e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Nqo1 | -7892 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Sms | -7762 |
Amd1 | -7587 |
Psma6 | -7580 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Azin1 | -6577 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Paox | -5468 |
Psmb7 | -5401 |
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Nqo1 | -7892 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Sms | -7762 |
Amd1 | -7587 |
Psma6 | -7580 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Azin1 | -6577 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Paox | -5468 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Psma4 | -4815 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Srm | -4333 |
Odc1 | -4329 |
Sat1 | -4125 |
Psme2 | -4121 |
Psma7 | -3980 |
Oaz2 | -3954 |
Psma8 | -3884 |
Psmd9 | -3332 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Oaz1 | -1519 |
Psmb4 | -1483 |
Azin2 | -406 |
Psmd11 | -127 |
Psmc4 | 123 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Agmat | 1868 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Psme4 | 3590 |
Oaz3 | 6299 |
Smox | 8841 |
COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDING
179 | |
---|---|
set | COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDING |
setSize | 26 |
pANOVA | 0.000446 |
s.dist | -0.398 |
p.adjustANOVA | 0.00428 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Vbp1 | -8262 |
Cct6a | -7953 |
Tuba1c | -7927 |
Cct4 | -7432 |
Pfdn4 | -7390 |
Tcp1 | -7383 |
Cct2 | -6966 |
Cct5 | -5869 |
Cct7 | -5850 |
Cct8 | -5469 |
Tuba8 | -4989 |
Tuba1b | -4438 |
Pfdn1 | -4319 |
Tuba4a | -3800 |
Cct3 | -2878 |
Tubb4b | -2642 |
Actb | -2632 |
Pfdn5 | -2071 |
Tuba1a | -1728 |
Pfdn6 | -1533 |
GeneID | Gene Rank |
---|---|
Vbp1 | -8262 |
Cct6a | -7953 |
Tuba1c | -7927 |
Cct4 | -7432 |
Pfdn4 | -7390 |
Tcp1 | -7383 |
Cct2 | -6966 |
Cct5 | -5869 |
Cct7 | -5850 |
Cct8 | -5469 |
Tuba8 | -4989 |
Tuba1b | -4438 |
Pfdn1 | -4319 |
Tuba4a | -3800 |
Cct3 | -2878 |
Tubb4b | -2642 |
Actb | -2632 |
Pfdn5 | -2071 |
Tuba1a | -1728 |
Pfdn6 | -1533 |
Tubb3 | 483 |
Tubb2a | 880 |
Pfdn2 | 4037 |
Tubb2b | 4298 |
Tubb4a | 4734 |
Tubb6 | 5550 |
NEGATIVE REGULATION OF NOTCH4 SIGNALING
611 | |
---|---|
set | NEGATIVE REGULATION OF NOTCH4 SIGNALING |
setSize | 54 |
pANOVA | 4.32e-07 |
s.dist | -0.398 |
p.adjustANOVA | 1.34e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Ywhaz | -6972 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Psma4 | -4815 |
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Ywhaz | -6972 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Psma4 | -4815 |
Rbx1 | -4727 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Fbxw7 | -4341 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
Psma7 | -3980 |
Psmd9 | -3332 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Tacc3 | -1588 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Psmd11 | -127 |
Psmc4 | 123 |
Akt1 | 440 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ubc | 3480 |
Uba52 | 3691 |
Notch4 | 8969 |
FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC
340 | |
---|---|
set | FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC |
setSize | 19 |
pANOVA | 0.00278 |
s.dist | -0.396 |
p.adjustANOVA | 0.0195 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cct6a | -7953 |
Tuba1c | -7927 |
Cct4 | -7432 |
Tcp1 | -7383 |
Cct2 | -6966 |
Cct5 | -5869 |
Cct7 | -5850 |
Cct8 | -5469 |
Tuba8 | -4989 |
Tuba1b | -4438 |
Tuba4a | -3800 |
Cct3 | -2878 |
Tubb4b | -2642 |
Tuba1a | -1728 |
Tubb3 | 483 |
Tubb2a | 880 |
Tubb2b | 4298 |
Tubb4a | 4734 |
Tubb6 | 5550 |
GeneID | Gene Rank |
---|---|
Cct6a | -7953 |
Tuba1c | -7927 |
Cct4 | -7432 |
Tcp1 | -7383 |
Cct2 | -6966 |
Cct5 | -5869 |
Cct7 | -5850 |
Cct8 | -5469 |
Tuba8 | -4989 |
Tuba1b | -4438 |
Tuba4a | -3800 |
Cct3 | -2878 |
Tubb4b | -2642 |
Tuba1a | -1728 |
Tubb3 | 483 |
Tubb2a | 880 |
Tubb2b | 4298 |
Tubb4a | 4734 |
Tubb6 | 5550 |
ASSEMBLY OF THE PRE REPLICATIVE COMPLEX
77 | |
---|---|
set | ASSEMBLY OF THE PRE REPLICATIVE COMPLEX |
setSize | 65 |
pANOVA | 3.29e-08 |
s.dist | -0.396 |
p.adjustANOVA | 1.69e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Psma6 | -7580 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
E2f2 | -6976 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Orc2 | -5807 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Psma6 | -7580 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
E2f2 | -6976 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Orc2 | -5807 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Psma4 | -4815 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
E2f3 | -4111 |
Mcm4 | -4077 |
Psma7 | -3980 |
Psma8 | -3884 |
Mcm5 | -3618 |
Psmd9 | -3332 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Mcm8 | -2252 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Orc3 | -1296 |
Mcm6 | -1096 |
Cdt1 | -1095 |
Gmnn | -591 |
Psmd11 | -127 |
Mcm2 | -30 |
Psmc4 | 123 |
Mcm7 | 442 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ubc | 3480 |
Psme4 | 3590 |
Uba52 | 3691 |
E2f1 | 3868 |
SIGNALING BY LEPTIN
967 | |
---|---|
set | SIGNALING BY LEPTIN |
setSize | 10 |
pANOVA | 0.0301 |
s.dist | 0.396 |
p.adjustANOVA | 0.118 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Sh2b1 | 8845 |
Stat3 | 7899 |
Ptpn11 | 7387 |
Stat5b | 5594 |
Stat5a | 4171 |
Irs1 | 3445 |
Irs2 | 3242 |
Socs3 | 2059 |
Jak2 | -2188 |
Lepr | -2548 |
GeneID | Gene Rank |
---|---|
Sh2b1 | 8845 |
Stat3 | 7899 |
Ptpn11 | 7387 |
Stat5b | 5594 |
Stat5a | 4171 |
Irs1 | 3445 |
Irs2 | 3242 |
Socs3 | 2059 |
Jak2 | -2188 |
Lepr | -2548 |
TIGHT JUNCTION INTERACTIONS
1081 | |
---|---|
set | TIGHT JUNCTION INTERACTIONS |
setSize | 17 |
pANOVA | 0.00474 |
s.dist | -0.396 |
p.adjustANOVA | 0.0304 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cldn2 | -8385 |
Cldn1 | -7898 |
Cldn10 | -7694 |
Crb3 | -7193 |
Pals1 | -6579 |
Cldn23 | -4946 |
Pard6a | -4738 |
F11r | -4695 |
Cldn14 | -3402 |
Cldn12 | -2380 |
Cldn11 | -2050 |
Pard6g | -1513 |
Prkci | -1137 |
Pard6b | -920 |
Cldn5 | 566 |
Patj | 2870 |
Pard3 | 7067 |
GeneID | Gene Rank |
---|---|
Cldn2 | -8385 |
Cldn1 | -7898 |
Cldn10 | -7694 |
Crb3 | -7193 |
Pals1 | -6579 |
Cldn23 | -4946 |
Pard6a | -4738 |
F11r | -4695 |
Cldn14 | -3402 |
Cldn12 | -2380 |
Cldn11 | -2050 |
Pard6g | -1513 |
Prkci | -1137 |
Pard6b | -920 |
Cldn5 | 566 |
Patj | 2870 |
Pard3 | 7067 |
UNWINDING OF DNA
1160 | |
---|---|
set | UNWINDING OF DNA |
setSize | 12 |
pANOVA | 0.0186 |
s.dist | -0.392 |
p.adjustANOVA | 0.0847 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Gins4 | -7425 |
Mcm3 | -7063 |
Gins1 | -6211 |
Mcm4 | -4077 |
Mcm5 | -3618 |
Cdc45 | -3505 |
Mcm8 | -2252 |
Gins2 | -1938 |
Mcm6 | -1096 |
Gins3 | -341 |
Mcm2 | -30 |
Mcm7 | 442 |
GeneID | Gene Rank |
---|---|
Gins4 | -7425 |
Mcm3 | -7063 |
Gins1 | -6211 |
Mcm4 | -4077 |
Mcm5 | -3618 |
Cdc45 | -3505 |
Mcm8 | -2252 |
Gins2 | -1938 |
Mcm6 | -1096 |
Gins3 | -341 |
Mcm2 | -30 |
Mcm7 | 442 |
CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES
189 | |
---|---|
set | CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES |
setSize | 47 |
pANOVA | 3.49e-06 |
s.dist | -0.391 |
p.adjustANOVA | 7.49e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Psma6 | -7580 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Fcgr1 | -5383 |
Psmc2 | -5064 |
Psma4 | -4815 |
Psmd5 | -4603 |
Psmb3 | -4590 |
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Psma6 | -7580 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Fcgr1 | -5383 |
Psmc2 | -5064 |
Psma4 | -4815 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Psme2 | -4121 |
Psma7 | -3980 |
Psma8 | -3884 |
Psmd9 | -3332 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Psmb10 | -2155 |
Mrc1 | -1887 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Psmd11 | -127 |
Psmc4 | 123 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Psme4 | 3590 |
Mrc2 | 7439 |
RESPIRATORY ELECTRON TRANSPORT
836 | |
---|---|
set | RESPIRATORY ELECTRON TRANSPORT |
setSize | 102 |
pANOVA | 1.02e-11 |
s.dist | -0.39 |
p.adjustANOVA | 2.41e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Sco2 | -8357 |
Ndufaf1 | -7780 |
Ndufaf4 | -7557 |
Coq10b | -7517 |
Ndufv2 | -7287 |
Nubpl | -7180 |
Etfdh | -7137 |
mt-Nd2 | -7057 |
Uqcrc2 | -7010 |
Ndufc2 | -6893 |
Cycs | -6845 |
Etfa | -6716 |
mt-Nd6 | -6545 |
Uqcrfs1 | -6297 |
mt-Nd4 | -6197 |
Ndufs4 | -6192 |
Ndufaf5 | -6126 |
Sdhb | -6076 |
mt-Nd1 | -5998 |
Ndufaf2 | -5957 |
GeneID | Gene Rank |
---|---|
Sco2 | -8357 |
Ndufaf1 | -7780 |
Ndufaf4 | -7557 |
Coq10b | -7517 |
Ndufv2 | -7287 |
Nubpl | -7180 |
Etfdh | -7137 |
mt-Nd2 | -7057 |
Uqcrc2 | -7010 |
Ndufc2 | -6893 |
Cycs | -6845 |
Etfa | -6716 |
mt-Nd6 | -6545 |
Uqcrfs1 | -6297 |
mt-Nd4 | -6197 |
Ndufs4 | -6192 |
Ndufaf5 | -6126 |
Sdhb | -6076 |
mt-Nd1 | -5998 |
Ndufaf2 | -5957 |
mt-Nd5 | -5921 |
Ndufb5 | -5763 |
Ndufs1 | -5653 |
mt-Co1 | -5647 |
Sdhd | -5575 |
mt-Co2 | -5539 |
mt-Cytb | -5502 |
Sco1 | -5156 |
mt-Co3 | -5129 |
Sdhc | -5048 |
Ndufb11 | -4979 |
Cox7a2l | -4713 |
Ndufs8 | -4550 |
Uqcrh | -4429 |
Ndufs3 | -4358 |
Surf1 | -4315 |
Ndufa10 | -4299 |
Cox5a | -4288 |
Ndufab1 | -4269 |
Ndufb4 | -4254 |
Ndufb9 | -4240 |
Ndufb3 | -4238 |
Cyc1 | -4095 |
Etfb | -4069 |
Ndufb8 | -3922 |
Cox6b1 | -3860 |
Ndufa4 | -3836 |
Uqcrb | -3736 |
Ndufb6 | -3352 |
Tmem126b | -3342 |
Cox7b | -3317 |
Cox16 | -3255 |
Ndufa11 | -3129 |
Ndufb10 | -2954 |
Cox7c | -2945 |
Ecsit | -2884 |
Ndufa9 | -2857 |
Ndufs5 | -2848 |
Cox6a1 | -2782 |
Cox14 | -2704 |
Coq10a | -2700 |
Ndufa7 | -2650 |
Ndufs2 | -2591 |
Cox4i1 | -2505 |
Ndufb2 | -2480 |
Ndufc1 | -2357 |
Cox11 | -2219 |
Ndufa8 | -1983 |
Uqcrc1 | -1869 |
Cox20 | -1722 |
Ndufv1 | -1558 |
Ndufa2 | -1531 |
Cox6c | -1398 |
Ndufa5 | -1343 |
Uqcrq | -1293 |
Cox8a | -1268 |
Ndufaf3 | -1245 |
Ndufb1 | -1103 |
Cox18 | -1099 |
Timmdc1 | -816 |
Sdha | -746 |
Acad9 | -691 |
Ndufb7 | -650 |
Ndufa6 | -561 |
Ndufa1 | -470 |
Uqcr11 | -114 |
mt-Nd3 | 257 |
Ndufaf6 | 359 |
Uqcr10 | 654 |
Taco1 | 754 |
Ndufs6 | 991 |
Cox5b | 1153 |
Ndufv3 | 1179 |
Ndufa13 | 1623 |
Cox19 | 1642 |
Ndufa3 | 1807 |
Ndufaf7 | 1850 |
Ndufs7 | 1885 |
Lrpprc | 2494 |
Ndufa12 | 3482 |
Trap1 | 4979 |
Tmem186 | 6996 |
SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1
1054 | |
---|---|
set | SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1 |
setSize | 13 |
pANOVA | 0.0149 |
s.dist | -0.39 |
p.adjustANOVA | 0.0725 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Spcs3 | -7821 |
Pax6 | -6309 |
Spcs2 | -6276 |
Spcs1 | -5474 |
Tcf7l2 | -5464 |
Sec11c | -4609 |
Grp | -4260 |
Dpp4 | -2461 |
Gng13 | -1953 |
Pcsk1 | -731 |
Sec11a | -585 |
Ctnnb1 | 1478 |
Gnb3 | 4560 |
GeneID | Gene Rank |
---|---|
Spcs3 | -7821 |
Pax6 | -6309 |
Spcs2 | -6276 |
Spcs1 | -5474 |
Tcf7l2 | -5464 |
Sec11c | -4609 |
Grp | -4260 |
Dpp4 | -2461 |
Gng13 | -1953 |
Pcsk1 | -731 |
Sec11a | -585 |
Ctnnb1 | 1478 |
Gnb3 | 4560 |
PHOSPHORYLATION OF THE APC C
699 | |
---|---|
set | PHOSPHORYLATION OF THE APC C |
setSize | 18 |
pANOVA | 0.00469 |
s.dist | -0.385 |
p.adjustANOVA | 0.0303 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Ube2e1 | -7973 |
Anapc10 | -7447 |
Cdk1 | -6989 |
Cdc26 | -6729 |
Cdc16 | -6482 |
Cdc27 | -5031 |
Ube2s | -4651 |
Anapc7 | -4519 |
Anapc16 | -4035 |
Cdc23 | -3456 |
Anapc4 | -3097 |
Anapc15 | -2459 |
Anapc11 | -2257 |
Plk1 | -337 |
Anapc1 | 5839 |
Anapc5 | 5965 |
Anapc2 | 7413 |
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Ube2e1 | -7973 |
Anapc10 | -7447 |
Cdk1 | -6989 |
Cdc26 | -6729 |
Cdc16 | -6482 |
Cdc27 | -5031 |
Ube2s | -4651 |
Anapc7 | -4519 |
Anapc16 | -4035 |
Cdc23 | -3456 |
Anapc4 | -3097 |
Anapc15 | -2459 |
Anapc11 | -2257 |
Plk1 | -337 |
Anapc1 | 5839 |
Anapc5 | 5965 |
Anapc2 | 7413 |
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12
40 | |
---|---|
set | ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12 |
setSize | 20 |
pANOVA | 0.0029 |
s.dist | -0.385 |
p.adjustANOVA | 0.0201 |
Top enriched genes
GeneID | Gene Rank |
---|---|
P2ry12 | -8001 |
Gng10 | -7642 |
Gng11 | -6965 |
Gnai3 | -6812 |
Gnai1 | -6455 |
Gng2 | -6301 |
Gnb4 | -5817 |
Gnb5 | -4608 |
Gnb2 | -3579 |
Gng12 | -3211 |
Gng5 | -2765 |
Gng3 | -2285 |
Gnai2 | -2236 |
Gng13 | -1953 |
Gng7 | -1332 |
Gngt2 | -973 |
Gnb1 | -707 |
Gng8 | 1182 |
Gnb3 | 4560 |
Gng4 | 5427 |
GeneID | Gene Rank |
---|---|
P2ry12 | -8001 |
Gng10 | -7642 |
Gng11 | -6965 |
Gnai3 | -6812 |
Gnai1 | -6455 |
Gng2 | -6301 |
Gnb4 | -5817 |
Gnb5 | -4608 |
Gnb2 | -3579 |
Gng12 | -3211 |
Gng5 | -2765 |
Gng3 | -2285 |
Gnai2 | -2236 |
Gng13 | -1953 |
Gng7 | -1332 |
Gngt2 | -973 |
Gnb1 | -707 |
Gng8 | 1182 |
Gnb3 | 4560 |
Gng4 | 5427 |
SYNAPTIC ADHESION LIKE MOLECULES
1033 | |
---|---|
set | SYNAPTIC ADHESION LIKE MOLECULES |
setSize | 21 |
pANOVA | 0.00231 |
s.dist | 0.384 |
p.adjustANOVA | 0.017 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ptprs | 8609 |
Ptprf | 8311 |
Grin2d | 8047 |
Grin1 | 7424 |
Lrfn4 | 7355 |
Lrfn1 | 6937 |
Grin2b | 6801 |
Dlg4 | 6247 |
Ptprd | 6013 |
Flot2 | 5644 |
Lrfn3 | 5256 |
Grin2a | 4970 |
Lrfn2 | 3928 |
Gria1 | 3626 |
Grin2c | 2567 |
Flot1 | 2126 |
Gria4 | 716 |
Dlg3 | -140 |
Gria3 | -3696 |
Rtn3 | -6403 |
GeneID | Gene Rank |
---|---|
Ptprs | 8609 |
Ptprf | 8311 |
Grin2d | 8047 |
Grin1 | 7424 |
Lrfn4 | 7355 |
Lrfn1 | 6937 |
Grin2b | 6801 |
Dlg4 | 6247 |
Ptprd | 6013 |
Flot2 | 5644 |
Lrfn3 | 5256 |
Grin2a | 4970 |
Lrfn2 | 3928 |
Gria1 | 3626 |
Grin2c | 2567 |
Flot1 | 2126 |
Gria4 | 716 |
Dlg3 | -140 |
Gria3 | -3696 |
Rtn3 | -6403 |
Dlg1 | -6962 |
GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATION
374 | |
---|---|
set | GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATION |
setSize | 31 |
pANOVA | 0.000237 |
s.dist | -0.381 |
p.adjustANOVA | 0.00245 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cdc42 | -8020 |
Mtap | -7909 |
Gsto1 | -7814 |
Rap1b | -7601 |
Tcp1 | -7383 |
Capza1 | -7276 |
Hnrnpdl | -6896 |
Taldo1 | -6865 |
Rala | -5876 |
Arf1 | -5534 |
Ppia | -5353 |
Pak2 | -4849 |
Psme2 | -4121 |
Rplp0 | -3862 |
Hspa9 | -3340 |
Cfl1 | -3126 |
Pitpna | -2996 |
Pdcd4 | -2815 |
Snrpa1 | -2396 |
Aip | -2302 |
GeneID | Gene Rank |
---|---|
Cdc42 | -8020 |
Mtap | -7909 |
Gsto1 | -7814 |
Rap1b | -7601 |
Tcp1 | -7383 |
Capza1 | -7276 |
Hnrnpdl | -6896 |
Taldo1 | -6865 |
Rala | -5876 |
Arf1 | -5534 |
Ppia | -5353 |
Pak2 | -4849 |
Psme2 | -4121 |
Rplp0 | -3862 |
Hspa9 | -3340 |
Cfl1 | -3126 |
Pitpna | -2996 |
Pdcd4 | -2815 |
Snrpa1 | -2396 |
Aip | -2302 |
Lcp1 | -2082 |
Hnrnpf | -1008 |
Hnrnpa2b1 | -975 |
Lmnb1 | 8 |
Bola2 | 324 |
Sod1 | 393 |
Sod2 | 1697 |
Mif | 1965 |
Cnn2 | 2192 |
Msn | 4109 |
Anxa2 | 6922 |
SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE
1032 | |
---|---|
set | SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE |
setSize | 87 |
pANOVA | 7.74e-10 |
s.dist | -0.381 |
p.adjustANOVA | 5.71e-08 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Ccne2 | -8217 |
Psmc6 | -8204 |
Ube2e1 | -7973 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Anapc10 | -7447 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
Cdc26 | -6729 |
Psma1 | -6555 |
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Ccne2 | -8217 |
Psmc6 | -8204 |
Ube2e1 | -7973 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Anapc10 | -7447 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
Cdc26 | -6729 |
Psma1 | -6555 |
Cdc16 | -6482 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Orc2 | -5807 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Cdc27 | -5031 |
Psma4 | -4815 |
Rbx1 | -4727 |
Ube2s | -4651 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Anapc7 | -4519 |
Psma3 | -4517 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
Mcm4 | -4077 |
Anapc16 | -4035 |
Psma7 | -3980 |
Psma8 | -3884 |
Ccne1 | -3683 |
Mcm5 | -3618 |
Cdc23 | -3456 |
Psmd9 | -3332 |
Anapc4 | -3097 |
Anapc15 | -2459 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Anapc11 | -2257 |
Mcm8 | -2252 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Orc3 | -1296 |
Mcm6 | -1096 |
Cdt1 | -1095 |
Fzr1 | -1003 |
Skp2 | -450 |
Psmd11 | -127 |
Mcm2 | -30 |
Psmc4 | 123 |
Mcm7 | 442 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ccna1 | 3446 |
Ubc | 3480 |
Psme4 | 3590 |
Uba52 | 3691 |
Ccna2 | 5456 |
Anapc1 | 5839 |
Anapc5 | 5965 |
Cdk2 | 6752 |
Anapc2 | 7413 |
METHYLATION
561 | |
---|---|
set | METHYLATION |
setSize | 11 |
pANOVA | 0.0299 |
s.dist | -0.378 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Gsto1 | -7814 |
Mat2a | -7551 |
Mat2b | -7543 |
N6amt1 | -7197 |
Tpmt | -6187 |
Ahcy | -4611 |
Comt | -4026 |
Mtrr | -418 |
Trmt112 | 2118 |
As3mt | 2458 |
Mtr | 8136 |
GeneID | Gene Rank |
---|---|
Gsto1 | -7814 |
Mat2a | -7551 |
Mat2b | -7543 |
N6amt1 | -7197 |
Tpmt | -6187 |
Ahcy | -4611 |
Comt | -4026 |
Mtrr | -418 |
Trmt112 | 2118 |
As3mt | 2458 |
Mtr | 8136 |
ADENYLATE CYCLASE INHIBITORY PATHWAY
36 | |
---|---|
set | ADENYLATE CYCLASE INHIBITORY PATHWAY |
setSize | 13 |
pANOVA | 0.0183 |
s.dist | 0.378 |
p.adjustANOVA | 0.0847 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Adcy6 | 8807 |
Adcy4 | 8795 |
Adcy5 | 7460 |
Adcy8 | 7205 |
Adcy2 | 6106 |
Adcy9 | 5535 |
Adcy3 | 5523 |
Adcy7 | 5402 |
Gnal | 4616 |
Adcy1 | 3287 |
Gnai2 | -2236 |
Gnai1 | -6455 |
Gnai3 | -6812 |
GeneID | Gene Rank |
---|---|
Adcy6 | 8807 |
Adcy4 | 8795 |
Adcy5 | 7460 |
Adcy8 | 7205 |
Adcy2 | 6106 |
Adcy9 | 5535 |
Adcy3 | 5523 |
Adcy7 | 5402 |
Gnal | 4616 |
Adcy1 | 3287 |
Gnai2 | -2236 |
Gnai1 | -6455 |
Gnai3 | -6812 |
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS
1 | |
---|---|
set | A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS |
setSize | 26 |
pANOVA | 0.000917 |
s.dist | 0.376 |
p.adjustANOVA | 0.00766 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Cspg4 | 8443 |
Ncan | 8140 |
Gpc2 | 8054 |
Sdc4 | 7950 |
Agrn | 7772 |
Bcan | 7329 |
Xylt2 | 6935 |
Gpc4 | 6870 |
Gpc3 | 5369 |
B3gat1 | 5208 |
Sdc3 | 4437 |
Hspg2 | 4411 |
Gpc1 | 4370 |
Bgn | 4058 |
Vcan | 4052 |
B4galt7 | 3013 |
Xylt1 | 2354 |
Gpc6 | 1263 |
B3galt6 | 288 |
B3gat2 | 271 |
GeneID | Gene Rank |
---|---|
Cspg4 | 8443 |
Ncan | 8140 |
Gpc2 | 8054 |
Sdc4 | 7950 |
Agrn | 7772 |
Bcan | 7329 |
Xylt2 | 6935 |
Gpc4 | 6870 |
Gpc3 | 5369 |
B3gat1 | 5208 |
Sdc3 | 4437 |
Hspg2 | 4411 |
Gpc1 | 4370 |
Bgn | 4058 |
Vcan | 4052 |
B4galt7 | 3013 |
Xylt1 | 2354 |
Gpc6 | 1263 |
B3galt6 | 288 |
B3gat2 | 271 |
Dcn | 238 |
Sdc1 | -59 |
Gpc5 | -316 |
Cspg5 | -584 |
B3gat3 | -1287 |
Sdc2 | -4724 |
ORC1 REMOVAL FROM CHROMATIN
668 | |
---|---|
set | ORC1 REMOVAL FROM CHROMATIN |
setSize | 68 |
pANOVA | 8.69e-08 |
s.dist | -0.375 |
p.adjustANOVA | 3.63e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Orc2 | -5807 |
Psma5 | -5800 |
Psmb1 | -5506 |
GeneID | Gene Rank |
---|---|
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Orc5 | -7806 |
Orc6 | -7773 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Orc4 | -7371 |
Psma2 | -7177 |
Psmd6 | -7172 |
Mcm3 | -7063 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Orc2 | -5807 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Psma4 | -4815 |
Rbx1 | -4727 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
Mcm4 | -4077 |
Psma7 | -3980 |
Psma8 | -3884 |
Mcm5 | -3618 |
Psmd9 | -3332 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Mcm8 | -2252 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Orc3 | -1296 |
Mcm6 | -1096 |
Cdt1 | -1095 |
Skp2 | -450 |
Psmd11 | -127 |
Mcm2 | -30 |
Psmc4 | 123 |
Mcm7 | 442 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ccna1 | 3446 |
Ubc | 3480 |
Psme4 | 3590 |
Uba52 | 3691 |
Ccna2 | 5456 |
Cdk2 | 6752 |
PCNA DEPENDENT LONG PATCH BASE EXCISION REPAIR
682 | |
---|---|
set | PCNA DEPENDENT LONG PATCH BASE EXCISION REPAIR |
setSize | 20 |
pANOVA | 0.00373 |
s.dist | -0.375 |
p.adjustANOVA | 0.0247 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Rfc3 | -8029 |
Apex1 | -7963 |
Pole4 | -7961 |
Pcna | -7539 |
Pole3 | -6994 |
Rfc4 | -6968 |
Rpa3 | -6924 |
Rfc5 | -4478 |
Pold2 | -4368 |
Rpa2 | -4351 |
Polb | -4253 |
Fen1 | -3967 |
Rpa1 | -3830 |
Pold4 | -3362 |
Pole | 152 |
Pold3 | 2035 |
Rfc2 | 3274 |
Rfc1 | 3955 |
Pold1 | 4153 |
Lig1 | 8705 |
GeneID | Gene Rank |
---|---|
Rfc3 | -8029 |
Apex1 | -7963 |
Pole4 | -7961 |
Pcna | -7539 |
Pole3 | -6994 |
Rfc4 | -6968 |
Rpa3 | -6924 |
Rfc5 | -4478 |
Pold2 | -4368 |
Rpa2 | -4351 |
Polb | -4253 |
Fen1 | -3967 |
Rpa1 | -3830 |
Pold4 | -3362 |
Pole | 152 |
Pold3 | 2035 |
Rfc2 | 3274 |
Rfc1 | 3955 |
Pold1 | 4153 |
Lig1 | 8705 |
SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN
1053 | |
---|---|
set | SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN |
setSize | 12 |
pANOVA | 0.025 |
s.dist | -0.374 |
p.adjustANOVA | 0.104 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Pla2g7 | -8174 |
Spcs3 | -7821 |
Bche | -6522 |
Spcs2 | -6276 |
Spcs1 | -5474 |
Sec11c | -4609 |
Klf4 | -4236 |
Pcsk1 | -731 |
Sec11a | -585 |
Igf1 | -186 |
Crhr2 | 1636 |
Ache | 7823 |
GeneID | Gene Rank |
---|---|
Pla2g7 | -8174 |
Spcs3 | -7821 |
Bche | -6522 |
Spcs2 | -6276 |
Spcs1 | -5474 |
Sec11c | -4609 |
Klf4 | -4236 |
Pcsk1 | -731 |
Sec11a | -585 |
Igf1 | -186 |
Crhr2 | 1636 |
Ache | 7823 |
SCF SKP2 MEDIATED DEGRADATION OF P27 P21
910 | |
---|---|
set | SCF SKP2 MEDIATED DEGRADATION OF P27 P21 |
setSize | 59 |
pANOVA | 7.83e-07 |
s.dist | -0.372 |
p.adjustANOVA | 2.2e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ccne2 | -8217 |
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Cdkn1b | -7418 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
GeneID | Gene Rank |
---|---|
Ccne2 | -8217 |
Psmc6 | -8204 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Skp1 | -7764 |
Psma6 | -7580 |
Cul1 | -7450 |
Cdkn1b | -7418 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Psma1 | -6555 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Psmc2 | -5064 |
Ccnd1 | -4876 |
Psma4 | -4815 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Psma3 | -4517 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
Psma7 | -3980 |
Ccne1 | -3683 |
Psmd9 | -3332 |
Cks1b | -3106 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Skp2 | -450 |
Psmd11 | -127 |
Psmc4 | 123 |
Cdk4 | 372 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Cdkn1a | 1167 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ccna1 | 3446 |
Ubc | 3480 |
Uba52 | 3691 |
Ccna2 | 5456 |
Cdk2 | 6752 |
PROTEIN UBIQUITINATION
754 | |
---|---|
set | PROTEIN UBIQUITINATION |
setSize | 70 |
pANOVA | 7.66e-08 |
s.dist | -0.372 |
p.adjustANOVA | 3.34e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ube2w | -8355 |
Ube2e3 | -8352 |
Ube2g1 | -8298 |
Ube2d1 | -8221 |
Ube2v2 | -8214 |
Ube2q2 | -8178 |
Ube2d3 | -8173 |
Uchl3 | -8038 |
Ube2e1 | -7973 |
Ube2b | -7942 |
Ube2a | -7921 |
Ube2l3 | -7831 |
Ube2n | -7815 |
Ube2k | -7805 |
Ube2d2a | -7701 |
Pcna | -7539 |
Pex13 | -7516 |
Pex2 | -7320 |
Selenos | -7112 |
Ube2j2 | -6881 |
GeneID | Gene Rank |
---|---|
Ube2w | -8355 |
Ube2e3 | -8352 |
Ube2g1 | -8298 |
Ube2d1 | -8221 |
Ube2v2 | -8214 |
Ube2q2 | -8178 |
Ube2d3 | -8173 |
Uchl3 | -8038 |
Ube2e1 | -7973 |
Ube2b | -7942 |
Ube2a | -7921 |
Ube2l3 | -7831 |
Ube2n | -7815 |
Ube2k | -7805 |
Ube2d2a | -7701 |
Pcna | -7539 |
Pex13 | -7516 |
Pex2 | -7320 |
Selenos | -7112 |
Ube2j2 | -6881 |
Rnf181 | -6841 |
Wdr61 | -6291 |
Bcl10 | -6256 |
Rnf152 | -6149 |
Derl1 | -5942 |
H2-D1 | -5834 |
Ube2r2 | -5535 |
Cdc73 | -5406 |
H2bc6 | -5191 |
H2bc21 | -5030 |
Wac | -4869 |
H2bc4 | -4786 |
Ube2s | -4651 |
H2-Q7 | -4557 |
Otulin | -4523 |
Cdc34 | -4472 |
Ubb | -4221 |
Rps27a | -4124 |
Rraga | -3744 |
Ube2t | -3528 |
Uba6 | -3395 |
H2-Q2 | -3151 |
Rad18 | -3031 |
Leo1 | -2492 |
Usp9x | -2427 |
Pex14 | -2364 |
Rnf144a | -1704 |
Ube2z | -1185 |
Ctr9 | -1053 |
Pex12 | 172 |
H2-Q10 | 705 |
Hltf | 1250 |
Vcp | 1694 |
Pex10 | 2167 |
Usp5 | 2235 |
Shprh | 2247 |
Ube2h | 2263 |
Ube2g2 | 2747 |
Usp7 | 2984 |
Ubc | 3480 |
H2bc12 | 3667 |
Uba52 | 3691 |
Rnf40 | 4188 |
Uba1 | 4503 |
Paf1 | 4791 |
Pex5 | 5912 |
Tmem129 | 5961 |
Rtf1 | 6095 |
Prkdc | 7225 |
Rnf20 | 9017 |
PROCESSING AND ACTIVATION OF SUMO
738 | |
---|---|
set | PROCESSING AND ACTIVATION OF SUMO |
setSize | 10 |
pANOVA | 0.0422 |
s.dist | -0.371 |
p.adjustANOVA | 0.147 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Sumo2 | -7743 |
Sumo1 | -7652 |
Rwdd3 | -6572 |
Sumo3 | -5431 |
Uba2 | -4592 |
Senp2 | -2623 |
Ube2i | -2351 |
Sae1 | -35 |
Senp5 | 2142 |
Senp1 | 5794 |
GeneID | Gene Rank |
---|---|
Sumo2 | -7743 |
Sumo1 | -7652 |
Rwdd3 | -6572 |
Sumo3 | -5431 |
Uba2 | -4592 |
Senp2 | -2623 |
Ube2i | -2351 |
Sae1 | -35 |
Senp5 | 2142 |
Senp1 | 5794 |
FORMATION OF ATP BY CHEMIOSMOTIC COUPLING
331 | |
---|---|
set | FORMATION OF ATP BY CHEMIOSMOTIC COUPLING |
setSize | 18 |
pANOVA | 0.00698 |
s.dist | -0.367 |
p.adjustANOVA | 0.0403 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Atp5c1 | -8076 |
Atp5pb | -7499 |
Dmac2l | -7278 |
mt-Atp6 | -5071 |
Atp5b | -4886 |
Atp5h | -4812 |
Atp5o | -4698 |
Atp5l | -4684 |
Atp5a1 | -4502 |
Atp5g3 | -4458 |
Atp5g2 | -3059 |
Atp5j2 | -1520 |
Atp5e | -1120 |
Atp5j | -1104 |
Atp5d | 320 |
Atp5g1 | 1349 |
Atp5k | 2050 |
mt-Atp8 | 7353 |
GeneID | Gene Rank |
---|---|
Atp5c1 | -8076 |
Atp5pb | -7499 |
Dmac2l | -7278 |
mt-Atp6 | -5071 |
Atp5b | -4886 |
Atp5h | -4812 |
Atp5o | -4698 |
Atp5l | -4684 |
Atp5a1 | -4502 |
Atp5g3 | -4458 |
Atp5g2 | -3059 |
Atp5j2 | -1520 |
Atp5e | -1120 |
Atp5j | -1104 |
Atp5d | 320 |
Atp5g1 | 1349 |
Atp5k | 2050 |
mt-Atp8 | 7353 |
COMPLEX I BIOGENESIS
170 | |
---|---|
set | COMPLEX I BIOGENESIS |
setSize | 56 |
pANOVA | 2.06e-06 |
s.dist | -0.367 |
p.adjustANOVA | 4.67e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ndufaf1 | -7780 |
Ndufaf4 | -7557 |
Ndufv2 | -7287 |
Nubpl | -7180 |
mt-Nd2 | -7057 |
Ndufc2 | -6893 |
mt-Nd6 | -6545 |
mt-Nd4 | -6197 |
Ndufs4 | -6192 |
Ndufaf5 | -6126 |
mt-Nd1 | -5998 |
Ndufaf2 | -5957 |
mt-Nd5 | -5921 |
Ndufb5 | -5763 |
Ndufs1 | -5653 |
Ndufb11 | -4979 |
Ndufs8 | -4550 |
Ndufs3 | -4358 |
Ndufa10 | -4299 |
Ndufab1 | -4269 |
GeneID | Gene Rank |
---|---|
Ndufaf1 | -7780 |
Ndufaf4 | -7557 |
Ndufv2 | -7287 |
Nubpl | -7180 |
mt-Nd2 | -7057 |
Ndufc2 | -6893 |
mt-Nd6 | -6545 |
mt-Nd4 | -6197 |
Ndufs4 | -6192 |
Ndufaf5 | -6126 |
mt-Nd1 | -5998 |
Ndufaf2 | -5957 |
mt-Nd5 | -5921 |
Ndufb5 | -5763 |
Ndufs1 | -5653 |
Ndufb11 | -4979 |
Ndufs8 | -4550 |
Ndufs3 | -4358 |
Ndufa10 | -4299 |
Ndufab1 | -4269 |
Ndufb4 | -4254 |
Ndufb9 | -4240 |
Ndufb3 | -4238 |
Ndufb8 | -3922 |
Ndufb6 | -3352 |
Tmem126b | -3342 |
Ndufa11 | -3129 |
Ndufb10 | -2954 |
Ecsit | -2884 |
Ndufa9 | -2857 |
Ndufs5 | -2848 |
Ndufa7 | -2650 |
Ndufs2 | -2591 |
Ndufb2 | -2480 |
Ndufc1 | -2357 |
Ndufa8 | -1983 |
Ndufv1 | -1558 |
Ndufa2 | -1531 |
Ndufa5 | -1343 |
Ndufaf3 | -1245 |
Ndufb1 | -1103 |
Timmdc1 | -816 |
Acad9 | -691 |
Ndufb7 | -650 |
Ndufa6 | -561 |
Ndufa1 | -470 |
mt-Nd3 | 257 |
Ndufaf6 | 359 |
Ndufs6 | 991 |
Ndufv3 | 1179 |
Ndufa13 | 1623 |
Ndufa3 | 1807 |
Ndufaf7 | 1850 |
Ndufs7 | 1885 |
Ndufa12 | 3482 |
Tmem186 | 6996 |
APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1
62 | |
---|---|
set | APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1 |
setSize | 71 |
pANOVA | 9.26e-08 |
s.dist | -0.367 |
p.adjustANOVA | 3.64e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Psmc6 | -8204 |
Ube2e1 | -7973 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Psma6 | -7580 |
Anapc10 | -7447 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Cdc26 | -6729 |
Psma1 | -6555 |
Cdc16 | -6482 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
GeneID | Gene Rank |
---|---|
Ube2d1 | -8221 |
Psmc6 | -8204 |
Ube2e1 | -7973 |
Psmd14 | -7965 |
Psmd12 | -7878 |
Psmb9 | -7862 |
Psma6 | -7580 |
Anapc10 | -7447 |
Psma2 | -7177 |
Psmd6 | -7172 |
Psmf1 | -7032 |
Cdc26 | -6729 |
Psma1 | -6555 |
Cdc16 | -6482 |
Psmd8 | -6194 |
Psmb8 | -6188 |
Psma5 | -5800 |
Psmb1 | -5506 |
Psmd10 | -5497 |
Psmb7 | -5401 |
Pttg1 | -5340 |
Psmc2 | -5064 |
Cdc27 | -5031 |
Aurka | -4987 |
Psma4 | -4815 |
Ube2s | -4651 |
Psmd5 | -4603 |
Psmb3 | -4590 |
Anapc7 | -4519 |
Psma3 | -4517 |
Ubb | -4221 |
Rps27a | -4124 |
Psme2 | -4121 |
Anapc16 | -4035 |
Psma7 | -3980 |
Psma8 | -3884 |
Rb1 | -3755 |
Cdc23 | -3456 |
Psmd9 | -3332 |
Anapc4 | -3097 |
Anapc15 | -2459 |
Psmd13 | -2449 |
Sem1 | -2432 |
Psme3 | -2373 |
Psmc3 | -2347 |
Anapc11 | -2257 |
Psmb10 | -2155 |
Psmc1 | -1692 |
Psmb6 | -1661 |
Psmb2 | -1638 |
Psmc5 | -1555 |
Psmb4 | -1483 |
Fzr1 | -1003 |
Skp2 | -450 |
Plk1 | -337 |
Psmd11 | -127 |
Psmc4 | 123 |
Psme1 | 709 |
Psmb5 | 728 |
Psmd1 | 1046 |
Psmd7 | 1453 |
Psmd4 | 2248 |
Psmd3 | 2918 |
Psmd2 | 3350 |
Ubc | 3480 |
Psme4 | 3590 |
Uba52 | 3691 |
Anapc1 | 5839 |
Anapc5 | 5965 |
Cdc20 | 6094 |
Anapc2 | 7413 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so; LAPACK version 3.10.0
##
## locale:
## [1] LC_CTYPE=en_AU.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_AU.UTF-8 LC_COLLATE=en_AU.UTF-8
## [5] LC_MONETARY=en_AU.UTF-8 LC_MESSAGES=en_AU.UTF-8
## [7] LC_PAPER=en_AU.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_AU.UTF-8 LC_IDENTIFICATION=C
##
## time zone: /usr/share/zoneinfo/Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] GGally_2.1.2 gtools_3.9.4
## [3] echarts4r_0.4.5 beeswarm_0.4.0
## [5] pkgload_1.3.2.1 vioplot_0.4.0
## [7] sm_2.2-5.7.1 kableExtra_1.3.4
## [9] topconfects_1.16.0 limma_3.56.2
## [11] eulerr_7.0.0 mitch_1.12.0
## [13] MASS_7.3-60 fgsea_1.26.0
## [15] gplots_3.1.3 DESeq2_1.40.2
## [17] SummarizedExperiment_1.30.2 Biobase_2.60.0
## [19] MatrixGenerics_1.12.3 matrixStats_1.0.0
## [21] GenomicRanges_1.52.0 GenomeInfoDb_1.36.2
## [23] IRanges_2.34.1 S4Vectors_0.38.1
## [25] BiocGenerics_0.46.0 reshape2_1.4.4
## [27] lubridate_1.9.2 forcats_1.0.0
## [29] stringr_1.5.0 dplyr_1.1.2
## [31] purrr_1.0.2 readr_2.1.4
## [33] tidyr_1.3.0 tibble_3.2.1
## [35] ggplot2_3.4.3 tidyverse_2.0.0
## [37] zoo_1.8-12
##
## loaded via a namespace (and not attached):
## [1] bitops_1.0-7 gridExtra_2.3 rlang_1.1.1
## [4] magrittr_2.0.3 compiler_4.3.1 polylabelr_0.2.0
## [7] systemfonts_1.0.4 vctrs_0.6.3 rvest_1.0.3
## [10] pkgconfig_2.0.3 crayon_1.5.2 fastmap_1.1.1
## [13] XVector_0.40.0 ellipsis_0.3.2 labeling_0.4.2
## [16] caTools_1.18.2 utf8_1.2.3 promises_1.2.1
## [19] rmarkdown_2.24 tzdb_0.4.0 xfun_0.40
## [22] zlibbioc_1.46.0 cachem_1.0.8 jsonlite_1.8.7
## [25] highr_0.10 later_1.3.1 DelayedArray_0.26.7
## [28] reshape_0.8.9 BiocParallel_1.34.2 parallel_4.3.1
## [31] R6_2.5.1 bslib_0.5.1 stringi_1.7.12
## [34] RColorBrewer_1.1-3 jquerylib_0.1.4 assertthat_0.2.1
## [37] Rcpp_1.0.11 knitr_1.43 httpuv_1.6.11
## [40] Matrix_1.6-1 timechange_0.2.0 tidyselect_1.2.0
## [43] rstudioapi_0.15.0 abind_1.4-5 yaml_2.3.7
## [46] codetools_0.2-19 lattice_0.21-8 plyr_1.8.8
## [49] shiny_1.7.5 withr_2.5.0 evaluate_0.21
## [52] polyclip_1.10-4 xml2_1.3.5 pillar_1.9.0
## [55] KernSmooth_2.23-22 generics_0.1.3 RCurl_1.98-1.12
## [58] hms_1.1.3 munsell_0.5.0 scales_1.2.1
## [61] xtable_1.8-4 glue_1.6.2 tools_4.3.1
## [64] data.table_1.14.8 webshot_0.5.5 locfit_1.5-9.8
## [67] fastmatch_1.1-4 cowplot_1.1.1 grid_4.3.1
## [70] colorspace_2.1-0 GenomeInfoDbData_1.2.10 cli_3.6.1
## [73] fansi_1.0.4 viridisLite_0.4.2 S4Arrays_1.0.5
## [76] svglite_2.1.1 gtable_0.3.4 sass_0.4.7
## [79] digest_0.6.33 farver_2.1.1 htmlwidgets_1.6.2
## [82] htmltools_0.5.6 lifecycle_1.0.3 httr_1.4.7
## [85] mime_0.12
END of report